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Abbreviation 
Ab Antibody 
ACAT Acetyl-Coenzyme A acetyltransferase 
ADAM17 ADAM Metallopeptidase Domain 17 
Ago Argonaute 
AP1 Activator protein 1 
ApoA1 Apolipoprotein A1 
ApoB Apolipoprotein B 
Apoe Apolipoprotein E 
AT1R Angiotensin II type 1 receptor 
α-SMA α -smooth muscle actin 
BCL6 B-cell lymphoma 6 
BIC B-cell receptor inducible 
BM Bone marrow 
BMC Bone marrow cell 
BMDMs Bone marrow-derived macrophages 
BSA Bovine serum albumin 
CAD Coronary artery disease 
CCA  Common carotid artery 
CCL2 Chemokine (C-C motif) ligand 2 
Ccdc18 Coiled-coil domain-containing protein 18 
CEBPα CCAAT/enhancer‐binding protein alpha 
CXCL5 Chemokine (C-X-C motif) ligand 5 
CXCL12 Chemokine (C-X-C motif) ligand 12 
CXCR4 Chemokine (C-X-C motif) receptor 4 
d Day 
DAPI  4',6-Diamidino-2-phenylindol  
DGCR8 Double-stranded RNA binding protein 
DIG Digoxigenin 
Dlk1 Delta-like 1 homologue 
dsRNA double-stranded RNA 
EC  Endothelial cell 
ECA  External carotid artery 
EDTA Ethylenediaminetetraacetic Acid 
EEL  External elastic lamina 
EGF  Epidermal growth factor  
EGFL7 EGF-like domain 7 
EIF2C2 Eukaryotic translation initiation factor 2C, 2 
ELISA  Enzyme-linked immunosorbant assay 
EPC Endothelial progenitor cells 
ERK Extracellular signal-regulated kinase 
ETS E26 transformation-specific sequence 
EVG Elastic van Gieson 
FA1 Fetal Antigen1 
FGF Fibroblast Growth Factor 
FITC Fluorescein Isothiocyanate 
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GAS1 Growth arrest-specific 1  
GC Germinal center 
HCD  High cholesterol diet 
HDL High-density lipoprotein 
Hif-1α Hypoxia induced factor-1 alpha 
HRP Horse radish peroxidase 
ICA  Internal carotid artery 
IEL  Internal elastic lamina 
IFNγ Interferon gamma 
Ig  Immunoglobulin 
IL1β Interleukin-1 beta 
IL4 Interleukin 4 
IL6 Interleukin 6 
IL10 Interleukin 10 
IL17 Interleukin 17 
IL13 Interleukin 13 
IL13Rα1 IL13 receptor alpha 1 
INPP5d Inositol polyphosphate-5-phosphatase, 145kDa 
IP Intraperitoneal 
IV  Intravenous 
KLF2 Kruppel-Like Factor 2 
LDL  Low-density lipoprotein 
LPS  Lysophosphatidylserine 
MAC2  Galectin-3 (MAC 2 antigen) 
mc  Monoclonal 
MiR MicroRNA 
moxLDL Mildly oxidized LDL 
MPO Myeloperoxidase 
MRE miR recognition element 
mTOR Mammalian target of rapamycin 
MyD88 Myeloid differentiation primary response 88 
NF-κB Nuclear factor kappa B 
NO Nitric oxide 
Nos2 Nitric oxide synthase 2 
NOTCH1 Neurogenic locus notch homolog protein 1 
Nrf2 Nuclear factor E2-related factor 2 
OCT Optimal cutting temperature 
ON Overnight 
oxLDL  Oxidized LDL 
PACT Protein activator of PKR 
PBMC Peripheral blood mononuclear cells. 
PBS  Phosphate buffered saline 
PC  Polyclonal 
PCNA Proliferating cell nuclear antigen 
PCR  Polymerase chain reaction 
Pde6h  Phosphodiesterase 6H  
PDGF Platelet-derived growth factor 
PFA Paraformaldehyde 
PI3K Phosphatidylinositide 3-kinase 
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PIK3R2 Phosphoinositol-3 kinase regulatory subunit 2 
PPARγ Peroxisome proliferator-activated receptor gamma 
Pref1 Preadipocyte Factor 1 
Pre-miR Precursor miR 
Pri-miR Primary miR 
qRT-PCR Quantitative real time PCR 
RELA v-rel reticuloendotheliosis viral oncogene homolog A 
RGS16 Regulator of G-protein signaling 16 
RIN RNA integrity number 
RISC RNA-induced silencing complex 
RT Reverse transcription 
rt Room temperature 
RXR Retinoid X receptor 
SCP1 Stromal cell-derived protein1 
SMC Smooth muscle cell 
SMAD2 Sma- and Mad-related protein 2 
SFPI1 SFFV proviral integration 1 
SHIP1 Src homology-2 domain containing inositol 5-phosphatase 1 
SOCS1 Suppressor of cytokine signaling 1 
SPRED1 Sprouty-related, EVH1 domain-containing protein 1 
SPC Smooth muscle progenitor cell 
SSC Saline-sodium citrate 
STA Superior thyroid artery 
TAB2 TAK1-binding protein 2 
Tcf7l2 Transcription factor 7-like 2 (T-cell specific, HMG-box) 
TE Tris-EDTA 
TGF-β transforming growth factor-beta 
TLR Toll like receptor 
TNB Tris-NaCl-blocking 
TNFα Tumour necrosis factor alpha 
TRBP Tar RNA binding protein 
TRIF TIR-domain-containing adapter-inducing interferon-betta 
TUNEL TdT-mediated dUTP-X nick end labeling 
UP water Ultra pure water 
UTR Untranslated region 
VCAM1  Vascular cell adhesion molecule 1 
VEGF Vascular endothelial growth factor 
vWF  Von Willebrand factor 
WBC White blood cells 
ZOG Zona glomerulosa-specific factor 
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1 Introduction 
1.1 Atherosclerosis 
Cardiovascular diseases are the leading cause of death worldwide and are mainly caused by 
CAD1-4. The underlying pathology of CAD is atherosclerosis (also known as arteriosclerotic 
vascular disease) that is a chronic inflammatory disease of blood vessels due to the intimal 
accumulation of lipids and inflammatory cells in medium- and large-sized arteries (also 
known as plaques)5 6. Although atherosclerosis can remain asymptomatic for decades, plaques 
may narrow the arterial lumen and thus impair blood flow and lead to ischemia7 8 9 10. In 
addition, plaques can rupture and expose their highly thrombogenic core to the blood, which 
can trigger coagulation and atherothrombosis, the most common cause for myocardial 
infarction and stroke7 11 12 (Fig. 1). 
 
Figure 1: Progression of atherosclerosis: Atherosclerosis is a progressive disease that is initiated by fatty 
streaks formation due to macrophage infiltration and lipid accumulation in arteries. During progression, 
atherosclerotic lesions develop into more complex fibrous plaques in which SMCs and T cells also infiltrate the 
intima. Vulnerable plaques are prone to rupture and characterized by the accumulation of apoptotic cells due to 
impaired phagocytic clearance, which results in the formation of a lipid-rich necrotic core. Eventually, 
complicated lesions can narrow the artery and reduce the blood flow or they can rupture, which may lead to 
occlusion of the artery by thrombus formation. The latter is the main cause for life-threatening clinical events, 
such as myocardial infarction and stroke [Redrawn from13]. 
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1.1.1 Pathogenesis of atherosclerosis 
The complex events involved in atherogenesis have been subject of numerous studies for 
decades. Three main hypotheses for the development of atherosclerotic lesions have been 
postulated. These hypotheses are known as the response-to-injury hypothesis, the response-to-
retention hypothesis, and the oxidative modification hypothesis14. However, these models are 
not mutually exclusive, but highlight rather specific components in atherogenesis. 
1.1.2 The response-to-injury hypothesis  
The response-to-injury hypothesis proposed that atherosclerosis is initiated by a denuding 
injury to the endothelium, which leads to adhesion of platelets and leukocytes to the arterial 
wall15. Furthermore, Ross and coworkers suggested that mitogens, like PDGF, are released 
from platelets and induce proliferation of SMCs in the intima16. However, endothelial 
denudation in response to atherosclerotic risk factors is a very rare event in the initiation of 
lesion formation and occurs primarily in advanced plaques17. Notably, non-denuding injuries 
by modified lipoproteins, cigarette smoking, and diabetes, which result in functional 
disturbance of the endothelium, have been identified to play a role in triggering atherogenesis 
and the response-to-injury hypothesis has been modified accordingly8. This activation of 
endothelial cells increases permeability to macromolecules, impairs endothelial regeneration, 
and promotes the adhesion and subendothelial recruitment of monocytes and T-cells due to 
up-regulation of adhesion molecules and chemokines18 (Fig. 2). In the intima, monocytes 
transform into macrophages, which engulf modified lipoproteins and accumulate cholesterol 
esters (i.e., develop into foam cells)19. The continuous influx of monocytes and T-cells via the 
dysfunctional endothelium perpetuates the inflammatory response and drives the expansion of 
the lesion20 21. In the course of atherosclerosis, foam cells become necrotic or apoptotic and 
lipids accumulate in the extracellular space, thus forming a highly thrombogenic lesion core22-
25. In an advanced stage, smooth muscle cells enter the intima and build up a fibrous cap that 
covers the necrotic core and increases the stability of lesions against rupture9 13 (Fig. 2). The 
modified response-to-injury hypothesis introduced the important role of the inflammatory 
response in atherosclerosis. 
1 Introduction 
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Figure 2: Response-to-injury hypothesis of atherosclerosis. According to the response-to-injury hypothesis, 
endothelial injury or dysfunction initiates atherosclerosis. (A) EC permeability and LDL deposition in the sub-
endothelial space is enhanced, which promotes the adhesion and transmigration of leukocytes across the 
endothelium. (B) In the intermediate stage, atherosclerosis is characterized by foam cell formation, T-cell 
activation, platelets adhesion and aggregation, enhanced leukocytes adherence, and SMC migration into the 
intima. (C) Advanced atherosclerosis results from continued macrophage accumulation and fibrous cap and lipid 
core formation9 14. 
1.1.3 The response-to-retention hypothesis 
In contrast to the prominent role of endothelial dysfunction in the response-to-injury 
hypothesis, the sub-endothelial retention of cholesterol-rich atherogenic lipoproteins, such as 
LDL and its microaggregates, are in the focus of the response-to-retention hypothesis26 27. 
Arterial sites prone to atherosclerosis are characterized by enhanced accumulation of 
lipoproteins due to the binding of ApoB-100 to proteoglycans, which are enriched in diffuse 
intimal thickening28 29. The response-to-retention hypothesis is mainly based on finding that 
mice expressing a proteoglycan binding-deficient ApoB mutant show reduced intimal LDL 
accumulation and decreased atherosclerosis. Interestingly, in a very advanced stage of 
atherosclerosis, plaque formation is accelerated in mice expressing the proteoglycan binding-
defective ApoB30 31. A mainstay of the response-to-retention hypothesis is the observation that 
arterial accumulation of LDL in predilection sites of atherosclerosis is mainly due to increased 
retention and reduced degradation of LDL rather than to enhanced endothelial permeability32. 
Therefore, endothelial dysfunction is not regarded as a prerequisite according to the response-
to-retention hypothesis, but rather as a consequence of subendothelial LDL retention. 
However, increased permeability at predilection sites of atherosclerosis associated with 
endothelial mitosis has been validated and may further increase the LDL deposition33. 
Lipoprotein lipases found in the extracellular matrix can enhance the retention of LDL by 
bridging LDL and proteoglycans via a non-enzymatic mechanism or by promoting the 
formation of LDL aggregates26 27 
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1.1.4 The oxidative modification hypothesis 
The oxidative modification hypothesis of atherosclerosis introduces chemical modification of 
LDL as a sine qua non in lesion development, because native LDL does not lead to 
macrophage foam cell formation. Goldstein and Brown discovered in 1979 that the uptake of 
acetylated-LDL by macrophages is much higher than that of native LDL and leads to 
intracellular accumulation of cholesteryl esters34. In contrast to the uptake of native LDL by 
the LDL receptor, which is negatively regulated by the cellular cholesterol content, modified 
LDL is engulfed by scavenger receptors, such as scavenger receptor A1 (mediates the uptake 
of acetylated LDL) and CD36 (mediates the uptake of oxLDL), which do not recognize native 
LDL35. ECs, SMCs, and macrophages can modify LDL by peroxidation of polyunsaturated 
fatty acids in the LDL lipids36. These oxidative modifications of LDL result in mildly 
oxidized (or minimally modified) LDL, which is still recognized by the LDL receptor, but not 
by scavenger receptors14 37. MoxLDL can induce an inflammatory response in ECs 
characterized by up-regulation and secretion of chemokines38. Moreover, moxLDL can bind 
and activate TLRs in macrophages and thus enhance proinflammatory gene expression39 40.  
Secondarily, the lipid oxidation products can oxidatively modify ApoB (the so 
called oxidized LDL), which is then no longer recognized by the LDL receptor, but now binds 
to scavenger receptors, preferentially CD3614. In contrast to the uptake by the LDL receptor, 
endocytosis of oxLDL by CD36 up-regulates the expression of CD36 via activation of 
PPARγ/RXR41. According to the anti-inflammatory effects of PPARγ activation in 
macrophages, oxLDL treatment suppresses NF-κB activation and cytokine expression42-45. 
The oxLDL-derived cholesterol is stored intracellularly in its esterified form in lipid droplets, 
which are lipoprotein-like cytoplasmic organelles with specific structural proteins46 47. 
Esterification of cholesterol is achieved by the ATP-consuming activity of ACAT, which is 
balanced by continuous hydrolysis of cholesteryl esters, thereby tightly regulating the 
intracellular free cholesterol content48. Excessive free cholesterol can be removed from 
macrophages by the cholesterol acceptors ApoA1 or HDL and further transported to the 
liver49. However, if cholesterol uptake exceeds its removal, the free cholesterol content of the 
macrophages increases and triggers an NF-κB-dependent inflammatory response and 
apoptosis through endoplasmic reticulum stress50-53. Insufficient phagocytic removal of 
apoptotic macrophages in advanced lesions leads to secondary necrosis of the apoptotic 
macrophages, which contributes to the formation of a necrotic core and impairs the resolution 
of the inflammatory response54. Moreover, oxLDL can induce Fas-mediated EC apoptosis, 
which may further increase the endothelial permeability and recruitment of monocytes55. 
1.1.5 Hemodynamic forces and atherosclerosis 
Atherosclerosis develops at predilections sites along the arterial tree, such as the inner 
curvature of the aortic arch and in the vicinity of branch points, which are subjected to 
disturbed flow18 56. In contrast to athero-protective laminar flow, which subjects the 
endothelium to high shear stress, low shear stress associated with disturbed flow pre-activates 
the endothelium towards inflammatory stimulation by hypercholesterolemia57 58. The anti-
inflammatory effects of high shear stress are mediated by the transcription factors KLF2 and 
1 Introduction 
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Nrf2, whereas activation of AP1 and NF-κB by low shear stress stimulates pro-inflammatory 
gene expression59. In addition to inflammatory activation, the proliferation rate of ECs at 
lesion-prone sites is substantially enhanced, which may be causally related to the increased 
permeability to macromolecules at these sites60-62. In vitro, low shear stress triggers EC 
proliferation, indicating that disturbed flow plays an important role in increasing the mitotic 
rate of ECs at predilection sites of atherosclerosis63 64. The endothelial proliferation rate is 
further increased by hypercholesterolemia, indicating that both disturbed flow and 
dyslipidemia damage the endothelium61. Moreover, disturbed flow also induces EC apoptosis, 
which may be followed by regenerative endothelial cell proliferation65 66. Despite the 
association of EC proliferation and atherogenesis, it remains unclear how endothelial 
proliferation affects lesion formation. 
 
  
Figure 3: Atherosclerosis preferentially develops 
at arterial branches and the inner curvature of 
the aortic arch. The distribution of atherosclerotic 
lesions in the arterial tree is indicated (grey 
shading). 1, Aortic sinus; 2, ascending aorta; 3, 
inner (lesser) curvature of aortic arch; 4, outer 
(greater) curvature of aortic arch; 5, innominate 
artery; 6, right common carotid artery; 7, left 
common carotid artery; 8, left subclavian artery; 9, 
thoracic aorta; 10, renal artery; 11, abdominal aorta; 
12, iliac artery18  
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1.2 Neointimal hyperplasia following vascular injury 
In contrast to the chronic, lipid-induced damage to the vessel wall in atherosclerosis, acute 
mechanical injury is induced by the main interventional treatment procedures of narrowed, 
atherosclerotic arteries, such as balloon angioplasty and stent implantation67. This mechanical 
injury acutely removes the endothelium and induces apoptosis of most of the medial SMCs, 
and thus more closely resembles the scenario of the original response-to-injury hypothesis by 
Ross and co-workers than diet-induced atherosclerosis68. Platelets adhere to the denuded 
artery, secrete cytokines and growth factors, and mediate the recruitment of leukocytes69. 
Subsequently, phenotypically altered smooth muscle cells accumulate in the neointima and 
thereby restore the integrity of the vessel wall70. The origin of these SMCs depends on the 
degree of injury and apoptosis; whereas in neointima formation following ligation the 
apoptosis rate is low and most neointimal SMCs are derived from the vessel wall, most 
medial SMCs undergo apoptosis circulating SPCs partly form the neointima71. These findings 
suggest that the endogenous repair capability of the arterial wall is limited when most medial 
SMCs are apoptotic. Interestingly, apoptotic SMCs trigger the expression of the chemokine 
CXCL12, which mobilizes and recruits SMC progenitor cells during vascular repair68. This 
process represents a classical wound healing response in the vasculature. However, extensive 
damage to the arterial wall may lead to exacerbated neointima formation and re-narrowing of 
the artery, clinically encountered as restenosis.  
Although stents, which elute anti-proliferative drugs, such as sirolimus and 
paclitaxel, substantially reduce the risk for restenosis by inhibiting SMC proliferation, the 
associated delay in endothelial recovery harbours an increased risk for late stent thrombosis 
and neo-atherosclerosis72 73. This finding highlights the crucial role of endothelial 
regeneration in vascular repair. Therefore, stents covered with an antibody against the 
hematopoietic stem cell marker CD34 have been developed to enhance re-endothelialization 
and reduce the risk for late stent thrombosis. However, the first results did not show a 
reduction in the rate of in-stent restenosis or an improved angiographic outcome74 75. 
Re-endothelialization progresses continuously during vascular repair and may 
suppress neointimal SMC proliferation by enhanced generation of NO76-79. Subtle endothelial 
denudation is rapidly repaired by migration and spreading of ECs, while regeneration of 
extensive EC injury is mediated by additional EC proliferation80-83. In normal, postnatal 
arteries, EC proliferation is infrequent due to contact inhibition mediated by sequestering of 
β-catenin through homotypic interaction of VE-cadherins at the inter-endothelial junctions, 
which prevents mitogenic signalling of the endothelial growth factor VEGF84 85. Loss of 
contact inhibition activates ERK1/2 signalling, induces the PI3K/Akt/mTOR pathway, and 
down-regulates p27, which promotes EC proliferation86-88. Treatment with endothelial growth 
factors, such as VEGF and FGF, increases re-endothelialization and reduces neointimal 
hyperplasia; however, the role of endogenous growth factors in endothelial recovery is 
unclear89-92. Although re-endothelialization is generally considered as a beneficial response 
after vascular injury, regeneration by dysfunctional endothelial cells may occur, which 
promotes monocyte recruitment69 93-95. Moreover, incomplete endothelial recovery after 
extensive injury can result in formation of a pseudo-endothelium by inflammatory SMCs, 
which may lead to neo-atherosclerosis96-98. 
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Akin to the repair by SPCs, the degree of endothelial denudation determines the 
mechanism of recovery of the endothelial lining. Primarily resident endothelial cells quite 
effectively repair limited denuded areas by migration into this area and by subsequent 
proliferation. In addition, endothelial repair by circulating endothelial progenitor cells (EPCs) 
can occur during extensive endothelial denudation, although the reported frequency of EPCs 
incorporated in the recovered endothelium is low99 100. Moreover, circulating angiogenic cells 
from a myeloid origin share many features of EPCs and promote endothelial regeneration via 
a paracrine route101-103. Treatment with estrogens, erythropoietin, granulocyte colony-
stimulating factor, or statins, increase the number of circulating EPCs or angiogenic cells, 
promote re-endothelialization, and limit neointima formation104 105. Of note, both SPCs and 
EPCs appear to play only a minor role in atherosclerotic lesion formation106-108.  
1.3 MicroRNAs in arterial pathologies 
In 1993, the finding that the lin-4 gene encodes for small RNAs, which control the timing of 
C. elegans larval development instead of translated proteins, paved the way for the discovery 
of a whole new class of gene expression regulators, termed miRs109 110. Seven years later, it 
became clear that miRs can be highly conserved across a wide range of species and that 
multiple different miRs exist111 112. MiRs regulate posttranscriptional gene expression through 
translational repression or mRNA cleavage113 and play key roles in determining cell fate and 
tissue homeostasis by providing robustness to transcriptional programs114-116. In addition to 
the typical RNA transcript length of 22nt, miRs are defined by the biogenesis from a single 
precursor miRNA with a fold-back (hairpin) structure that is cleaved by the RNAse Dicer117. 
In contrast, endogenous siRNAs, which have the same length, are processed from a dsRNA 
precursor117. More than 2000 human mature miRs and 1600 hairpin precursor sequences have 
been published so far (www.mirbase.org)118. In mammals, miRs regulate the expression of 
50% of all protein-coding genes119. An individual miR can target hundreds of mRNAs and a 
single mRNA transcript may be regulated by multiple miRs, which explains the diverse roles 
of miRs in the fine-tuning of a wide range of biological processes115 120. Moreover, miR 
expression patterns are altered in various disease states, including cancer and inflammatory 
diseases121. 
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1.3.1 The biogenesis and function of miRs 
MiR genes reside mostly in the introns in the sense orientation (70%) of protein-coding genes 
and noncoding RNAs, but also in genomic regions distinct from known transcription units 
(intergenic) (Fig. 4)122 123. More rarely, miR genes are located in the exons or in both intronic 
and exonic regions (“mixed”)124. Intergenic miR genes can be monocistronic with their own 
promoter or polycistronic with several miRs transcribed as a cluster or primary transcripts 
with a shared promoter122. Intronic miR genes, which can be encode for a single miR or for a 
cluster of several miRs, are likely to share their promoter elements and primary transcript with 
their host genes122 125. Exonic miRs are thought to be transcribed by their host gene promoter 
and their maturation often excludes host gene function124. 
 
Figure 4: Genomic locations of miR encoding genes. (A) Intergenic miRs are located in genomic regions 
distinct from annotated transcription units. These miRs can be monocistronic (top part) with their own promoters 
(black arrowhead) or polycistronic (bottom part) with a shared promoter (black arrowhead). (B) Intronic miR 
genes reside in the introns of protein-encoding genes or of non-coding RNAs. The intronic miR genes can 
encode a single miR (top part) or a cluster of several miRs (bottom part). These miRs are presumably transcribed 
from the same promoter as their host genes (black arrowhead, all parts). In mirtrons (middle part), the short 
introns comprise exactly the sequence of the pre-miR flanked by splicing sites (denoted by white asterisks). (C) 
Exonic miR genes often overlap an exonic and an intronic region.122 
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Most of the miR genes are transcribed by RNA polymerase II as capped and polyadenylated 
transcripts, so-called pri-miRs, which can be several thousand bases long and are formed into 
a hairpin stem (33bp), a terminal loop, and two single-stranded flanking regions126 127. In the 
first step of miR maturation, a microprocessor complex in the nucleus that contains Drosha 
(RNAse III enzyme) and DGCR8 cleaves the long pri-miR 11bp away from the single-
stranded RNA/dsRNA junction at the hairpin stem to a shorter, ~60-70 nt long intermediate, 
known as pre-miR128. Pre-miRs are actively exported from the nucleus by binding to 
Exportin-5–Ran-GTP129. In the cytoplasm, another RNase III enzyme, known as Dicer, 
together with a multi-protein complex composed of TRBP, PACT, and an Ago protein, 
process the pre-miR hairpin into a short (~22 nt) miR duplex130-132. The guide strand of the 
dsRNA is loaded into the RISC and binds to the target mRNAs, while the other strand, known 
as passenger strand or miR*, is mostly degraded133 134. However, the steady-state level of each 
strand of the miR pair can be independently regulated in a tissue-specific manner and both 
strands can stably associate with an Argonaut family protein133 135. Moreover, the regulatory 
activity of miR* strands has been proved, which supports the hypothesis that both strands of a 
miR pair can regulate the expression levels of their target genes136 137. The miR strand in the 
RISC binds to the target mRNA via MREs, which are primarily located in the 3'-UTR. The 
miR seed sequence (i.e., nucleotides 2-7 in the 5' end of the miRs) mediates the interaction of 
miRs and their mRNA targets although other regions in the 3’ end of the miRs perhaps have a 
modifying effect138-140. MiRs regulate gene expression predominantly by mRNA degradation, 
but also by translational repression141 142. 
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Figure 5: Biogenesis and function of miRs. MiR processing includes the following steps: (1) production of the 
pri-miR transcript by RNA polymerase II or III; (2) pri-miRs are cleaved by the Drosha–DGCR8 (Pasha) 
complex in the nucleus to the precursor hairpin, pre-miR; (3) the pre-miR is exported from the nucleus by 
Exportin-5–Ran-GTP; (4) the RNase Dicer/TRBP complex cleaves the pre-miR hairpin to a miR duplex in the 
cytoplasm; (5) the mature miR is loaded together with Ago proteins into the RISC, where it guides the RISC to 
the target mRNAs and mediates either mRNA decay by cleavage or deadenylation, or translational inhibition. 
The passenger strand (black) is usually degraded126. 
1.3.2 miR-126 modulates endothelial function in atherosclerosis 
MiRs play key roles in the development of ECs and regulate EC function in response to 
various atherogenic stimuli and hemodynamic stress143. MiR-126-3p encoded by intron 7 of 
the Egfl7 gene is one of the most abundant endothelial miRs144-146 (Fig. 6A). The mechano-
sensitive transcription factor KLF2 induces miR-126-3p expression during development in 
response to blood flow and thus mediates angiogenic sprouting of aortic arch vessels by 
targeting the activation of VEGF signaling147. Moreover, functional binding sites for the 
transcription factor ETS have been identified in the promoter region of the miR-126 gene148.  
Inhibition of miR-126-3p/-5p or genetic deletion of the miR-126 gene causes 
vascular leakage due to increased permeability during development mainly by reduced VEGF 
signaling through disinhibition of the miR-126-3p targets SPRED-1 and PIK3R146 149. The 
finding that 40% of miR-126-/- mice die embryonically due to severe edema, multifocal 
hemorrhages, and ruptured blood vessels highlights this important role of the miR-126 gene 
during development146. However, surviving miR-126-/- mice appear normal and do not display 
obvious abnormalities146. Postnatally, miR-126 enhances angiogenesis and VEGF-induced EC 
migration in vitro and following myocardial infarction146 149. Moreover, miR-126 reduces 
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leukocyte adhesion to endothelial cells by inhibition of VCAM1 expression, suggesting an 
essential role in vascular inflammation150. Apoptosis of ECs results in enrichment of miR-126-
3p in apoptotic bodies, which transfer miR-126-3p to vascular cells. MiR-126-3p delivery in 
EC-derived apoptotic bodies reduces the progression of atherosclerosis through repression of 
RGS16, which leads to disinhibition of CXCR4 signaling and thus enhanced autoinduction of 
atheroprotective CXCL12151 (Fig. 6B). 
 
 
Figure 6: MiR-126 regulates EC function in response to hemodynamic forces and atherogenic stimuli. (a) The 
stem loop structure of the murine and human miR-126 precursor (pre-miR-126) is shown, which is further 
processed by Dicer to the miR-126-3p/miR-126-5p duplex (blue). The orange boxes indicate the seed sequences 
of the miR-126 strands. (b) MiR-126-3p regulates VEGF signaling, angiogenesis and vascular integrity within 
ECs by targeting Spred1 and PIK3R. Furthermore, miR-126 regulates vascular inflammation by targeting 
VCAM-1 in ECs. MiR-126-3p expression is regulated by flow-induced transcription factors KLF2 and ETS in 
ECs. Moreover, transfer of miR-126 via endothelial-derived apoptotic bodies to vascular cells reduces the 
progression of atherosclerosis through repression of RGS16, which leads to up-regulation of CXCL12 
expression by unleashing CXCR4 signaling and thus autoinduction of CXCL12.  
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1.3.3 miR-155 in atherogenic macrophage function 
Macrophages contribute to the initiation and progression of atherosclerotic lesions and drive 
the chronic, unresolved inflammatory response in atherogenesis19. MiRs control the 
differentiation and inflammatory activation of macrophages by fine-tuning signaling cascades, 
such as the NF-κB pathway152. The inflammatory activation of macrophages is characterized 
by up-regulation of several miRs, such as miR-155, miR-146, miR-147, miR-21, and miR-9153. 
MiR-155 is transcribed from exon 3 of the BIC gene, which encodes a non-coding RNA154 155 
(Fig. 7A). Although miR-155 and BIC RNA increase upon up-regulation of BIC transcription, 
the relative amounts of these RNAs can vary considerably. Nuclear export of BIC RNA, 
which is unlikely to have any function in the cytoplasm, may reduce the precursors of miR-
155 and thus controls the miR-155 production155. MiR-155 is induced in macrophages by 
activation of various TLRs through MyD88- and TRIF-dependent signaling156 (Fig. 7B). In 
addition, stimulation of macrophages and monocytes by oxLDL regulates miR-155 
expression; however, up- and down-regulation of miR-155 in oxLDL-stimulated myeloid cells 
have been reported157-159.  
In inflammatory macrophages, increased expression of miR-155 can promote the 
transcription of inflammatory mediators by targeting Socs1160 161. Furthermore, suppression of 
the IL13R1 expression by miR-155 appears to prevent polarization of macrophages to a 
alternatively-activated M2 phenotype162. In contrast, miR-155 limits the effects of TGF- on 
macrophages through suppression of SMAD2163. Of note, miR-155 is part of a negative 
feedback loop that limits the inflammatory activation of monocyte-derived dendritic cells, 
presumably by targeting TAB2164 (Fig. 7B). Taken together, miR-155 expression is increased 
in inflammatory macrophages, but its role in the regulation of the inflammatory response is 
unclear.  
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Figure 7: MiR-155 regulates macrophage inflammatory responses. (a) Stem loop structure of murine pre-miR-
155 containing miR-155/miR-155* duplex (blue). The yellow boxes indicate the seed sequences of the miR-155 
strands. The red characters indicate the differences in the nucleotide sequence between murine and human pre-
miR-155) (b) MiR-155 expression is induced by oxLDL and by TLR ligands in macrophages. Induction of miR-
155 shows both anti- and pro-inflammatory effects in macrophages. The pro-inflammatory role of miR-155 is 
associated with targeting SOCS1, SHIP1, and IL13Rα1. However, the anti-inflammatory role of miR-155 is 
driven by inhibition of SMAD2 and TAB2. 
1.4 Delta-like 1 homologue (DLK1) 
Delta-like 1 homologue (DLK1), also known as pG2, FA-1, Pref-1, SCP-1, or ZOG, is a cell-
surface, transmembrane protein characterized by six EGF-like repeats in the extracellular 
domain, a single transmembrane domain, a juxtamembrane region, and a short intracellular 
tail165-169 (Fig. 8). DLK1 is proteolytically cleaved, for example by ADAM17, at two sites in 
the extracellular domain, which can generate two soluble forms (a 25-kDa or a 50-kDa 
protein)170. The EGF repeats in DLK1 are very similar to those found in canonical NOTCH1 
ligands, but misses the second NOTCH1-binding DSL domain171. Dlk1 is highly expressed in 
various tissues during development, such as placenta, liver, adipose tissue, skeletal muscle, 
lung, vertebrae, and the pituitary- and adrenal glands, and is involved in differentiation and 
cell fate determination171-174. However, the expression of Dlk1 is restricted to (neuro) 
endocrine tissues in adults171. The soluble DLK1 plays a crucial role in adipogenesis, because 
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it inhibits the differentiation of preadipocytes into mature adipocytes by repressing CEBPα 
and PPARγ168 175 176. Accordingly, Dlk1 is only expressed in preadipocytes but not in mature 
adipocytes176. In contrast to the effect of the soluble DLK1, inhibitory effects of DLK1 on the 
differentiation and proliferation of hematopoietic cells is mediated by intracellular domain 
interactions177. Moreover, DLK1 plays an important role in postnatal neurogenesis by 
maintaining the number of neural stem cells during aging174. This effect on neurogenesis was 
due to astrocyte-derived soluble DLK1 that signals via membrane-bound DLK1 on neural 
stem cells indicating that membrane-bound DLK1 can serve as a receptor for soluble 
DLK1174. Moreover, silencing of DLK1 in fibroblasts results in loss of contact inhibition and 
increased proliferation178. This anti-proliferative effect of DLK1 may be mediated by binding 
to GAS1 and acrogranin, which are both involved in the control of cell growth178. Another 
mechanism of the DLK1 function is based on the homology to canonical NOTCH1 ligands. In 
contrast to canonical NOTCH1 ligands, DLK1 inhibits NOTCH1 signaling probably by acting 
as a competitive antagonist through interaction with EGF-like repeats179 180. Expression of 
Dlk1 has been found also in developing and adult ECs, and inhibits angiogenesis most likely 
through inhibition of NOTCH1 activation181 182. Therefore, DLK1 might be involved in the 
endothelial regeneration following vascular injury and in atherosclerosis. 
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Figure 8: Structure of DLK1 in the cell membrane. DLK1 is consisting of six EGF-like repeats at the 
extracellular domain, a single transmembrane domain, a juxtamembrane region, and a short intracellular tail. The 
soluble form of DLK1 is generated by proteolytic cleavage (e.g., by ADAM17) in the extracellular domain. 
DLK1 can inhibit NOTCH1-mediated angiogenesis. The intracellular domain of DLK1 (membrane DLK1) can 
inhibit differentiation and proliferation of hematopoietic cells. 
1.5 B-cell CLL/lymphoma 6 (BCL6) 
The proto-oncogene BCL6 is a sequence-specific transcriptional repressor, which is expressed 
in B cells during the GC phase of differentiation183 184. BCL6 controls the GC-specific gene 
expression program by repressing genes involved in B-cell activation, such as NF-κB1, or 
cell-cycle progression185. Moreover, BCL6 plays a role in the transcriptional response to DNA 
damage and during plasma cell differentiation186 187. BCL6 inhibits the NF-κB signaling 
pathway by different mechanisms, such as direct repression of p50, inhibitory binding of 
BCL6 to NF-κB proteins, and opposing regulation of NF-κB target genes188. 
In macrophages, Bcl6 is up-regulated during differentiation and NF-κB-mediated 
activation, directly represses Ccl2 expression, and counter-regulates the transcriptional 
activation of many genes by NF-κB, indicating that Bcl6 is a negative regulator of 
inflammatory macrophage activation and proliferation188-191. Thus, BCL6 may also play an 
important role in the regulation of the inflammatory activation of macrophages during 
atherosclerosis. 
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1.6 Aims of the study 
ECs play a crucial role in neointima formation following vascular injury and in 
atherosclerosis. MiRs are key regulators of EC function during angiogenesis and 
inflammation. However, the specific role of endothelial miRs in vascular repair and 
atherosclerosis is unclear. The miR-126 gene is highly expressed in ECs and regulates many 
EC functions in vivo that are important in neointima formation and atherosclerotic lesion 
formation. The hypothesis was tested that the expression of the miR-126 gene is crucial for 
endothelial repair after vascular injury and thus limits neointima formation in a mouse model. 
Moreover, it was hypothesized that the expression of the miR-126 gene also enhances 
endothelial regeneration during atherosclerosis and thereby reduces plaque formation. In 
addition, the current study was aimed to identify which miR-126 strand mediates the 
protective effect and the target(s) involved. Furthermore, it was studied whether the 
mechanisms of the protective effects of the miR-126 gene were similar in neointima formation 
following vascular injury and in atherosclerosis. Another aim of the current study was to 
investigate whether the findings in the mouse studies are transferable to human 
atherosclerosis. Finally, the effect of a therapeutic administration of a miR-126 strand in 
mouse models of atherosclerosis was studied to assess the potential of a miR-based therapy in 
atherosclerosis.  
Macrophages are the most abundant cell type in atherosclerotic lesions and the non-
resolving inflammation driven by lesional macrophages is supposed to promote the 
progression of atherosclerosis. MiRs play a crucial role in regulation of the inflammatory 
activation of macrophages. However, miRs that control the atherogenic response of 
macrophages during lesion formation and progression are not well defined. The first aim of 
the second part of this study was to characterize the role of miRs in macrophages during 
atherosclerosis. In this regard, it was planned to identify miRs that are highly expressed in 
lesional macrophages amongst miRs that are up-regulated in murine atherosclerotic lesions. 
The next aim was to study the functional role in the inflammatory response of macrophages 
and the targets of these macrophages miRs in atherosclerosis, and to assess the effect of a 
miR-based therapy on lesion formation.  
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2 Materials and methods 
All solutions were prepared with UP (Type 1) water (Milli-Q Plus ultrapure purification, 
Millipore, Billerica, USA). The reagents were purchased from Sigma-Aldrich (Steinheim, 
Germany), Carl Roth (Karlsruhe, Germany), Merck (Darmstadt, Germany), and Fluka (Buchs, 
Switzerland) unless stated otherwise in the text. 
2.1 General equipment 
Balance - Sartorius CPA64 (Sartorius mechatronics, Göttingen, Germany) 
Centrifuges - Heraeus multifuge 3S-R (Heraeus, Osterode, Germany) and Hettich 
mikro 200R (Hettich Laborapparate, Germany) 
Microscopes - Leica DMLB (Leica-Microsystems, Wetzlar, Germany) and 
Olympus SZX10 (Olympus optical, Hamburg, Germany) 
Laminar flow hood - Herasafe (Heraeus, Osterode, Germany) 
pH-meter - SCHOTT Instruments Lab 850 (SI Analytics GmbH, Mainz, 
Germany) 
Spectrophotometer - nanoVue plus (GE Healthcare, Uppsala, Sweden) and nanodrop 
1000 (PeqLab, Erlangen, Germany) 
PCR thermocyclers - MyCycler (Bio-Rad, Hercules, USA) and 7900HT fast real-time 
PCR system (Applied Biosystems, Darmstadt, Germany) 
Tissue homogenizer - TissueLyserLT (Qiagen, Hilden, Germany) 
Autoclave - systec 2540EL (systec, Wettenberg, Germany) 
Microtome - Cut 6062 (SLEE medical GmBH, Mainz, Germany) 
Plate reader - microplate reader SpectraFluor Plus (Tecan, Crailsheim, Germany) 
Imaging system - LAS 3000 (Fujifilm, Düsseldorf, Germany) 
Thermoblocks - Exchangeable thermoblocks for slides (Eppendorf AG, Hamburg, 
Germany) 
Thermomixer - Thermomixer comfort (Eppendorf AG) 
Cryostat - Leica CM1860 (Leica-Microsystems) 
Tissue processor MTM I/II (SLEE medical GmbH, Mainz, Germany) 
Embedding center- Leica EG1160 (Leica-Microsystems)
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2.2 Antibodies 
2.2.1 Primary antibodies 
Antigen Clone Host Catalog # Company 
α-SMA 1A4 mouse  M0851 Dako 
MAC2 M3/38 rat  CL8942AP Cedarlane 
vWF F8/86 mouse  ab778 Abcam 
CD31 polyclonal  rabbit  ab28364 Abcam 
CD31 polyclonal  goat  sc-1506 Santa Cruz 
Ki67 TEC-3 rat  M7249 Dako 
PCNA PC10 mouse  ab29 Abcam 
DLK1 polyclonal  rabbit  ABN40 Millipore 
DLK1 EPR3486 rabbit  2880-1 Epitomics 
CD3E polyclonal  rabbit  A 0452 Dako 
CD68 PG-M1 mouse  M 0876 Dako 
Notch1 polyclonal  rabbit  ab8925 Abcam 
MPO polyclonal  rabbit  ab9535 Abcam 
collagen 
type I 
polyclonal  rabbit  CL50151AP Cedarlane 
BCL6 polyclonal  rabbit  ab19011 Abcam 
MCP1 polyclonal  goat  SC-1784 
Santa Cruz 
Biotechnology 
SM22 
alpha 
polyclonal rabbit  ab14106 Abcam 
IgG N/A rat sc-2026 Santa Cruz 
IgG N/A mouse sc-2025 Santa Cruz 
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IgG N/A goat Sc-2028 Santa Cruz 
IgG polyclonal rabbit  ab27472 abcam 
2.2.2 Secondary antibodies  
Antigen Host Catalog # Supplier 
anti-rabbit IgG 
Dylight549-
conjugated 
goat 042-04-15-06 KPL 
anti-mouse IgG 
FITC-conjugated donkey 715-096-150 
Jackson 
immunoResearch 
anti-rat IgG 
FITC-conjugated donkey 712-095-153 
Jackson 
immunoResearch 
anti-mouse IgG 
Dylight488-
conjugated 
goat 072-03-18-06 KPL 
anti-rabbit IgG 
FITC-conjugated donkey 711-095-152 
Jackson 
immunoResearch 
anti-goat IgG 
FITC-conjugated donkey 705-095-147 
Jackson 
immunoResearch 
anti-mouse IgG 
cy3-conjugated donkey 715-165-150 
Jackson 
immunoResearch 
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2.3 In situ hybridization probes 
Probe Label Supplier 
scramble double DIG-labeled Exiqon, Inc. 
miR-126-3p double DIG-labeled Exiqon, Inc. 
miR-126-5p double DIG-labeled Exiqon, Inc. 
miR-155 double DIG-labeled Exiqon, Inc. 
2.4 Buffers and solutions 
20× SSC buffer: 3 M NaCl, 0.3 M Na citrate (pH 7.0). 
Tris/EDTA buffer: 100 mM Tris (pH 7.4), 10 mM EDTA 
 (pH 8.0). 
Ago2-IP lysis buffer: 100 mM KCl, 5 mM MgCl2, 10 mM HEPES (pH 7.0), 0.5% NP40, 5 
mM DTT, 250 U/ml RNase OUT (Invitrogen), 400 μM vanadyl ribonucleoside complexes 
(New England Biolabs), and protease inhibitors (Complete Protease Inhibitor Cocktail 
Tablets; Roche). 
ELISA lysis buffer: 100 mM NaCl, 0.1 mM EDTA, 20 mM Tris (pH-7.4), 10% glycerol, 0.2% 
NP-40, and 0.1% Triton-100 containing protease inhibitors (1 tablet in 10 ml of lysis buffer, 
Roche). 
Citrate buffer: 630 ml UP water, 12.6 ml solution A (2.101 g citric acid in 100 ml UP water), 
57.4 ml solution B (14.70 g sodium citrate in 500 ml UP water), 320 μl Tween 20, pH 6. 
Movat’s staining solutions: 
a) Alcian blue solution (1%):  
1g Alcian blue 8 GX (Sigma A5268) was dissolved in 100 ml of UP water, filtered and 1 
ml of acetic acid was added. 
b) Alkaline ethanol: 
5 ml ammonium hydroxide was mixed with 95 ml of 96% ethanol. 
c) Orcein-Verhoeffschem Hematoxylin solution (stock solution): 
Solution A- 1 g Orcein (Merck, 1071000025), 98 ml 70% ethanol, 1 ml 25% HCL 
Solution B- 8 g Hematoxylin (Sigma, H3136), 160 ml 100% ethanol 
Solution C- 9.6 g Iron (III)-Chloride (Merck, 8039450500), 90 ml UP water 
Solution D- 1 g Iodine, 2 g Potassium iodide, 97 ml UP water  
d) Orcein-Verhoeffschem Hematoxylin solution (working solution):  
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was prepared fresh by mixing: 25 ml solution A, 20 ml solution B, 8 ml solution C, and 8 
ml solution D. 
e) Acidic alcohol: 
1ml 25% HCL was added to 100 ml 95% ethanol. 
f) Brilliant Crocein Scarlet MOO (stock solution): 
Solution A- 0.1 g Brilliant Crocein Scarlet, 0.5 ml Acetic acid, 99.5 ml UP water 
Solution B- 0.1 g Acid fuchsin (Merck, 105231), 0.5 ml Acetic acid, 99.5 ml UP water 
g) Brilliant Crocein Scarlet MOO (working solution): 
Solution A- 40 ml 
Solution B- 10 ml 
h) 0.5% acetic acid: 
1 ml acetic acid was added to 200 ml of UP water. 
i) 6% alcoholic saffron: 
6 g saffron was dissolved in 94 ml absolute ethanol and stored at 56ºC for 48 h before use. 
EVG staining solutions: 
Solution A: 10 g of hematoxylin was dissolved in 100 ml of 96% ethanol 
Solution B: 29% Iron (III)-Chloride solution (145 g of Iron (III)-Chloride was dissolved in 
500 ml of UP water) and 7.5 ml of 37% HCL was added to 950 ml of UP water. 
4% PFA: 
16 g of PFA was added to 184 ml of UP water and dissolved by adding 5 ml of 10 M NaOH 
during heating at 100°C. The pH was decreased to 7.4-8 by adding 25% HCl. Subsequently, 
an equal volume of 2×PBS was added and the solution was filtered through a filter paper. 
Immunofluorescence staining: 
Blocking solution A: 5.4 ml PBS, 600 μl 10% BSA (SERVA Electrophoresis GmbH, 
Heidelberg, Germany) 3 drops 2.5% normal horse serum (Vector laboratories, INC., 
Burlingame, USA) 
Oil red O stock solution: 
1 g Oil red O powder (Sigma-Aldrich, St. Louis, USA) was dissolved in 200 ml 99% 
isopropanol 
Oil red O working solution: 
160 ml Oil-Red-O stock solution was mixed with 120 ml UP water and stored at room 
temperature for 1 h. The solution was filtered through a filter paper. 
2 Materials and methods 
28 
 
2.5 Mouse husbandry 
All mice were housed in a barrier facility and were maintained on a 12 h light-dark cycle 
within the Institute for Laboratory Animal Science of the University Hospital, RWTH 
Aachen. Mice had free access to water and mouse chow. The animal experiments were 
reviewed and approved by local authorities (LANUV NRW) in accordance with the German 
animal protection law. 
2.6 Mouse strains 
MiR-155-/-192 (Jackson Laboratory) and miR-126-/-146 (courtesy provided by Eric Olson, 
University of Texas Southwestern Medical Center, Department of Molecular Biology, Dallas, 
USA) mice were crossed with Apoe-/- mice to obtain miR-155-/-Apoe-/- and miR-126-/-Apoe-/- 
mice. MiR-155+/+Apoe-/- and miR-126+/+Apoe-/- littermate mice served as control in this study.   
2.7 Animal models of atherosclerosis 
2.7.1 Wire-induced injury of the carotid artery 
Female Apoe-/-, miR-126-/-Apoe-/-, and miR-126+/+Apoe-/- mice (8-12 weeks old), which were 
fed a HCD for one week (21% crude fat, 0.15% cholesterol and 19.5% casein, Altromin, 
Germany) were subjected to wire-induced endothelial denudation of the left carotid artery 
using a flexible angioplasty guide wire (0.36 mm diameter). The mice were anesthetized with 
ketamine hydrochloride (80 mg/kg, IP) and xylazine (5 mg/kg, IP), and the left carotid artery 
was surgically exposed. The common, the external, and the internal carotid arteries were 
transiently ligated to interrupt the blood flow. The angioplasty guide wire inserted into the 
CCA via a transverse arteriotomy made in the ECA. The wire was advanced by 1 cm and 
moved back and forth 3 times in a rotating motion resulting in endothelial denudation of the 
CCA. After removal of the wire, the ECA was completely ligated and the blood flow restored 
through the common and the ICA193 (Fig. 9).  
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Figure 9: Wire-induced endothelial denudation of carotid arteries: Blood flow was transiently interrupted by 
ligating the CCA, the ECA and the ICA. Endothelial denudation of the CCA was achieved by 3 rotational passes 
using an angioplasty guide wire inserted into the ECA. The blood flow was restored through the CCA and the 
ICA. The ECA was permanently occluded. 
2.7.2 Diet-induced atherosclerosis 
Apoe-/-, miR-126-/-Apoe-/-, and miR-126+/+Apoe-/- mice (6-8 weeks old) were fed a HCD for 3 
or 10 months before sacrifice. To harvest the aortic tissues, perfusion fixation with 4% PFA or 
RNAlater was performed as stated in section 2.7.5. The carotid arteries and aortic roots were 
dissected and kept in formalin over night at 4ºC. On the following day, the samples were 
dehydrated and paraffin embedded (see also section 2.10.1.1). Blood was taken before the 
perfusion fixation by cardiac puncture for blood cell count and serum lipid measurements. 
The aortas were used for quantification of lipid deposition in the aortic wall by Oil red O 
staining (see also section 2.11). 
2.7.3 Partial ligation of the carotid artery 
Mice were anesthetized by ketamine hydrochloride (80 mg/kg, IP) and xylazine (5 mg/kg, IP). 
The left external carotid, internal carotid, and occipital arteries were ligated to restrict the 
blood outflow of the CCA through the STA. This model resulted in acutely decreased blood 
flow velocity and in turn reduced shear stress in the CCA194 (Fig. 10). The mice were fed a 
HCD after the partial ligation.  
The left and right carotid arteries were harvested 6 weeks after partial ligation 
following in situ perfusion with RNAlater (Ambion), PFA, or PAXgene Tissue Fix (PAXgene 
Tissue Containers; Qiagen) through the left ventricle as stated in section 2.7.5. The carotid 
arteries were harvested and either used for RNA isolation or tissue fixation and paraffin 
embedding (see also section 2.10.1.1). 
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Figure 10: Schematic illustration of partial ligation of the left carotid artery. ICA, internal carotid artery; 
ECA, external carotid artery; OA, occipital artery; STA, superior thyroid artery; RCA, right carotid artery; LCA, 
left carotid artery; RSA, right subclavian artery, LSA, left subclavian artery (image is from194). 
2.7.4 Bone marrow transplantation  
To study the role of macrophages in miR-mediated atherogenesis, BM cells from donor 
animals were transplanted into recipient mice (6-8 weeks). Recipient mice were subjected to 
an ablative dose of whole body irradiation (2×6.5 Gy, 4 h apart, Faxitron CP-160). 24 h 
following the irradiation, femurs and tibias were removed aseptically from donor mice. The 
marrow cavities were flushed with sterile PBS and a single cell suspension was prepared by 
pipetting the cells up and down repeatedly followed by passing the cells through a cell strainer 
(40 μm, BD Falcon) to remove any large pieces of tissue or bone which may be present. BM 
cells (5 to 10 million cells/mouse) were injected via the tail vein into recipient mice, which 
were fixed in a mouse strainer. Endoluminal denudation or partial ligation of the carotid artery 
was performed 4 weeks following BM transplantation (see also section 2.7.1/3).  
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2.7.5 Perfusion fixation 
Mouse tissues were harvested following in situ perfusion with RNAlater (Ambion), 4% PFA, 
or PAXgene Tissue Fix (PAXgene Tissue Containers; Qiagen). The animals were 
anesthetized with ketamine hydrochloride (80 mg/kg, IP) and xylazine (5 mg/kg, IP). Blood 
was taken by cardiac puncture for serum lipid measurements. The abdominal and chest 
cavities were opened. A catheter was inserted into the left ventricle through an incision in the 
apex. PFA (4%, 5 ml) was perfused using a syringe pump (Aladdin-1000, World Precision 
Instruments, Inc, 336 μl/min) for 10 min through the left ventricle and the solution was 
allowed to flow out through an incision in the right atrium. The carotid arteries were 
harvested and kept in formalin over night at 4ºC. On the next day, the samples were 
dehydrated and embedded in paraffin (see also section 2.10.1.1).  
To perform cryosectioning, the PAXgene-fixed carotid arteries were snap-frozen in 
liquid nitrogen and embedded in OCT (Tissue Tek, Sakura). OCT provides a matrix for 
cryostat sectioning at temperatures of -10°C and below. Sections (7-10 µm thick) were cut in 
the pre-cooled cryostat at −20°C and were transferred to a poly-L-lysine-coated microscope 
slide (Thermo scientific) at rt.  
PAXgene Tissue Fix is a novel fixation system without destructive nucleic acid 
crosslinking and degradation, which preserves morphology and nucleic acids. It includes the 2 
components PAXgene Tissue Fix, which rapidly penetrates and fixes the tissue, and PAXgene 
Tissue Stabilizer in which nucleic acids and morphology of the tissue are stable for up to 7 d 
at room temperature and for longer periods at 2-8°C or -20°C. To perfuse the animals with 
Paxgene Tissue Fix, the right atrium was cut and a needle connected to a 1 ml syringe was 
inserted into the left ventricle. The vascular system was then first perfused with 1 ml ice-cold 
PBS to remove blood and subsequently with 1 ml PAXgene Tissue Fix solution. After the 
perfusion, tissues were harvested and placed in PAXgene Tissue Fix solution for 2-4 h at rt. 
Following fixation, tissues were removed from the PAXgene Tissue Fix solution and 
transferred to the PAXgene Tissue Stabilizer solution. Stabilized samples were embedded in 
paraffin for histological studies. 
To stabilize RNA, the vascular tree was flushed with 0.5-1 ml RNAlater solution 
(Ambion). After this perfusion, tissues were dissected and placed in RNAlater solution. 
Samples were stored in RNAlater solution for 1-21 d at 4ºC before the RNA was isolated for 
qRT-PCR analysis. All instruments used during organ dissection were first treated with 
RNaseZap® (Ambion, Austin, TX, USA) to remove RNAses according to the manufacturer’s 
instructions.  
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2.7.6 Perivascular treatment 
To study loss-of-function in vivo, injured or partially ligated carotid arteries were treated 
perivascularly with small interfering RNAs or antisense oligonucleotides (siRNAs for 
mRNAs or antagomiRs for miRs) dissolved in a drug carrier, called pluronic gel. Pluronic F-
127 also known as poloxamer 407 is a hydrophilic non-ionic surfactant195, which mediates 
continuous release of compounds into the tissue. Pluronic F-127 consists of a hydrophobic 
block of polypropylene glycol in the center flanked by two hydrophilic blocks of polyethylene 
glycol. Due to the presence of both hydrophilic and hydrophobic molecules, at low 
concentrations they form monomolecular micelles and at high concentrations they form 
multimolecular aggregates195. Pluronic F-127 is a thermo-reversible gel that is liquid at low 
temperatures (4-5ºC) and becomes a gel upon warming to rt195. At low temperatures in an 
aqueous solution, a hydration layer surrounds the pluronic F-127 molecules. When the 
temperature is increased, the hydrogen bonds between the solvent and the hydrophilic chains 
of the pluronic F-127 molecules are broken, which results in hydrophobic interactions 
between the polypropylene domains and thus gel formation195. Pluronic gel (50%, Sigma 
Aldrich) was prepared by dissolving 5 g of pluronic F-127 powder in 10 ml of sterile water by 
continuous stirring at 4ºC. Subsequently, the pluronic gel was filter sterilized with a sterile 
syringe filter (pore size of 0.20 μm, Corning). In addition, a transfection reagent 
(DharmaFECT4, Thermo scientific) was diluted 50 times with sterile PBS (Dulbecco) and 
kept on ice until use. The siRNA and antisense oligonucleotides were dissolved in RNase free 
water (Bioo Scientific) and 5 μl aliquots were prepared. Aliquots were mixed with 0.5 μl of 
the diluted transfection reagent and kept on ice for 10 min. Then, 14.5 μl of the 50% pluronic 
gel was mixed with the 5.5 μl of the RNA silencer solution containing transfection reagent to 
achieve a final pluronic gel concentration of 35%.  This solution was applied perivascularly 
on the left carotid arteries (wire injured or partially ligated). The animal were anesthetized (80 
mg/kg ketamine hydrochloride, 5 mg/kg xylazine, IP) and fixed on the working table. The left 
carotid artery was exposed after cutting the skin in the left lateral anterior neck (carotid 
triangle) region, by moving the fat tissue and muscle covering the artery to the side. Pluronic 
gel (20 µl, 35%) containing the oligonucleotides were placed around the CCAs. Subsequently, 
the fat tissue and muscle were restored to its original position and the skin was closed using 
wound clips (Braun). This perivascular treatment of the carotid arteries was performed once a 
week. At the end of experiment, perfusion fixation with 4% PFA or PAXgene Tissue Fix 
(PAXgene Tissue Containers; Qiagen) was performed (see section 2.7.5). The carotid arteries 
were harvested and kept in formalin or PAXgene tissue fix over night at 4ºC and the next day 
the samples were dehydrated and paraffin embedded (see also section 2.10.1.1).  
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2.7.6.1 Antagomir treatment  
Antagomirs are novel class of chemically engineered, cholesterol-modified antisense RNA 
oligonucleotides that specifically inhibit endogenous miRs in mice196. To study the role of 
specific miR-126 strands in atherosclerosis, antisense RNA oligonucleotides with 2'-OMe-
modified nucleotides, a partial phosphorothioate backbone, and a cholesterol group at the 3' 
side were synthesized against miR-126-5p, miR-126-3p, and miR-342-5p (Dharmacon, Inc.). 
The control antagomir contained a random sequence of nucleotides not complementary to any 
known miR (Dharmacon, Inc.) (Table 1). Perivascular antagomir treatment of the carotid 
arteries in Apoe-/- mice (6-8 weeks old) was started 1 week after wire-induced injury or partial 
ligation (160 μg dissolved in 35% pluronic gel). Briefly, 5 μl antagomir aliquots were mixed 
with 15 μl pluronic gel (50%). This solution, containing 35% pluronic gel and antagomirs, 
was applied once per week perivascularly around the wire-injured or partially ligated carotid 
arteries (3 and 5 treatments per mouse after vascular injury and partial ligation of carotid 
arteries, respectively) (see also section 2.7.6).  
 
Target miR Antagomir sequence 
miR-126-5p 5'-mC(*)mG(*)mCmGmUmAmCmCmAmAmAmAmGmUmAmAmUmA(*) mA(*)mU(*) mG(*)-Chol-3' 
miR-126-3p 5'-mC(*)mG(*)mCmAmUmUmAmUmUmAmCmUmCmAmCmGmGmU 
mA(*)mC(*) mG(*)mA(*)-Chol-3' 
miR-342-5p 5'-mC(*)mU(*)mCmAmAmUmCmAmCmAmGmAmUmAmGmCmAmCmC 
(*)mC(*)mC(*)mU(*)-Chol-3', 
control 
5'-mA(*)mU(*)mGmAmCmUmAmUmCmGmCmUmAmUmUmCmGmC(*) 
mA(*)mU(*) mG(*)-Chol-3' 
Table 1: List of antagomirs used for strand specific miR silencing: m, 2'-OMe-modified 
nucleotides; (*), a partial phosphorothioate backbone; and Chol, a cholesterol group. 
2.7.6.2 siRNA application 
One week following endothelial denudation of the carotid artery (miR-126-/-Apoe-/- or miR-
126+/+Apoe-/- mice), siRNA against Dlk1 was applied perivascularly to the injured artery. The 
carotid arteries were harvested one week after siRNA treatment (see also section 2.7.5-6).  
Left carotid arteries of Apoe-/- mice were subjected to partial ligation, followed by 
perivascular treatment with siRNA against Dlk1 (after 1 week) or Bcl6 (after 2 weeks) once 
weekly. The left and right carotid arteries were harvested 6 weeks after partial ligation (see 
also section 2.7.3/5/6). 
For all siRNA experiments the mice in the control group were treated with non-
targeting siRNA. Moreover, 4 nmol of siRNA (Accell siRNA, Dharmacon) was used per 
treatment in all experiments.  
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2.7.7 Systemic treatment with miR mimics 
MiRs are transferred between cells via apoptotic bodies or microparticles, which indicates that 
packaging of miRs in membrane-based structures is an efficient way for the intercellular 
transport151 197 198. Trang and colleagues recently provided evidence that miR mimics can be 
delivered systemically via a nanoparticle carrier system, called neutral lipid emulsion (NLE), 
to inhibit tumor growth in mice199. Thus, systemic delivery of synthetic miRs mimics 
packaged in lipid nanoparticles is a promising approach for miR-based therapy199-201. In the 
current study, miR-126-5p mimics were packed in NLE and used for systemic treatment of 
miR-126-/-Apoe-/- or miR-126+/+Apoe-/- mice. MiR mimics are small, synthetic, chemically 
modified dsRNAs that mimic endogenous miRs and enable miR functional analysis by up-
regulation of miR activity. MiR-126-5p mimic or negative control miRs (mirVana™ miRNA 
mimics, Applied Biosystems) were packaged in a nanoparticle carrier system (MaxSuppressor 
In Vivo RNA Lancer Kit, BIOO Scientific) according to the manufacturer’s instructions. The 
carrier system is composed of neutral lipid, non-ionic detergent, and oil and enables highly 
efficient delivery of miRs into animals201. MiR-126-/-Apoe-/- or miR-126+/+Apoe-/- mice on a 
HCD were treated with miR-126-5p or negative control mimics (every 72 h, 100 μg per 
injection, IV) for 4 weeks. In miR-126-/-Apoe-/- and miR-126+/+Apoe-/- mice, partial ligation of 
the carotid artery was performed. Arteries and aortic roots were fixed using PAXgene Tissue 
Fix (PAXgene Tissue Containers, Qiagen). The aortas were used for quantification of lipid 
deposition in the aortic wall by Oil red O staining (see also section 2.7.5 and 2.10.1.1). 
2.7.8 Serum analysis 
After scarifying the animals, approximately 500-700 μl of blood was collected in serum 
separating tubes (SST, Sarstedt) and allowed to clot at rt for 2 h. Subsequently, the tubes were 
centrifuged at 2000g for 20 min and the serum in the supernatant was collected and stored at  
-20oC.  
2.8 Human carotid lesion samples 
Specimens from human atherosclerotic lesion were collected during carotid endarterectomy 
(Dr. J. Grommes, European Vascular Center Aachen-Maastricht, RWTH Aachen University, 
Aachen, Germany, and Medical University Maastricht, Maastricht, The Netherlands). One 
half of each carotid artery plaque was either immediately shock-frozen in liquid nitrogen or 
stored in RNAlater solution (Ambion), and the other half was fixed in PFA. Frozen carotid 
artery specimens were dissected macroscopically into plaques and non-atherosclerotic artery 
wall specimens in liquid nitrogen using a scalpel. The dissected frozen and the RNAlater-
preserved samples were used for RNA analysis (see also section 2.15). PFA-fixed samples 
were embedded in paraffin and used for immunohistochemistry analysis (see also section 
2.10.1.1).  
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The Ethics Committee of the Medical Faculty (RWTH Aachen University) 
approved the study protocol for the collection of human atherosclerotic plaque samples, and 
written informed consent was obtained from all participating subjects. 
2.9 Laser capture microdissection (LCM) 
All equipment used for sectioning, such as microtome and knife, forceps, and water bath was 
first treated with RNaseZap® (Ambion, Austin, TX, USA). Serial sections (20 μm thick) of 
the carotid and brachiocephalic arteries and the aortic roots were mounted on membrane-
mounted metal frame slides (Molecular Machines and Industries). Sections were 
deparaffinized and rehydrated under RNase-free conditions according to the following 
procedure: 
1. Xylol for 3 min (2×). 
2. 100% isopropanol for 3 min (2×). 
3. 96% isopropanol for 3 min. 
4. 70% isopropanol for 3 min. 
After deparaffinization, the sections were completely dried. Laser capture 
microdissection was performed using a laser microdissection system (MMI cell cut plus; 
Molecular Machines and Industries, Switzerland) attached to an inverted microscope (IX71; 
Olympus). At least 40 sections of plaque tissue or morphologically normal vessel wall tissue 
were collected from each mouse. RNA was isolated using the RecoverAll total nucleic acid 
isolation kit (Life Technologies) according to the manufacturer’s instructions. 
2 Materials and methods 
36 
 
2.10 Lesion characterization  
2.10.1 Histochemistry 
2.10.1.1 Paraffin embedding, sectioning, and deparaffinization 
To quantify the lesion size, samples (arteries and aortic roots) were harvested from mice 
following in situ perfusion and fixation. Next, tissues were dehydrated using tissue processor 
and embedded in liquid paraffin (approximate temperature 60ºC) according to the following 
protocol (see also section 2.1): 
1. 70% Ethanol, 30 min, 20ºC 
2. 70% Ethanol, 30 min, 20ºC 
3. 96% Ethanol, 30 min, 20ºC 
4. 96% Ethanol, 30 min, 20ºC 
5. 100% Ethanol, 30 min, 20ºC 
6. 100% Ethanol, 30 min, 20ºC 
7. 100% Ethanol, 30 min, 20ºC 
8. Xylol, 30 min, 45ºC 
9. Xylol, 30 min, 45ºC 
10. Xylol, 30 min 45ºC 
11. Paraffin, 30 min, 62ºC 
12. Paraffin, 30 min, 62ºC 
13. Paraffin, overnight, 62ºC 
The paraffin blocks were allowed to harden at 0°C (Leica EG1160) before 
sectioning using a microtome (see also section 2.1). Serial sections (5 μm thick) from the 
common carotid artery were collected on glass slides (Superfrost plus glass slides, Thermo 
Scientific, Braunschweig, Germany) within 1 mm of the area of bifurcation. The aortic root 
sections were collected when the first valve was visible. After sectioning, the slides were 
incubated in a 37ºC incubator for 5-6 h or at rt overnight to reduce detachment of the tissue 
during staining. 
To measure lesion size, Movat’s pentachrome or EVG staining was performed. 
Cross sections of the carotid artery (3-5 per mouse) obtained at a standardized distance (50 to 
100 μm) starting from the bifurcation and aortic root (3-5 per animal) with 3 valves was 
selected for staining. Deparaffinization and rehydration of the sections was performed 
according to the following protocol before staining: 
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1. Xylol for 30 min. 
2. 100% isopropanol for 5 min. 
3. 100% isopropanol for 5 min. 
4. 96% isopropanol for 5 min. 
5. 70% isopropanol for 5 min. 
6. UP water for 5 min. 
7. PBS for 5 min. 
2.10.1.2 Movat’s pentachrome staining  
1. Alcian blue solution (1%) for 20 min (see also section 2.4) 
2. Tap water for 5 min 
3. Alkaline ethanol for 10 min at 56ºC (see also section 2.4) 
4. Running tap water for 2 min 
5. Orcein-Verhoeffschem Hematoxylin solution for 30 min at 37ºC (see also section 2.4) 
6. Washing in running tap water for 3 min 
7. 2% Iron (III)-Chloride for 2 min 
8. Acidic alcohol for 2 min (see also section 2.4) 
9. Washing in tap water for 5 min 
10. Brilliant Crocein Scarlet MOO solution for 10 min (see also section 2.4). 
11. 0.5% acetic acid for 30 seconds (see also section 2.4)  
12. 5% phosphor-tungstic acid for maximum 4 min 
13. 0.5% acetic acid for 30 seconds 
14. 100% ethanol (3× 1 min) 
15. 6% alcoholic saffron for 8-15 min (see also section 2.4) in a closed container 
16. Dehydration in 100% ethanol (2× 3 min) 
17. Finally, the sections were dipped in xylol and mounted in Vitrocloud (Langenbrinck) 
2.10.1.3 EVG staining  
1. Resorcein-fuchsin solution (Roth, X877.1) for 15 min at 56ºC 
2. Tap water (1-2×). 
3. 80% ethanol 
4. Tap water  
5. UP water 
6. Solution A+B [100 ml solution A and 100 ml solution B, freshly prepared (see also 
section 2.4)] for 5 min 
7. 0.5% HCl-alcohol  
8. Tap water  
9. Picrofuchsin (Merck, 1.15974/4) for 1 min  
10. Tap water  
11. 70% ethanol 
12.  96% ethanol 
13. 100% ethanol for 3 min  
14. Xylol for 5 min 
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15. Sections were mounted in Vitrocloud 
2.10.1.4 Image acquisition and planimetry 
Images were obtained under a bright field microscope (Leica DMLB) connected to a CCD 
camera (JVC). The lesion area was quantified by planimetry of the luminal area, and the area 
enclosed by the IEL or EEL (Diskus software, Hilgers, Bonn). The lesion size was calculated 
by subtracting the lumen area from the area enclosed by the IEL. The medial area was 
measured by subtracting the area enclosed by the IEL from the area enclosed by the EEL (Fig. 
11). 
 
 
 
Figure 11: Morphometric analysis of the CCA. 
2.11 Oil red O staining 
The lipid area in the aorta was detected using Oil red O staining. The entire aorta including 
the aortic arch and the abdominal aorta was dissected using a dissection microscope and 
pinned with needles onto a rubber slide for fixation in 4% PFA ON. Next, the aortas were cut 
longitudinally and the adventitia was removed carefully. The cut aortas were then en face 
prepared by pinning it with the luminal surface upside on the rubber slides. The pinned aortas 
were dipped in 60% isopropanol for 15 to 20 seconds followed by incubation in Oil red 
working solution (see also section 2.4) for 15 min. Subsequently, the aortas were immersed in 
60% isopropanol for 10 to 15 seconds. Finally, the aortas were rinsed with tap water, mounted 
in glycerol gelatin (diluted 3:7 with tap water, Sigma), and covered using a cover slip after 
removal of the needles. The microscopic images were taken with a bright-field microscope 
and using DISKUS software (Hilgers). The area of the stained lipid deposition in the aortic 
wall was quantified in digitized images using ImageJ software (ImageJ 1.43n, NIH, USA). 
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The total aortic area was determined by planimetry and the percentage of the positively 
stained area was calculated. 
2.12 Immunofluorescence staining 
To study the lesion composition, quantitative immunostaining was performed in 
deparaffinized sections (5 μm thick) using antibodies against α-SMA, SM22, MAC2, vWF, 
CD31, CD68, CD3E, MPO, and collagen type I. In addition, double immunofluorescence 
stainings for DLK1, Ki67, or PCNA with endothelial-specific antibodies against CD31 or 
vWF was performed. Activated NOTCH1 in ECs was detected using an antibody against 
cleaved NOTCH1 followed by an anti-vWF antibody (Table 2, see also section 2.2.1). 
Moreover, combined immunostaining for CCL2/MAC2 or BCL6/MAC2 was performed by 
sequential incubation of the sections with either an anti-CCL2 antibody or an anti-BCL6 
antibody and an MAC2 antibody (Table 3, see also section 2.2.1).  
Combined TUNEL assay and MAC2 staining was performed in some of the carotid 
artery sections. TUNEL staining was done according to the kit protocol (In situ cell death 
detection kit, TMR red, Roche). The TUNEL assay detects and quantifies the apoptosis at the 
single cell level, based on non-radioactive labeling of DNA strand breaks. Briefly, the 
deparaffinized sections were permeabilized by cooking in 0.1 M citrate buffer (pH 6) for 20 
min. Then, the sections were incubated with the freshly prepared TUNEL reaction mixture 
(containing label and enzyme solution) in a humidified chamber in the dark at 37°C for 15 
min. Following TUNEL staining, the sections were used for MAC2 immunostaining.  
Oil red O and MAC2 double staining was performed in frozen carotid artery 
sections (see also section 2.7.5). The sections were stained with Oil red O stain (see also 
section 2.9.1) before MAC2 immunostaining was performed. Negative control antibodies 
were used to check the specificity of the antibodies being used (see also section 2.2.1).  
To detect the primary antibody, fluorescently conjugated secondary antibodies 
(FITC, Cy3, Dylight488, or Dylight549) were used (Table 3, see also section 2.2.2). The 
nuclei were counterstained with DAPI. Digital images were acquired with a fluorescence 
microscope (Leica, DMLB) connected to a CCD camera (JVC) (see also section 2.1). The 
percentage of the positively stained area or cell number (2–3 sections/mouse, 50- to 100 μm 
distance between sections) was quantified using image analysis software (ImageJ). The 
background of negative control staining was used to adjust the threshold. In addition, the 
number of immunostained cells in the plaques was determined by counting DAPI positive 
nuclei within the immunostained area. The number of the immunostained cells was expressed 
as the absolute cell number in the plaques or as the percentage of total plaque cells. 
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Antigen Antigen retrieval Blocking Primary Ab Detection system 
α-SMA none Blocking solution A*, 30 min 1:200, 4ºC, ON 
donkey-anti-mouse IgG, 
FITC-conjugated, 1:100, 
30 min 
MAC2 none Blocking solution A*, 30 min 1:400, 4ºC, ON 
donkey-anti-rat IgG-FITC-
conjugated, 1:100, 30 min 
SM22α none 10% goat serum, 30 min 1:200, 4ºC, ON 
goat-anti-rabbit IgG, 
Dylight549-conjugated, 
1:200, 30 min 
vWF CB, 20 min at 100ºC 
Blocking solution 
A*, 30 min 1:1000, 4ºC, ON 
goat-anti-rabbit IgG-
Dylight549-conjugated, 
1:200, 30 min 
CD31 CB, 20 min at 100ºC 
Blocking solution 
A*, 30 min 1:75, 37ºC, 2 h 
anti-goat Cy3-conjugated, 
1:300, 30 min 
Collagen 
type I 
CB, 20 min at 
100ºC 
Blocking solution 
A*, 30 min 1:400, 4ºC, ON 
anti-rabbit Cy3-
conjugated, 1:300, 30 min 
CD3 CB, 20 min at 100ºC 
10% goat serum, 30 
min 1:100, 4ºC, ON 
goat-anti-rabbit IgG-
Dylight549-conjugated, 
1:400, 30 min 
MPO CB, 20 min at 100ºC 
Blocking solution 
A*, 30 min 1:50, 4ºC, ON 
anti-rabbit Cy3-
conjugated, 1:300, 30 min 
CD68 CB, 20 min at 100ºC 
1. Blocking solution 
A*, 30 min  
2. Avidin/ biotin 
solution*, rt 
1:100, 4ºC, ON 
anti-mouse-biotinylated, 
1:100, 30 min, 
Streptavidin-Dylight488- 
conjugated, 1:100, 30 min 
Table 2: Immunostaining protocols: CB = Citrate buffer; Ab details are provided in sections 2.2.1-2; 
* see section 2.4 for more details.
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Antigen Antigen retrieval Blocking 
1st 
primary 
Ab 
1st secondary Ab 
2nd 
primary 
Ab 
2nd secondary 
Ab 
PCNA/CD31 
CB, 
2×10 min 
(100ºC) 
1. Blocking 
solution A*, 
30 min  
2. Avidin/ 
biotin 
solution*, rt 
PCNA, 
1:6000, 
37ºC, 2 h 
anti-mouse-
biotinylated, 1:100, 
30 min, Streptavidin-
Dylight488- 
conjugated, 1:100, 30 
min 
CD31, 
1:75, 37ºC, 
2 h 
anti-goat Cy3, 
1:300, 30 min 
Ki67/ 
CD31 
CB, 
1×17 min 
(100ºC) 
as for 
PCNA/CD3
1  
Ki67,  
1:25, 
4ºC, ON 
anti-rat-biotinylated, 
1:100, 30 min, 
Streptavidin-
Dylight488- 
conjugated, 1:100, 30 
min 
CD31, 
1:75, 37ºC, 
2 h 
anti-goat Cy3, 
1:300, 30 min 
Dlk1/CD31 
CB, 
1×15 min 
(100ºC) 
Blocking 
solution A*, 
30 min 
avidin/biotin 
solution*, rt 
Dlk1, 
1:75, 2 h, 
37ºC 
anti-rat-biotin, 1:100, 
30 min Streptavidin-
Dylight549- 
conjugated, 1:500, 30 
min 
goat CD31 
Ab, 1:75,  
37ºC, 2 h 
anti-goat-
biotin, 1:100, 
30 min, 
Streptavidin-
Dylight488- 
conjugated, 
1:100, 30 min 
Dlk1/vWF 
CB, 
2×10 min 
(100ºC) 
Blocking 
solution A*, 
30 min 
avidin/biotin 
solution*, rt 
Dlk1, 
1:75, 2 h, 
37ºC 
anti-rat-biotin, 1:100, 
30 min, Streptavidin-
Dylight549- 
conjugated, 1:500, 30 
min 
rabbit vWF 
Ab, 
1:1000, 
4ºC, ON 
anti-rabbit-
IgG-FITC 
conjugated,  
1:100, 30min 
Notch1/MAC2 
Tris/EDT
A 
buffer* 
2×10 min 
(100°C) 
Blocking 
solution A*, 
30 min, rt 
Notch1, 
1:10.000, 
4ºC, ON 
Goat-anti-rabbit 
Dylight549-
conjugated, 1:200, 
30min 
MAC2, 
1:400, 
37°C, 2h 
anti-rat-IgG-
FITC 
conjugated,  
1:100, 30min 
CCL2/MAC2 - 
Blocking 
solution A*, 
30 min, rt 
MCP1/C
CL2, 
1:100, 
4ºC, ON 
anti-goat-IgG-FITC-
conjugated, 1:100, 1 
h 
MAC2, 
1:400, rt, 1 
h 
anti-rat Cy3, 
1:300, 30 min 
Ki67/vWF 
CB, 
1×15 min 
(100ºC) 
Blocking 
solution A*, 
30 min 
avidin/biotin 
solution*, rt 
Ki-67, 
1:25, 
4ºC, ON 
anti-rat-biotin, 1:100, 
30 min, Streptavidin-
Dylight488- 
conjugated, 1:200, 30 
min 
vWF 
1:1000, 
37°C, 3-5h 
goat-anti-
rabbit IgG-
Dylight549- 
conjugated, 
1:200, 30 min 
Bcl6/MAC2 
CB, 
1×17 min 
(100ºC) 
Blocking 
solution A*, 
30 min, rt 
Bcl6, 
1:20, 
4ºC, ON 
Goat-anti-rabbit 
Dylight 549-
conjucated, 1:400, 30 
min 
MAC2, 
1:400, 
37°C, 2h 
anti-rat-IgG-
FITC-
conjugated, 
1:100, 30min 
Notch1/vWF 
Tris/EDT
A 
buffer*, 
2×10 min 
Blocking 
solution A*, 
30 min, rt 
Notch1, 
1:10.000, 
4ºC, ON 
Goat-anti-rabbit 
Dylight 549-
conjucated, 1:200, 30 
min 
vWF, 
1:1000, 
37°C, 3-5h 
anti-rabbit-
IgG-FITC 
conjugated,  
1:100, 30min 
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(100ºC) 
Table 3: Double-immunostaining protocols: Ab information are listed in sections 2.2.1-2; * see 
section 2.4 for more details. 
2.13 In situ hybridization  
Sections (7 μm thick) from carotid arteries fixed with PAXgene (Qiagen) and paraffin-
embedded were hybridized with double digoxigenin (DIG)-labeled probes (50 nM miR-126-
5p; 25 nM miR-126-3p; 50 nM and 25 nM scrambled; 50 nM miR-155 probes; 5 nM U6 in 
hybridization buffer, Exiqon) at 52°C (miR-126-3p, U6, and scrambled), 42°C (miR-126-5p 
and scrambled), or 51°C  (miR-155 and U6; scrambled) for 1 h in a Thermoblock 
(Eppendorf). After stringency washes with SSC buffer, and blockade of nonspecific and 
avidin/biotin binding sites using TNB (Perkin Elmer) and a avidin/biotin blocking kit (Vector 
Lab), respectively, sections were incubated with a peroxidase-conjugated anti-DIG antibody 
(Fab fragments from sheep, Roche, 1:100) for 1 h at 37°C. A tyramide-based amplification 
system (TSA Plus Biotin, Perkin Elmer) and Dylight549-conjugated streptavidin (KPL) were 
used to visualize the probes. To combine in situ hybridization of miR-155 with macrophage- 
and SMC-specific immunostainings, sections were subsequently incubated with anti-MAC2 
or anti-α-SMA antibodies followed by a FITC-conjugated secondary antibody. 
2.14 Global gene expression analysis by DNA 
microarray 
Two weeks after vascular injury, carotid arteries of miR-126-/-Apoe-/- and miR-126+/+Apoe-/- 
mice were harvested following in situ perfusion with RNAlater (see also section 2.7.5). Total 
RNA was isolated using RNeasy micro Kit (Qiagene). The quality of the RNA samples was 
checked by 2100 Bioanalyzer (Agilent Technologies). Bioanalyzer allows for analysis of total 
RNA samples by capillary electrophoresis. The RNA is separated according to fragment size, 
and results are returned as electropherograms and virtual gel images. An index for RNA 
quality, the RIN, is derived from the electrophoretic profile. The RIN scale ranges from 1 to 
10. A RIN of 10 denotes an excellent RNA quality, while a RIN value of 1 indicates massive 
degradation. For RIN calculation, the algorithm does not rely on the 28S/18S-rRNA ratio 
alone, but takes into account the entire electrophoretic profile (e.g., the fraction of short 
degraded RNA species). All samples were analyzed using RNA 6000 Nano LabChip Kits 
(Agilent Technologies). The samples with RIN ≥ 7.5 were used for the array. A one-color-
based hybridization protocol was applied (IMGM Laboratories, Munich) using SurePrint G3 
Mouse GE Microarrays (8x 60K format, Agilent). Quantile normalization and analysis of the 
raw data were performed using GeneSpring GX11.5 software (Agilent). Potential target genes 
of miR-126-5p and miR-126-3p were identified among the up-regulated genes (> 2-fold) 2 
weeks after injury in carotid arteries of miR-126-/-Apoe-/- mice. Array data have been 
deposited in the National Center for Biotechnology Information Gene Expression Omnibus 
(GEO; http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO series accession 
number GSE34262.  
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2.15 MiR real-time PCR array 
Total RNA was isolated from tissues collected by LCM, from carotid arteries, from whole 
aorta, and from cultured BMDMs using mirVana kit (Applied Biosystems) according to the 
standard protocol of kit. Briefly, the samples were disrupted and lysed in a denaturing lysis 
buffer, which stabilizes RNA and inactivates RNases. Next, the lysate were subjected to Acid-
Phenol:Chloroform extraction, which removes most of DNA and the other cellular 
components. The semi-pure RNA extract was further purified over a glass-fiber filter to yield 
total RNA. The quality of the RNA samples was determined using an Agilent 2100 
Bioanalyzer (Agilent Technologies, Inc.) (see also section 2.14). RNA samples with RIN ≥ 8 
were used for the array. Reverse transcription and preamplification was performed using the 
Megaplex RT & Preamp Rodent Pool Set (Life Technologies) according to the 
manufacturer’s instructions. Briefly, TaqMan microRNA revers transcription kit (Applied 
biosystems) and the Megaplex rodent RT primers (Life technologies) were used to synthesize 
single-stranded cDNA. To perform reverse transcription, 3 μL (1 to 350 ng) total RNA were 
added to the 4.5 μL of RT reaction mix. The RT reaction was carried out under the following 
thermal cycling conditions: 
Stage Temp Time 
Cycle 
(40 Cycles) 
16 °C 2 min 
42 °C 1 min 
50 °C 1 sec 
Hold 85 °C 5 min 
Hold 4 °C ∞ 
 
Next, the cDNA samples were preamplified using Megaplex rodent 
preamplification primers and Taqman preamplification master mix (Life technologies). To 
prepare the preamplification reaction 2.5 μL RT product were added to 22.5 μL 
preamplification reaction mix. Preamplification reaction was performed under the following 
conditions:
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Stage Temp Time 
Hold 95 °C 10 min 
Hold 55 °C 2 min 
Hold 72 °C 2 min 
Cycle 
(12 Cycles) 
95 °C 15 sec 
60 °C 4 min 
Hold‡ 99.9 °C 10 min 
Hold 4 °C ∞ 
‡ Required for enzyme inactivation. 
Preamplified products were diluted using 75 μL of 0.1x TE pH 8.0. In order to run 
the real time PCR reaction the PCR mix was prepared according to following protocol: 
Component Volume for one array (µl) 
Taqman universal PCR master 
mix, no ampErase UNG, 2x 450 
Diluted preamplified product 9 
Nuclease-free water 441 
Total 900 
 
Finally, the samples were loaded onto preconfigured 384-well microfluidic cards 
(TaqMan Array MicroRNA Cards) for real-time analysis of 518 mouse miRs (Sanger 
miRBase v10) using a 7900HT RT-PCR System (Life Technologies) according to the 
template CD provided by the company. The thermal cycling conditions are summarized 
below: 
Stage Temp Time 
Hold 50 °C 2 min 
Hold 94.5 °C 10 min 
Cycle 
(40 Cycles) 
97 °C 30 sec 
59.7 °C 1 min 
 
Data were analyzed using StatMiner software (Integromics) according to the ΔΔCt 
method using multiple internal control genes. The most stable combination of internal 
controls was selected using the Genorm algorithm. Ct values ≥ 40 were considered beyond the 
limit of detection of the individual miRs. The fold change in the expression of the miRs was 
calculated between the experimental groups and logarithmically transformed (Log10). Array 
data were deposited in GEO (http://www.ncbi.nlm.nih.gov/ geo/; accession numbers 
GSE34644, GSE34645, GSE26555, GSE26557 and GSE33453). 
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2.16 In vitro experiments 
2.16.1 Cell culture of BMDMs 
To harvest BMCs, tibias and femurs of miR-155+/+Apoe-/- and miR-155-/-Apoe-/- mice were 
aseptically removed and flushed with 20 ml of Dulbecco’s modified eagle medium (DMEM, 
PAA). After disaggregating the BM by pipetting up and down, cells were passed through a 
cell strainer (40 µm, BD Falcon) and centrifuged at 500g for 5 min. The cells in the pellet 
were re-suspended in DMEM-F12 medium supplemented with 10% fetal calf serum and 10% 
L929-conditioned medium. The cells were counted and diluted to 2×105 cells/ml. Macrophage 
colony stimulating factor (M-CSF) is a macrophage growth factor required for the 
differentiation of mononuclear phagocytic progenitor cells into macrophages. L929 cells 
secrete M-CSF constitutively into the medium. Cells (1 ml/well) were seeded to a 24-well 
plate and cultured (at 37°C, 5% CO2) for 7 d to allow differentiation into primary 
macrophages. F4/80 (APC-labeled anti-mouse rat IgG2a; eBiosciences) and CD11b (PerCP-
Cy™5.5-labeled anti-mouse rat IgG2b; BD Pharmingen) expression was determined by flow 
cytometry (FACSCanto II; BD Biosciences) to confirm the macrophage phenotype.  
On the 7th d, BMDMs were stimulated with moxLDL (50 μg/ml, 14 h) and IFNγ 
(10 ng/ml, 6 h), LPS (100 ng/ml, 14 h) and IFNγ (10 ng/ml, 6 h), IL4 (5 ng/ml, 6 h), moxLDL 
(50 μg/ml, 14 h), oxLDL (50 μg/ml, 14 h), or native LDL (50 μg/ml, 14 h). MoxLDL and 
IFNγ-stimulated BMDMs from miR-155-/-Apoe-/- mice were treated with non-targeting siRNA 
or siRNA against Socs1, Sfpi1, and Bcl6 (500 nM, Accell siRNA in Accell cell culture 
medium; Dharmacon) on day 4 and then stimulated with moxLDL and IFNγ on day 7. Total 
RNA was isolated using the mirVana microRNA Isolation Kit (Life Technologies).  
2.16.2 Preparation of oxLDL 
To generate moxLDL, human native LDL (1 mg/mL; Calbiochem, Darmstadt, Germany) was 
incubated with 5 μM CuSO4 at 37°C for 4 h38. The oxidation was stopped by adding 10 μM 
EDTA (final concentration) at the beginning of the propagation phase. Oxidation of LDL was 
monitored by semi-continuous monitoring conjugated diene formation at 234 nm (Nanodrop). 
The moxLDL was washed with PBS over a PD-10 desalting column (GE Healthcare). After 
measuring the protein concentration using a DC protein assay kit (Bio-Rad), the moxLDL was 
filtered through a 0.22 μm filter and stored at 4°C for no longer than 14 d. To generate highly 
oxidized LDL (oxLDL), moxLDL was stored for 4 months at 4°C.  
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2.16.3 Luciferase reporter assay 
To confirm that Dlk1 and Bcl6 are direct targets of miR-126-5p and miR-155, respectively, 
luciferase reporter assays were performed using HEK293 cell. The full length of the 3'UTR of 
murine Dlk1 was cloned in the psiCHECK-2 vector (Promega) at the Xhol/NotI sites. In 
addition, mutant 3'UTR of murine Dlk1 was generated using site-directed mutagenesis. In 
order to introduce base substitution (UAAU→AUUA) into the binding site of miR-126-5p, a 
PCR reaction was performed using following primers: 
5'-ATGCATGATAATGAAATTAAATAATAAGA-3'  
5'- TAATTTCATTATCATGCATTAATAGGGAG-3' 
Constructs of the pEZX-MT01 vector with or without the 3'UTR of the murine Bcl6 
gene were purchased from GeneCopoeia (GeneCopoeia, Inc. US). Mutagenesis PCR was 
performed at the miR-155 target site of Bcl6 (Eurofins MWG GmbH, Ebersberg, Germany).  
HEK293 cells were cultured in complete DMEM in 96-well plates. Subconfluent cells were 
transfected with 100 ng luciferase reporter or empty vector. Cells transfected with the Dlk1 
construct were treated with miR-126-5p or miR-126-3p mimic (15 nM or 30 nM, Ambion Pre-
miR miRNA Precusor; Life Technologies) or non-targeting control oligonucleotides (15 nM 
or 30 nM, scrambled Pre-miRNA, Ambion). The cells transfected with the Bcl6 construct 
were treated with miR-155 mimic or non-targeting control oligonucleotides (30 nM, Ambion) 
using Lipofectamine 2000 (Invitrogen). Firefly and Renilla luciferase activity were quantified 
using the Dual-Glo Luciferase Assay System (Promega) by a microplate reader (Tecan). The 
luciferase activity was measured at 48 h and 72 h after transfection with miR-126-5p and miR-
155 mimics, respectively. 
2.16.4 EIF2C2 IP 
BMDMs from miR-155+/+Apoe-/- and miR-155-/-Apoe-/- mice were washed in ice-cold PBS and 
incubated with lysis buffer (see also section 2.3) for 15 min on ice. After homogenization 
using a Dounce homogenizer, cell extracts were centrifuged. Input RNA was extracted from 
the supernatant using TRIzol (Invitrogen). Before IP, protein A/G conjugated to magnetic 
beads (Millipore) was incubated with a mouse monoclonal anti-EIF2C2 antibody (clone 
2E12-1C9; Abnova) or mouse IgG (Millipore). The antibody-conjugated beads were then 
incubated with the cell extracts for 5 h at 4°C before immobilization of the precipitate with a 
magnetic separator (Millipore). RNA was isolated from the precipitate with TRIzol and 
reverse transcribed with random primers. QRT-PCR was performed using the SYBR Green 
PCR Master Mix (Fermentas). The fold enrichment (FE) of target genes in the EIF2C2-IP 
RNA compared with that in IgG-IP RNA was measured as follows: (a) ΔCtEIF2C2-IP was 
calculated as Ctinput – CtEIF2C2-IP; (b) ΔCtIgG-IP was calculated as Ctinput – CtIgG-IP; (c) ΔΔCt was 
calculated as ΔCtEIF2C2-IP – ΔCtIgG-IP; and (d) FE was calculated as 2ΔΔCt 202. 
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2.17 Quantitative real time PCR 
Total RNA was isolated using the mirVana miRNA isolation kit, the RecoverAll total nucleic 
acid isolation kit (both from Applied Biosystems), or TRIzol (Invitrogen). The RNA 
concentration was determined by measuring the absorbance at 260 nm (A260) in a 
spectrophotometer (see also section 2.1). The absorbance at 280 nm was also measured to 
determine the RNA purity. RNA with an A260/A280 ratio of 1.8-2.0 was used for qRT-PCR. 
Total RNA was reverse transcribed to cDNA using Taqman microRNA RT kit (10 ng RNA, 
Life technology) or high capacity cDNA reverse transcription kit (Life technology). MiR 
expression levels were quantified using Taqman miRNA (Applied Biosystems), Taqman 
universal PCR master mix (Life Technologies), or miScript primer assays (Qiagen). QRT-
PCR for mRNAs was performed using Taqman Assays and Taqman universal PCR master 
mix (Life Technologies) or gene specific primers and SYBR Green master mix (Fermentas). 
All real-time PCR experiments were run on a 7900HT thermocycler (Applied Biosystems). 
Relative expression levels were normalized to a single or to multiple reference genes 
(snoRNA-135, snoRNA-429, RNU44, Rnu1a, or U6 for miR; Gapdh and Actb, or 18s RNA for 
mRNA), scaled to the sample with the lowest expression (qbase software; Biogazelle), and 
logarithmically transformed (Log2 or Log10). The levels of miR-126-3p and miR-126-5p in 
different murine tissues (Taqman assays) were corrected for differences in PCR efficiency 
(qbase 2.0, software, Biogazelle). 
2.18 Enzyme-linked immunosorbant assay  
Protein was isolated from carotid artery sections using Qproteome FFPE Tissue Kit (Qiagen). 
The aortas were homogenized in cell lysis buffer (Cell Signaling Technology) using a 
homogenizer (TissueLyser LT, Qiagen). The DLK1 and VCAM-1 levels in the carotid 
arteries were determined by a mouse DLK1 ELISA Kit (Cusabio) and a mouse VCAM-1 
ELISA kit (RayBiotech), respectively. The concentrations of CCL2 and TNFα were 
determined in BMDM cell lysates or cell culture medium using ELISA kits (both from Ray 
Biotech, Inc.) The absorbance was measured at 450 nm using a microplate reader 
(SPECTRAFluor Plus or Infinite M200, Tecan Group Ltd.). The DLK1 and VCAM-1 protein 
content was normalized to the total protein content (quantified by DC Protein Assay Kit, 
BioRad). 
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2.19 In silico prediction of mRNAs targeted by miRs  
To identify mRNA targets of miRs, 3 computional algorithms with different criteria for miR 
target prediction and ranking were applied. TargetScan (www.targetscan.org) predicts 
mRNAs targeted by miRs according to the target site conservation among orthologous 
3'UTRs of vertebrates and requires a 6-nt match comprising nucleotides 2-7 of the miR203 204. 
MicroCosm Targets (www.ebi.ac.uk/enrightsrv/microcosm/htdocs/targets/v5/) (formerly 
miRBase Targets) predicts every potential target site in 3'UTR of mRNAs according to the 
complementary binding to the seed sequence, site conservation in at least two species, site 
number, and overall pairing with targets204 205. MicroRNA.org (www.microrna.org) predicts 
miR targets based on the miRanda algorithm, which requires moderately stringent seed 
pairing and site number. Miranda incorporates miR expression profiles in various mammalian 
tissues and it can predict a set of genes regulated by a specific miR. Moreover, target sites of 
multiple miRs in particular mRNA can be explored with Miranda204 206. 
2.20 Statistical analysis 
MiR array data are presented as means and were compared using unpaired, moderated, 2-
tailed t-test (Statminer 4.2; Integromics). A false-positive discovery test (according to the 
Benjamini-Hochberg procedure) was applied to the array data. Welch’s approximate t-test 
was applied to the comparison of the different groups used in the genome-wide array and P 
values were corrected for multiple testing using the algorithm of Benjamini and Hochberg. 
Two experimental groups were compared using unpaired, 2-tailed Student’s t-test. More than 
two groups were compared using one-way or two-way analysis of variance followed by a 
Newman-Keuls post-test (Prism 5.0; GraphPad). Data from human plaque samples were 
analyzed by Pearson correlation calculations. All data except the miR array data represent 
mean ± s.e.m. A P value < 0.05 was considered significant.  
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3 Results 
3.1 Effects of miR-126 on endothelial repair and 
atherosclerosis  
3.1.1 Expression pattern of the mature miR-126 strands  
To investigate the abundance of miR-126 strands in various tissues, the expression levels of 
the miR-126 strands were studied in arteries, heart, kidney, brain, lungs, intestine, liver, 
spleen, BM, and WBC of Apoe-/- mice by qRT-PCR. The comparison between the miR-126-3p 
and the miR-126-5p expression levels in these tissues showed that both strands are detectable 
and the expression level of miR-126-5p is not significantly different from miR-126-3p in 
kidney, brain, intestine, liver, spleen, BM, and WBCs (Fig. 12a). Only in arteries, heart, and 
lung, the expression level of miR-126-3p was higher than that of miR-126-5p (Fig. 12a). Next, 
the localization of the two miR-126 strands in arteries of Apoe-/- mice was studied by in situ 
hybridization. The expression of miR-126-3p and miR-126-5p was only detectable in ECs of 
carotid arteries (Fig. 12b). In negative control stainings, the EC-specific staining of miR-126-
3p and miR-126-5p was absent in miR-126-/-Apoe-/- mice (Fig. 12b). 
 
Figure 12: Expression of miR-126-3p and miR-126-5p strands in mouse tissues. (a) The relative expression 
levels of miR-126-3p and miR-126-5p were quantified in different tissues of Apoe-/- mice by qRT-PCR (n = 4-5 
mice per group). The results for the individual strands were corrected for differences in primer efficiencies. (BM 
= bone marrow; WBC = white blood cells). *P < 0.001, compared to miR-126-3p. P values were obtained using 
two-way analysis of variance. The means ± s.e.m. are shown. (b) Localization of miR-126-3p and miR-126-5p 
expression in carotid arteries of miR-126+/+Apoe-/- mice using in situ hybridisation (red). Negative control 
staining was performed in miR-126-/-Apoe-/- mice. Nuclei were counterstained with DAPI (blue). Scale bars, 25 
µm.  
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3.1.2 Regulation of miR-126 expression following vascular 
injury 
To study the regulation of miR-126-3p and miR-126-5p following endothelial denudation, 
Apoe-/- mice were subjected to wire-induced carotid injury and the expression levels of the 
miR-126 precursor and both mature miR-126 strands were quantified at different time points 
after injury by qRT-PCR. The transcript levels of pre-miR-126, miR-126-3p, and miR-126-5p 
were reduced at 1 d and returned to control levels at 7 d after injury (Fig. 13). Subsequently, 
the expression of pre-miR-126, miR-126-3p, and miR-126-5p tended to decline between 7 d 
and 28 d, although the difference was not statistically significant (Fig. 13). These results 
indicate that the expression of pre-miR-126, miR-126-3p, and miR-126-5p is similarly 
regulated after vascular injury and that endothelial denudation results in a loss of miR-126 
gene expression, which recovers before the regeneration of the endothelium is completed.  
 
Figure 13: Time course analysis of pre-miR-126, miR-126-3p, and miR-126-5p expression after wire-
induced denudation. The relative expression levels of pre-miR-126, miR-126-3p, and miR-126-5p were 
quantified in the carotid artery 1, 7, 14, and 28 d after wire-injury (n = 3-6 mice per group). Uninjured carotid 
arteries were served as control group (CTRL, n = 5-8). *P < 0.05, compared to CTRL. P values were obtained 
by one-way analysis of variance. The means ± s.e.m. are shown.  
3.1.3 Role of miR-126 in vascular repair 
MiR-126 is known as an endothelial miR and deletion of miR-126 (which results in the loss of 
both miR-126-3p and miR-126-5p strands) impairs vascular integrity and angiogenesis during 
development146 149. The proliferation of resident ECs plays a crucial role in the re-
endothelialization of injured endothelium207. To study the contribution of miR-126 to 
endothelial repair, miR-126+/+Apoe-/- and miR-126-/-Apoe-/- mice fed a HCD were subjected to 
endothelial denudation of the carotid artery and neointima formation was studied in these 
mice at different time points (Figs.14-19).  
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3.1.3.1 The effect of miR-126 deficiency on lesion formation 
To assess the role of miR-126 deficiency in neointima formation, the neointimal size was 
quantified at different time points after wire-induced injury of the left carotid artery in miR-
126+/+Ape-/- and miR-126-/-Apoe-/- mice using planimetry of carotid sections stained with EVG 
stain or Movat’s pentachrome stain. While there was no difference in the neointimal area at 7 
d after injury, a significant increase in lesion size at 14 and 28 d was detected in miR-126-/-
Apoe-/- compared with miR-126-/-Apoe-/- mice (Fig. 14). These data indicate that miR-126 
deficiency prevented exuberant neointima formation in an advanced stage of vascular repair.  
 
Figure 14: Effect of miR-126 deficiency on neointima formation. Carotid artery sections from miR-
126+/+Apoe-/- and miR-126-/-Apoe-/- mice 28 d after wire injury were stained with Movat’s pentachrome stain to 
delineate the neointimal lesion. The lesional area was quantified by planimetry in a time course study in carotid 
sections stained by EVG or Movat’s pentachrome stain. n = 6-7 mice per group. Scale bars, 100 µm, *P < 0.05. 
P values were obtained using two-tailed Student’s t-test. The means ± s.e.m. are shown. 
3.1.3.2 Effect of miR-126 deficiency on neointimal macrophages content 
To determine the cause of the increased neointima formation in miR-126-/-Apoe-/- mice, the 
macrophage accumulation was analyzed by MAC2 immunostaining. The relative macrophage 
content in the lesions peaked at 14 d after injury and declined at 28 d in parallel in miR-126-/-
Apoe-/- and miR-126+/+Apoe-/- mice. However, the lesional accumulation of macrophages in 
the wire-injured carotid arteries was increased at 14 and 28 d in miR-126-/-Apoe-/- compared 
with miR-126+/+Apoe-/- mice (Fig. 15a, b). In contrast, the relative number of macrophages per 
lesional cells was similar at 28 d between both groups (Fig. 15c). The cell size of the 
individual macrophages calculated as the ratio of the MAC2 positive area and the number of 
neointimal macrophages was increased at 28 d after injury in miR-126-/-Apoe-/- mice. These 
enlarged macrophages appeared morphologically as foam cells indicating that the increased 
cell size is due to increased lipid accumulation (Fig. 15c).  
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Figure 15: Effect of miR-126 deficiency on neointimal macrophage content. Carotid artery sections of miR-
126+/+Apoe-/- and miR-126-/-Apoe-/- mice were immunostained with macrophage-specific MAC2 antibody (n = 6-
7 mice per group). (a) Representative images of MAC2 stainings of the carotid artery 28 d after wire injury. 
Scale bars, 200 µm. (b) Time course analysis of lesional accumulation of MAC2 positive macrophages (n = 6-7 
each group). (c) The number and size of lesional MAC2-positive macrophages was determined 28 d after injury 
(n = 5-6 each group). *P < 0.05. P values were obtained using two-tailed Student’s t-test. The means ± s.e.m. are 
shown.  
3.1.3.3 Effect of miR-126 deficiency on neointimal SMC content 
To study the effect of miR-126 deficiency on neointimal SMC accumulation, the lesional 
SMC content was quantified in wire-injured carotid arteries of miR-126-/-Apoe-/- and miR-
126+/+Apoe-/- mice by immunostaining of α-SMA. The relative SMC content in the neointima 
was not significantly different between miR-126-/-Apoe-/- and miR-126+/+Apoe-/- mice at 7, 14, 
and 28 d after vascular injury (Fig. 16), which indicates that miR-126 deficiency does not 
affect the neointimal SMC content. 
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Figure 16: Effect of miR-126 deficiency on neointimal SMC content. The relative lesional area of SMCs was 
determined 7, 14, and 28 d after carotid injury in miR-126+/+Apoe-/- and miR-126-/-Apoe-/- mice (n = 3-7 mice per 
group) by α-SMA immunostaining. Representative images of α-SMA stainings (green) of the carotid artery 28 d 
after wire injury are shown. Scale bars, 200 µm, P = ns. P values were obtained using two-tailed Student’s t-test. 
The means ± s.e.m. are shown. 
3.1.3.4 Effect of miR-126 deficiency on endothelial regeneration  
MiR-126 is highly expressed in ECs of the carotid artery. To investigate the role of miR-126 
in the endothelial recovery after arterial injury, the endothelial coverage of the luminal lining 
was studied in miR-126-/-Apoe-/- and miR-126+/+Apoe-/- mice after vascular injury. Endothelial-
specific staining for vWF revealed that the absence of miR-126 resulted in reduced endothelial 
coverage of the luminal lining at 14 and 28 d after vascular injury. However, there was no 
significant difference in the endothelial coverage between miR-126-/-Apoe-/- and miR-
126+/+Apoe-/- mice after 7 d (Fig. 17). These data indicate that miR-126 deficiency impairs re-
endothelialization following vascular injury. 
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Figure 17: Effect of miR-126 deficiency on endothelial recovery after endothelial denudation. The degree of 
endothelial recovery following carotid injury was assessed by immunostaining for vWF (red, n = 6-8 mice per 
group) in carotid sections from miR-126+/+Apoe-/- and miR-126-/-Apoe-/- mice. Representative images of vWF 
stainings of carotid arteries 28 d after wire-induced endothelial denudation are shown. The degree of endothelial 
recovery was determined at 7, 14, and 28 d after wire-induced denudation. Nuclei were counterstained with 
DAPI (blue). n = 6-8 mice per group; Scale bars, 100 μm. *P < 0.05. P values were obtained using two-tailed 
Student’s t-test. The means ± s.e.m. are shown. 
3.1.3.5 Role of miR-126 deficiency in endothelial proliferation  
Re-endothelialization was reduced after wire-induced carotid injury in miR-126 deficient 
mice. To identify the cause for the impaired endothelial coverage, EC proliferation was 
studied following vascular injury by double immunostaining of Ki67 and CD31. The 
percentage of Ki67+ ECs was reduced by 60% at 28 d after denudation in miR-126-/-Apoe-/- 
compared with miR-126+/+Apoe-/- mice (Fig. 18a), indicating that the inhibition of EC 
proliferation in miR-126 deficient mice leads to impaired endothelial recovery. 
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Figure 18: Role of miR-126 in EC proliferation after vascular injury. EC proliferation was studied in wire-
injured carotid arteries of miR-126+/+Apoe-/- and miR-126-/-Apoe-/- mice by double staining for Ki67 (green) and 
vWF (red) or PCNA (green) and CD31 (red) at 28 d after injury. (a) Representative overlays of Ki67 and vWF 
immunostainings are shown (yellow). Arrows indicate proliferating ECs. n = 6-7 mice per group. Scale bars, 10 
µm. (b) Representative images of PCNA (green) and CD31 (red) immunostaining are shown. The nuclei were 
stained with DAPI (blue). The arrows indicate PCNA+ endothelial nuclei. n = 8 mice per group. Scale bars, 20 
µm. *P < 0.05. P values were obtained using two-tailed Student’s t-test. The means ± s.e.m. are shown.  
 
To confirm the results of the Ki67 stainings, additional immunostainings for CD31 
and PCNA, a proliferation marker that is in contrast to Ki67 only expressed during the S 
phase of the cell cycle, were performed. A significant decrease in the number of PCNA+ ECs 
was detected at 28 d after injury in miR-126-/-Apoe-/- as compared to miR-126+/+Apoe-/- mice 
(Fig. 18b). Hence, the effect of miR-126 deficiency on EC proliferation as determined by 
Ki67/CD31 immunostaining was highly reproducible by the PCNA/CD31 immunostaining.  
3.1.3.6 Effect of miR-126 deficiency in resident arterial ECs 
Since BM-derived cells can contribute to endothelial regeneration61 151 and macrophage 
accumulation was increased in lesions of miR-126-/-Apoe-/- mice, miR-126-/-Apoe-/- BM 
chimeras were used in a crossover design to dissect the role of endothelial resident and BM-
derived miR-126. Wire-induced carotid injury was performed in miR126+/+Apoe-/- mice 
harboring miR-126-/-Apoe-/- BM cells and in miR-126-/-Apoe-/- mice harboring miR-126+/+Apoe-
/- BM cells. MiR-126+/+Apoe-/- mice repopulated with miR-126+/+Apoe-/- BM cells were used 
as controls. Neointima formation was quantified in EVG stained carotid sections at 28 d after 
vascular injury using planimetry. A significant increase in the neointimal size was observed in 
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miR-126-/-Apoe-/- mice harboring miR-126+/+Apoe-/- BM cells as compared with the other 
groups (Fig. 19a).  
In addition, endothelial recovery was measured in wire-induced carotid arteries 
using CD31 immunostaining. The luminal lining covered with ECs was greatly reduced in 
miR-126-/-Apoe-/- mice harboring miR-126+/+Apoe-/- BM cells compared with the other 2 
groups (Fig. 19b). These data indicate that miR-126 deficiency in resident arterial ECs rather 
than BM-derived cells is responsible for the impaired endothelial repair during lesion 
formation. 
 
 
Figure 19: Role of vascular wall-derived miR-126 in vascular repair. Following whole body irradiation, miR-
126+/+Apoe-/- (miR-126+/+) recipient mice received BM cells from miR-126-/-Apoe-/- (miR-126-/-) mice and vice 
versa. In the control group, miR-126+/+Apoe-/- BM cells were transplanted into miR-126+/+Apoe-/- mice. (a) The 
neointimal lesions were quantified 28 d after carotid injury by planimetry of EVG-stained sections (n = 4-6 mice 
per group). Representative images of carotid arteries stained with EVG stain at 28 d after injury are shown. Scale 
bars, 200 µm. (b) The endothelial coverage was determined by CD31 immunostaining of carotid sections 28 d 
after injury (n = 4-6 each group). The nuclei were counterstained with DAPI (blue).  Scale bars, 100 µm. *P < 
0.05. P values were obtained using one-way analysis of variance. The means ± s.e.m. are shown for all panels. 
3.1.3.7 Targets of miR-126 in endothelial recovery 
To study the mechanisms of the impaired re-endothelialization and to identify miR-126 targets 
that contribute to the enhanced lesion formation in miR-126 deficient mice, a global gene 
expression analysis was performed in carotid arteries of miR-126-/-Apoe-/- and miR-
126+/+Apoe-/- mice at 2 weeks after endothelial denudation by genome-wide microarray. 
Global gene expression analysis revealed a total number of 513 upregulated and 228 
downregulated gene transcripts (fold change ≥ 2.0; P ≤ 0.05, n = 4 mice per group) in the 
injured carotid arteries of miR-126-/-Apoe-/- versus miR-126+/+Apoe-/- mice. To identify miR-
126 targets among the upregulated gene transcripts, which are responsible for the reduced 
endothelial cell proliferation in miR-126-/-Apoe-/- mice, 3 different miR target prediction 
algorithms were applied. Using TargetScan, microCosm, and miRDB, 3 potential targets of 
miR-126-5p or miR-126-3p were identified among the up-regulated genes. Delta-like 1 
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homologue (Dlk1) and Ccdc18 were predicted mRNA targets of miR-126-5p, while Pde6h 
was identified as a potential miR-126-3p target (Table 4). 
Target 
prediction 
program 
miR-126-3p 
targets 
Fold change miR-126-5p 
targets 
Fold change 
Microcosm Pde6h 2.2 Ccdc18 and Dlk1 2.1 
miRDB - - Dlk1 2.0 
Target scan - - Dlk1 2.0 
Table 4: List of predicted targets of miR-126-3p and miR-126-5p among the up-regulated genes in miR-126 
deficient mice according to microCosm, miRDB, and TargetScan. 
3.1.3.8 Verification of the differential regulation of the predicted miR-126 targets  
To confirm the differential regulation of the predicted targets of miR-126 identified by global 
gene expression and in silico analysis, the expression levels of Dlk1, Ccdc18, and Pde6h were 
quantified in injured carotid arteries from miR-126-/-Apoe-/- and miR-126+/+Apoe-/- mice by 
qRT-PCR. Out of the 3 predicted miR-126 targets, only up-regulation of Dlk1 was verified in 
denuded arteries of miR-126-/-Apoe-/- compared with miR-126+/+Apoe-/- mice (Fig. 20). The 
up-regulation only of the potential miR-126-5p target Dlk1 indicates that miR-126-5p rather 
than miR-126-3p regulates the response to endothelial injury. 
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Figure 20: Confirmation of the up-regulation of potential miR-126 targets. Differential expression of in 
silico predicted targets of miR-126-3p (Pde6h) and miR-126-5p (Ccdc18; Dlk1) in carotid arteries of miR-
126+/+Apoe-/- and miR-126-/-Apoe-/- mice 2 weeks after endothelial denudation as assessed by qRT-PCR. Pde6h, 
Ccdc18, and Dlk1 were the only predicted miR-126-5p or miR-126-3p targets, which were up-regulated in the 
microarray analysis in the injured carotid arteries of miR-126 deficient mice. n = 4 mice per group. *P < 0.05. P 
values were obtained using two-tailed Student’s t-tests. The means ± s.e.m. are shown for all panels. 
3.1.3.9 Identification of a functional miR-126-5p binding site in the Dlk1 mRNA 
To experimentally prove that the 3'UTR of Dlk1 is targeted by miR-126-5p, luciferase 3'UTR 
reporter assays were performed. The luciferase activity of the Dlk1-3'UTR construct was 
efficiently suppressed by miR-126-5p mimics, whereas miR-126-3p mimics had no effect 
(Fig. 21a and b). Site-directed mutagenesis of 4 nucleotides in the predicted miR-126-5p 
recognition site in the Dlk1-3'UTR binding sites (Fig. 21c) prevented the suppression of the 
luciferase activity by miR-126-5p mimics (Fig. 21a). These data indicate that Dlk1 mRNA is a 
specific and direct target of miR-126-5p. 
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Figure 21: Targeting of the 3'UTR of Dlk1 by miR-126-5p and miR-126-3p. Luciferase activity was 
determined in HEK293 cells transfected with the psiCHECK2 vector with or without the 3'UTR or a mutated 
3'UTR (UTRmut) of Dlk1 after treatment with (a) either miR-126-5p mimics or a scrambled control (n = 3-4 
each group; *P < 0.05 versus control) or with (b) miR-126-3p mimics or a scrambled control (n = 3-4 each 
group; P = ns). P values were obtained using one-way analysis of variance. Data represent the mean ± s.e.m. (c) 
Sequence alignment of miR-126-5p with Dlk1 3'UTRs. Mutations in the 3'UTRs (bold) were engineered in the 
region complementary to the miR-126-5p seed region (yellow). 
 
3.1.3.10 Functional involvement of Dlk1 in endothelial recovery 
To further dissect the functional role of Dlk1 in EC proliferation following vascular injury in 
miR-126-/-Apoe-/- mice, the expression of Dlk1 was studied after wire-induced carotid injury in 
Apoe-/- mice at different time points by qRT-PCR. Dlk1 mRNA levels were transiently 
increased 7 d after denudation before they reverted to control levels during the progress of 
arterial repair (Fig. 22). Furthermore, DLK1 expression was studied at the protein level in 
injured carotid arteries of Apoe-/- mice using double immunostainings for CD31 and DLK1. 
DLK1 immunostaining was primarily detectable in CD31+ ECs covering the lesion (Fig. 23). 
These data indicate that Dlk1 is up-regulated in ECs during the early phase endothelial 
recovery.  
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Figure 22: Time course analysis of Dlk1 mRNA expression levels. The mRNA expression levels of Dlk1 were 
assessed in wire-injured carotid arteries of Apoe-/- mice by qRT-PCR at 1, 7, 14, and 28 d following vascular 
injury (n = 3-7 each group). Uninjured carotid arteries were used as controls (ctrl). *P < 0.05, #P < 0.05 versus 
ctrl. P values were obtained using one-way analysis of variance. Data represent the mean ± s.e.m. 
 
 
Figure 23: Cellular localization of DLK1 in the neointima. DLK1 expression was detected in wire-injured 
carotid arteries of Apoe-/- mice 14 d after injury using combined immunostaining for DLK1 (left panel, red) and 
CD31 (middle panel, green). Co-localization of DLK1+ and CD31+ cells is shown (right; yellow). The nuclei 
were counterstained with DAPI (blue). Scale bars, 50 μm. 
 
DLK1 is an inhibitor of the NOTCH1 receptor and therefore a regulator of the 
Notch signaling pathway208. To assess whether miR-126 deficiency results in increased DLK1 
activity, the activation of NOTCH1 was studied in luminal ECs of injured arteries in miR-126-
/-Apoe-/- and miR-126+/+Apoe-/- mice. Immunostaining for activated NOTCH1 demonstrated 
that increased DLK1 expression in miR-126-/-Apoe-/- mice is associated with reduced 
endothelial NOTCH1 activation as compared to miR-126+/+Apoe-/- mice (Fig. 24). These 
results indicate that the DLK1 activity is increased in miR-126-/-Apoe-/- mice and that 
diminished NOTCH1 signaling may mediate the effects of DLK1 in ECs. 
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Figure 24: Endothelial NOTCH1 in miR-126-/- mice. Activation of NOTCH1 in ECs was assessed by double 
staining for cleaved NOTCH1 (red) and vWF (green) in carotid arteries of miR-126+/+Apoe-/- and miR-126-/-
Apoe-/- mice 2 weeks after endothelial denudation (n = 3-4 mice per group). The nuclei were counterstained with 
DAPI (blue). The rectangle delineated by the solid line shows a high magnification view of the area delineated 
by the dashed rectangle. Scale bars, 20 μm and 5 μm (inset). *P < 0.05 versus ctrl. P value was obtained using 
two-tailed Student’s t-tests. The means ± s.e.m. are shown.  
3.1.4 Differential roles of miR-126-5p and -3p in vascular repair 
To verify the differential roles of the miR-126 strands in endothelial repair, denuded arteries 
of Apoe-/- mice were subjected to perivascular treatment with strand-specific, anti-sense miR 
inhibitors, called antagomirs, which deplete the target miRs.  
3.1.4.1 Specificity of the miR-126-5p and -3p antagomir treatments  
To study the specificity of the antagomir treatment, the expression levels of pre-miR-126 and 
the miR-126 stands were quantified by qRT-PCR in injured carotid arteries of Apoe-/- mice, 
which were locally treated with strand-specific antagomirs or non-targeting antagomir-like 
oligonucleotides. Treatment with the strand-specific antagomirs specifically reduced the 
expression of either miR-126-5p (Fig. 25a) or miR-126-3p (Fig. 25b), whereas the expression 
of pre-miR-126 (Fig. 25c) was unaltered. These data show that perivascular application of 
strand-specific antagomirs effectively and specifically reduce the respective target miR-126 
strand and do not affect the processing of pre-miR-126. 
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Figure 25: Specificity of the miR-126-5p and miR-126-3p antagomirs in vivo. MiR-126-5p (a; n = 5-8 mice 
per group), miR-126-3p (b; n = 5-8 mice per group), and pre-miR-126 (c; n = 5-6 mice per group) expression 
was quantified using qRT-PCR in injured carotid arteries after treatment with nontargeting control antagomirs 
(control), miR-126-3p-, or miR-126-5p-specific antagomirs (once weekly, 160 μg per treatment). *P < 0.05. P 
values were obtained using one-way analysis of variance. The means ± s.e.m. are shown. 
3.1.4.2 Role of strand-specific miR-126 inhibition in vascular repair 
To investigate the effects of the strand-specific inhibitors of miR-126 on neointima formation, 
Apoe-/- mice were subjected to wire-induced carotid injury and perivascularly treated with 
miR-126-3p-, miR-126-5p-, or control antagomirs. Lesion size was studied by planimetry of 
EVG-stained carotid sections at 28 d after vascular injury. Interestingly, only the inhibition of 
miR-126-5p but not miR-126-3p increased lesion size to an almost similar level as observed in 
miR-126 deficient mice (Fig. 26). These data indicate that miR-126-5p limits neointima 
formation following vascular injury. 
 
Figure 26: Differential roles of miR-126-3p and miR-126-5p in lesion formation. Carotid arteries of Apoe-/- 
mice were treated perivascularly with an inhibitor against miR-126-3p (miR-126-3p antagomir) or miR-126-5p 
(miR-126-5p antagomir) dissolved in pluronic gel (once weekly, 160 μg per treatment, n = 6-7 mice per group). 
A non-targeting antagomir-like oligonucleotide (control antagomir) was used as control (n = 3 mice per group). 
Representative images of EVG-stained sections from carotid arteries 28 d after wire injury were shown. Scale 
bars, 200 μm. *P < 0.05. P values were obtained using one-way analysis of variance. The means ± s.e.m. are 
shown.  
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The neointimal macrophage content was studied using MAC2 immunostaining of 
carotid arteries 28 d after vascular injury. The MAC2 immunostaining showed a significant 
increase in the relative neointimal macrophage content in Apoe-/- mice treated with miR-126-
5p antagomir as compared with the other groups (Fig. 27). These data suggest that miR-126-
5p antagomir treatment mimics the same effect on neointima formation as miR-126 
deficiency.  
 
Figure 27: Differential roles of miR-126-3p and miR-126-5p on lesional macrophage content. The lesional 
macrophages were quantified in wire-injured carotid arteries from Apoe-/- mice treated with miR-126-3p, miR-
126-5p, or control antagomirs (once weekly, 160 μg per treatment; n = 3-7 mice per group). Representative 
images of immunostaining with a MAC2 antibody (green) are shown. Scale bars, 100 μm.*P < 0.05 compared to 
all other groups, P values were obtained using one-way analysis of variance. The means ± s.e.m. are shown. 
 
To study the role of miR-126 strands on endothelial recovery after vascular injury, 
the coverage of the luminal lining with ECs was quantified in Apoe-/- mice treated with miR-
126 strand-specific antagomirs using CD31 immunostaining. Quantification of the EC 
coverage in the wire-injured carotid artery sections at 4 weeks after vascular injury showed a 
33% reduction in the endothelial luminal lining of miR-126-5p antagomir-treated as compared 
with miR-126-3p antagomir-treated mice and the control group (Fig. 28). These findings 
suggest that miR-126-5p promotes endothelial recovery after endothelial denudation. 
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Figure 28: Differential roles of miR-126-3p and miR-126-5p on endothelial recovery. ECs were visualized 
with CD31 immunostaining (red) in carotid sections from Apoe-/- mice treated with strand-specific antagomirs 
(miR-126-3p, -5p, or control) (once weekly, 160 μg per treatment). The nuclei were counterstained with DAPI 
(blue). Re-endothelialization was assessed by quantifying the luminal lining of the endothelium covering the 
lesional area. Scale bars, 100 μm. *P < 0.05 compared to all other groups, P values were obtained using one-way 
analysis of variance. The means ± s.e.m. are shown.  
 
Next, the effect of strand-specific antagomirs against miR-126 on EC proliferation 
was studied using double immunostainings for Ki67 and CD31. The EC proliferation in the 
injured arteries of miR-126-5p antagomir-treated mice was significantly reduced as compared 
to miR-126-3p antagomir-treated mice and the control group (Fig. 29). These findings indicate 
that miR-126-5p but not miR-126-3p promotes EC proliferation and thereby endothelial repair 
after vascular injury.  
 
Figure 29: Differential roles of miR-126-3p and miR-126-5p on EC proliferation. The effect of local 
treatment with miR-126 strand-specific antagomirs or a non-targeting antagomir (once weekly, 160 μg per 
treatment) on endothelial cell proliferation was assessed using double immunostaining for Ki67 and CD31 at 28 
d after carotid injury in Apoe-/- mice. n = 5-6 mice per group. *P < 0.05 compared to all other groups, P values 
were obtained using one-way analysis of variance. The means ± s.e.m. are shown. 
3 Results 
65 
 
3.1.4.3 Regulation of miR-126-5p and -3p targets after antagomir treatment 
To further assess whether miR-126-3p and miR-126-5p antagomirs specifically affect the 
expression of known targets of miR-126-3p or miR-126-5p after vascular injury, the 
expression of Dlk1 (miR-126-5p target), Spred1, and VCAM-1 (both are miR-126-3p targets) 
was quantified at the mRNA or protein level. First, Dlk1 mRNA and protein levels were 
quantified using qRT-PCR and immunostaining for DLK1, respectively. A significant 
increase in Dlk1 mRNA (Fig. 30a) and in DLK1+/CD31+ lesional ECs (Fig. 30b) was found 
in arteries treated with the miR-126-5p antagomirs compared to arteries treated with the 
negative control or the miR-126-3p antagomirs.  
 
Figure 30: Regulation of the miR-126-5p target DLK1 by strand-specific miR-126-5p antagomirs. (a) Dlk1 
mRNA (n = 4-5 mice per group) and (b) the number of DLK1 expressing CD31+ ECs was studied (n = 5-8 mice 
per group) in carotid arteries 4 weeks after vascular injury and treatment with non-targeting control antagomir 
(control), miR-126-3p-, or miR-126-5p-specific antagomirs (once weekly, 160 μg per treatment) by qRT-PCR 
and immunostaining of DLK1 and CD31, respectively. *P < 0.05 compared to all other groups. P values were 
obtained using one-way analysis of variance. The means ± s.e.m. are shown. 
 
Additionally, the expression levels of known targets of miR-126-3p, such as Spred1 
and VCAM1, was analyzed following antagomir treatment of wire-injured carotid arteries in 
Apoe-/- mice. Although the Spred1 mRNA expression levels were increased at 4 weeks after 
vascular injury in arteries treated with the miR-126-3p antagomirs compared to non-targeting 
control or miR-126-5p antagomirs (Fig. 31a), the VCAM-1 protein expression levels were not 
significantly different between the groups (Fig. 31b). Taken together, these data indicate that 
both the miR-126-5p and the miR-126-3p antagomirs specifically inhibit the target expression 
of the respective miR-126 strand and that the increased DLK1 expression mediates the effect 
of the miR-126-5p antagomirs on neointima formation. 
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Figure 31: Regulation of the miR-126-3p targets Spred1 and VCAM-1 by strand-specific antagomirs. (a) 
Spred1 mRNA (n = 5-7 mice per group) and (b) VCAM-1 protein (n = 5-7 mice per group) expression was 
quantified in carotid arteries 4 weeks after vascular injury and treatment with non-targeting control antagomir 
(control), miR-126-3p-, or miR-126-5p-specific antagomirs (once weekly, 160 μg per treatment). *P < 0.05 
compared to all other groups. P values were obtained using one-way analysis of variance. The means ± s.e.m. are 
shown. 
3.1.5 Functional role of DLK1 in EC proliferation  
To further study the role of Dlk1 in endothelial recovery, the DLK1 expression was silenced 2 
weeks after endothelial denudation in miR-126-/-Apoe-/- mice using Dlk1-specific siRNA 
(Dlk1-siRNA). Dlk1 mRNA levels in wire-injured carotid arteries of miR-126-/-Apoe-/- mice 
treated with either control- or Dlk1-siRNA were quantified using qRT-PCR. Local application 
of Dlk1-siRNA significantly reduced the Dlk1 mRNA levels as compared to control-siRNA 
(Fig. 32a). In addition, DLK1 protein levels were determined using DLK1 immunostaining 
and ELISA. DLK1 protein levels were remarkably suppressed in Dlk1-siRNA treated carotid 
arteries as compared to control-siRNA (Fig. 33b and c). These data demonstrate that Dlk1 
expression in injured carotid arteries was effectively suppressed by the treatment with the 
siRNA. Moreover, treatment with the Dlk1-siRNA did not considerably change the expression 
of the miR-126-3p target Spred1 (Fig. 32d), indicating that the Dlk1-siRNA specifically 
reduced Dlk1 expression. 
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Figure 32: Effect of Dlk1-siRNA treatment on the expression of miR-126 targets in injured carotid 
arteries. Injured carotid arteries of miR-126-/-Apoe-/- mice were subjected to perivascular treatment with non-
targeting (Ctrl-siRNA) or Dlk1-specific siRNA (Dlk1-siRNA) and harvested 2 weeks after wire injury. (a) 
Immunostaining for DLK1 (red) was performed in the carotid arteries. The nuclei were counterstained with 
DAPI (blue). Scale bars, 20 μm. The expression of Dlk1 mRNA (b, n = 3 mice per group) and DLK1 protein (c, 
n = 3-4 mice per group) was quantified in the injured carotid arteries by qRT-PCR and ELISA, respectively. *P 
< 0.05. The mRNA expression of Spred1 (d, n = 3 mice per group) was studied by qRT-PCR.  P = ns. P values 
were obtained using two-tailed Student’s t-test. The means ± s.e.m. are shown.  
 
Next, the effects of Dlk1 inhibition on lesion formation in injured carotid arteries 
were studied. The neointimal area was significantly reduced in miR-126-/-Apoe-/- mice treated 
with Dlk1-siRNA as compared with control-siRNA group as determined in EVG-stained 
carotid artery sections (Fig. 33a). Interestingly, the endothelial recovery was increased in 
carotid arteries of miR-126-/-Apoe-/- mice after Dlk1 inhibition as detected by CD31 
immunostaining (Fig. 33b). In addition, EC proliferation was determined by combined 
immunostainings for Ki67 and CD31. In comparison to miR-126-/-Apoe-/- mice treated with 
control-siRNA, EC proliferation was remarkably increased in Dlk1-siRNA-treated mice (Fig. 
33c). These data suggest that increased Dlk1 expression in ECs after vascular injury promotes 
neointima formation by impaired EC regeneration. 
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Figure 33: Effects of DLK1-siRNA treatment on vascular repair. Injured carotid arteries of miR-126-/-Apoe-/- 
mice were treated perivascularly with non-targeting (Ctrl-siRNA) or Dlk1-specific siRNA (Dlk1-siRNA). The 
lesion area (a, n = 3-4 mice per group), endothelial recovery (b, n = 3 mice per group), and endothelial 
proliferation (c, n = 3- 4 mice per group) were studied 2 weeks after vascular injury by histomorphometry and 
immunostaining for Ki67 and CD31, respectively. Scale bars, 100µm. *P < 0.05 versus ctrl. P values were 
obtained using two-tailed Student’s t-tests. The means ± s.e.m. are shown for all panels.  
3.1.6 Role of miR-126 in atherosclerotic lesion formation 
3.1.6.1 Expression of the mature miR-126 strands during atherosclerosis 
To determine the expression of miR-126 strands in atherosclerotic plaques, qRT-PCR was 
performed in laser-microdissected samples from atherosclerotic lesions of Apoe-/- mice fed 
with HCD for 3 or 10 months and from morphologically normal vessels (healthy). MiR-126-
5p expression levels were reduced in the normal vessel wall and in atherosclerotic lesions 
after 10 months compared with 3 months of a HCD (Fig. 34a). Moreover, the miR-126-5p 
expression was lower in atherosclerotic lesions than in the normal vessel wall after 3 months 
and after 10 months of a HCD (Fig. 34a). In contrast, no significant changes in miR-126-3p 
expression levels were observed between these groups (Fig. 34b). These data suggest that 
down-regulation of miR-126-5p by hyperlipidemia plays a functional role in atherosclerotic 
plaque development. 
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Figure 34: Expression of miR-126-5p and miR-126-3p during the progression of atherosclerosis. The 
relative expression levels of miR-126-5p (a) and miR-126-3p (b) were quantified in laser-microdissected samples 
from atherosclerotic lesions (lesion) and non-atherosclerotic arteries (healthy) of Apoe-/- mice (n = 3-4 mice per 
group) fed a HCD for 3 months (3 m) or 10 months (10 m). *P < 0.05. P values were obtained using two-tailed 
Student’s t-test. The means ± s.e.m. are shown. 
3.1.6.2 Effect of miR-126 deficiency on atherosclerotic plaque development  
To evaluate the role of miR-126-mediated mechanisms of endothelial regeneration in an 
atherosclerosis model without denudation, miR-126-/-Apoe-/- and miR-126+/+Apoe-/- mice were 
subjected to a HCD only. Atherosclerosis was quantified in miR-126-/-Apoe-/- and miR-
126+/+Apoe-/- mice after 3 months of a HCD by Oil red O staining of en face prepared thoraco-
abdominal aortas and in sections of aortic roots by planimetry. Lesion formation was greatly 
exacerbated in the thoraco-abdominal aortas (Fig. 35) but not in the aortic roots (Fig. 36) of 
miR-126-/-Apoe-/- compared with miR-126+/+Apoe-/- mice. These results indicate that miR-126 
plays a protective role in diet-induced atherosclerosis in specific regions of the arterial tree.  
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Figure 35: miR-126 deficiency and atherosclerosis in the thoraco-abdominal aorta. Atherosclerotic lesions 
were analyzed in miR-126-/-Apoe-/- and miR-126+/+Apoe-/- mice fed a HCD for 3 months. Lesion formation was 
quantified in en face prepared aortas (n = 11-12 mice per group) stained with Oil Red O. **P < 0.01. P values 
were obtained using a two-tailed Student’s t-test. The means ± s.e.m. are shown. 
 
 
Figure 36: Lesion formation in the aortic root of miR-126-/-Apoe-/- mice. The atherosclerotic lesion size was 
studied in the aortic root of miR-126-/-Apoe-/- and miR-126+/+Apoe-/- mice after 3 months of a HCD in cross-
sections that were stained with EVG stain (n = 11-12 mice per group). Representative images are shown. Scale 
bars, 250 µm. P = ns. P values were obtained using a two-tailed Student’s t-test. The means ± s.e.m. are shown. 
3.1.6.3 Effect of miR-126 deficiency on the lesion formation in carotid arteries 
To further investigate the athero-protective role of miR-126 in different regions of the arterial 
tree, lesion formation in the carotid arteries of miR-126-/-Apoe-/- and miR-126+/+Apoe-/- mice 
fed a HCD were studied by planimetry of EVG-stained sections. The lesion area was 
remarkably increased in the carotid arteries of miR-126-/-Apoe-/- as compared to miR-
126+/+Apoe-/- mice (Fig. 37).  
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Figure 37: Lesion formation in carotid arteries of miR-126-/-Apoe-/- mice. Atherosclerotic lesions were 
analyzed in miR-126-/-Apoe-/- and miR-126+/+Apoe-/- mice fed a HCD for 3 months. Lesion formation was 
quantified in EVG-stained sections of carotid arteries (n = 22-24 each group) by planimetry. Representative 
images are shown. Scale bar, 200 µm. *P < 0.05. P values were obtained using a two-tailed Student’s t-test. The 
means ± s.e.m. are shown. 
 
Moreover, the effect of miR-126 on the lesional macrophage content in carotid 
arteries was determined by MAC2 immunostaining. A significant increase of the lesion size 
was found in carotid arteries of miR-126-/-Apoe-/- as compared to miR-126+/+Apoe-/- mice (Fig. 
38).  
 
Figure 38: Effect of miR-126 deficiency on the macrophage content in lesions of the carotid artery. The 
macrophage content in carotid lesions of miR-126-/-Apoe-/- and miR-126+/+Apoe-/- mice after 3 months of a HCD 
was evaluated by MAC2 immunostaining (n = 22-24 each group). **P < 0.01. P values were obtained using a 
two-tailed Student’s t-test. The means ± s.e.m. are shown. 
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Similar to the effect on neointima formation after endothelial denudation, the lesion 
size and the macrophage content were increased in carotid lesions of miR-126 deficient mice 
fed a HCD. To study whether deletion of miR-126 also reduces EC proliferation during diet-
induced atherosclerosis, EC proliferation in carotid atherosclerotic lesions was determined 
using combined immunostaining of CD31 and Ki67 or PCNA, both of which are specific for 
proliferating cells. Notably, the proliferation of luminal EC determined as the percentage of 
Ki67+ (Fig. 39) or PCNA+ ECs (Fig. 40) was reduced in the carotid arteries of miR-126-/-
Apoe-/- compared with miR-126+/+Apoe-/- mice. 
 
 
Figure 39: Expression of the proliferation marker Ki67 in ECs of the carotid artery from miR-126-/- mice 
during diet-induced atherosclerosis. EC proliferation was determined in sections of carotid arteries of miR-
126+/+Apoe-/- and miR-126-/-Apoe-/- mice (n = 3-5 mice each group) by double immunostaining for CD31 (red) 
and Ki67 (green) after 3 months of a HCD. The arrows indicate the Ki67+ ECs. Scale bars, 20 μm. ***P < 
0.001. P values were obtained using a two-tailed Student’s t-test. The means ± s.e.m. are shown. 
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Figure 40: Expression of the proliferation marker PCNA in ECs of the carotid artery from miR-126-/- mice 
during diet-induced atherosclerosis. The proliferation of ECs was studied in carotid arteries of miR-
126+/+Apoe-/- and miR-126-/-Apoe-/- mice after 3 months of a HCD by combined immunostaining for CD31 (red) 
and PCNA (green) (n = 9-10 mice each group). The nuclei were stained with DAPI (blue). Scale bars, 25 μm. *P 
< 0.05. P values were obtained using two-tailed Student’s t-test. The means ± s.e.m. are shown.  
 
To further study whether miR-126 deficiency also increases endothelial DLK1 
expression in diet-induced atherosclerosis, DLK1 expression was determined in lesions of the 
carotid artery using combined immunostaining of DLK1 and CD31. The percentage of DLK1 
expressing CD31+ ECs was significantly increased in the carotid arteries of miR-126-/-Apoe-/- 
compared with miR-126+/+Apoe-/- mice (Fig. 41). Taken together, these data suggest that miR-
126-5p also controls endothelial DLK1 expression and endothelial proliferation in diet-
induced atherosclerosis. 
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Figure 41: Effects of miR-126 deficiency on DLK1 expression in ECs during atherosclerosis. DLK1 
expression in ECs was studied in cross sections of carotid arteries from miR-126+/+Apoe-/- and miR-126-/-Apoe-/- 
mice after 3 months of feeding a HCD. Endothelial DLK1 in carotid arteries was visualized by combined 
immunostaining for DLK1 (red) and CD31 (green). Scale bars, 25 μm. (n = 4 mice each group). ***P < 0.001. P 
values were obtained using a two-tailed Student’s t-test. The means ± s.e.m. are shown for all panels. 
3.1.6.4 EC proliferation in the aortic root of miR-126-/-Apoe-/- mice 
Atherosclerotic lesion formation in miR-126-/-Apoe-/- mice was not altered in aortic roots, but 
was diminished in the thoraco-abdominal aorta and in the carotid arteries, suggesting regional 
difference in the effect of miR-126. To check whether miR-126 deficiency affects EC 
proliferation in the aortic root, double immunostaining of PCNA and CD31 was performed. In 
contrast to the results from the carotid arteries, the percentage of PCNA+ ECs in the 
endothelial lining of the aortic roots was not significantly different between miR-126-/-Apoe-/- 
and miR-126+/+Apoe-/- mice (Fig. 42). 
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Figure 42: Role of miR-126 deficiency on EC proliferation in the aortic root during atherosclerosis. EC 
proliferation was determined in cross sections of aortic roots of miR-126+/+Apoe-/- and miR-126-/-Apoe-/- mice 
after 3 months of a HCD (n = 11-12 mice per group) by double immunostaining for PCNA (green) and CD31 
(red). Scale bars, 25 µm P = ns. P values were obtained using a two-tailed Student’s t-test. The means ± s.e.m. 
are shown. 
3.1.6.5 Regional differences in the expression of miR-126-5p and Dlk1 
In contrast to the thoraco-abdominal aorta, the lesion size in aortic roots was similar in miR-
126-/-Apoe-/- and miR-126+/+Apoe-/- mice. To investigate the cause of the differences between 
the plaque development in the aortic root and the thoraco-abdominal aorta of miR-126-/-Apoe-/- 
mice, the expression levels of miR-126-5p and Dlk1 was studied in different aortic regions by 
qRT-PCR. The miR-126-5p expression levels were markedly lower in the aortic root of Apoe-
/- mice than in the aortic arch, the thoracic, or the abdominal aorta (Fig. 43a). Conversely, the 
Dlk1 expression levels were significantly higher in the aortic root than in the aortic arch, the 
thoracic, or the abdominal aorta of Apoe-/- mice (Fig. 43b). These data suggest that the lesion 
size in the aortic roots of miR-126-/-Apoe-/- mice remains unchanged, because the miR-126-5p 
expression in the aortic roots is constitutively low. Moreover, these reduced miR-126-5p and 
increased Dlk1 levels may play a role in the enhanced plaque formation in the aortic roots 
compared to the thoraco-abdominal aorta in Apoe-/- mice. 
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Figure 43: MiR-126-5p and Dlk1 expression levels in different parts of the aorta. The relative expression of 
miR-126-5p (a) and Dlk1 (b) was quantified in different aortic regions of Apoe-/- mice by qRT-PCR (n = 3-4 each 
group). *P < 0.05. P values were obtained using a one-way analysis of variance. The means ± s.e.m. are shown. 
 
To examine whether the miR-126-5p expression is generally reduced in predilection 
sites for atherosclerosis, the miR-126-5p and Dlk1 expression levels in straight parts (non-
predilection sites) were compared with those in branching points of the aorta (predilection 
sites). The miR-126-5p expression was substantially decreased in predilection sites of the 
aorta of Apoe-/- mice compared to non-predilection sites (Fig. 44a). Reciprocally, the 
expression levels of Dlk1 were significantly higher in predilection sites than in non-
predilection sites of the aorta (Fig. 44b). These data suggest that the miR-126-5p expression is 
generally reduced in predilection sites, which may result in enhanced atherosclerosis due to 
derepression of Dlk1. Moreover, the effect of miR-126 deficiency on atherosclerosis may be 
primarily found in non-predilection sites, because of the comparably high miR-126-5p 
expression. 
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Figure 44: MiR-126-5p and Dlk1 expression levels at predilection and non-predilection sites for 
atherosclerosis. The relative expression levels of miR-126-5p (a) and Dlk1 (b) at predilection sites, such as 
branching points of the aorta were compared with non-predilection sites (n = 4-5 each group). *P < 0.05. **P < 
0.01. P values were obtained using a two-tailed Student’s t-test. The means ± s.e.m. are shown. 
 
To study whether miR-126 deficiency primarily increases atherosclerosis in non-
predilection sites, lesion formation at predilection and non-predilection aortic sites was 
compared between miR-126-/-Apoe-/- and miR-126+/+Apoe-/- mice. The analysis of the Oil red 
O-stained thoraco-abdominal aortas revealed that miR-126 deficiency exacerbated lesion 
formation only at non-predilection sites (Fig. 45). 
 
 
Figure 45: Effect of miR-126 deficiency on lesion formation at predilection and non-predilection sites. 
Lesion formation at predilection and non-predilection sites was compared between miR-126-/-Apoe-/- and miR-
126+/+Apoe-/- mice after 3 months of a HCD in Oil Red O-stained aortas (n = 12 mice each group). Scale bars, 
500 µm. *P < 0.05. P values were obtained using a two-tailed Student’s t-test. The means ± s.e.m. are shown. 
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3.1.6.6 Effect of disturbed blood flow on miR-126-5p and Dlk1 expression 
To assess whether disturbed flow could reduce miR-126-5p expression (e.g., at predilection 
sites), low shear stress was induced in the carotid artery by partial ligation. The expression of 
miR-126-5p continuously declined after 3 d and 1 week as compared to 1 d after partial 
ligation, whereas the Dlk1 mRNA expression was higher after 1 week than after 1 and 3 d 
(Fig. 46). These data suggest that miR-126-5p expression is suppressed by disturbed blood 
flow. 
 
Figure 46: Regulation of miR-12-5p and Dlk1 expression by disturbed blood flow. Time course analysis of 
the relative miR-126-5p and Dlk1 mRNA expression in the carotid artery of Apoe-/- mice after inducing disturbed 
flow by partial carotid ligation (n = 3-4 mice per group). *P < 0.05 compared with 1 and 3 d, #P < 0.05 
compared with 1 d. P values were obtained using one-way analysis of variance. The means ± s.e.m. are shown. 
3.1.6.7 Effect of miR-126 deficiency on flow-induced atherosclerosis  
The role of miR-126 in lesion formation induced by disturbed blood flow was studied 
following partial ligation of the carotid artery in miR-126-/-Apoe-/- and miR-126+/+Apoe-/- mice. 
Lesion formation was quantified by planimetry of EVG-stained carotid artery sections 6 
weeks after partial ligation and feeding a HCD. The lesion size in the carotid arteries of miR-
126-/-Apoe-/- mice was not significantly different from that in miR-126+/+Apoe-/- mice, 
indicating that miR-126 deficiency does not aggravate lesion formation in arteries in which 
miR-126-5p is down-regulated by disturbed flow (Fig. 47). 
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Figure 47: Effect of miR-126 deficiency on lesion formation induced by disturbed flow in carotid arteries. 
Carotid arteries of miR-126-/-Apoe-/- and miR-126+/+Apoe-/- mice were subjected to partial ligation. Flow induced 
lesion formation was determined in carotid sections stained with EVG stain by planimetry after 6 weeks of a 
HCD. Representative images are shown. Scale bars, 100 µm. n = 4-5 mice per group. P = ns. P values were 
obtained using two-tailed Student’s t-test. The means ± s.e.m. are shown. 
 
Furthermore, the role of disturbed blood flow on EC proliferation was studied by 
double immunostaining of Ki67 and CD31 in carotid artery sections from miR-126-/-Apoe-/- 
and miR-126+/+Apoe-/- mice. The percentage of Ki67+ ECs in the carotid artery was not 
significantly different between miR-126-/-Apoe-/- and miR-126+/+Apoe-/- mice 6 weeks after 
partial ligation (Fig. 48). These results suggest that miR-126 deficiency does not reduce 
endothelial proliferation when miR-126-5p is downregulated by disturbed flow. 
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Figure 48: Effects of miR-126 deficiency on EC proliferation during disturbed flow-induced lesion 
formation. EC proliferation was quantified by immunostaining for Ki67 (green) and CD31 (red) in partially 
ligated carotid arteries of miR-126-/-Apoe-/- and miR-126+/+Apoe-/- mice after 6 weeks of a HCD (n = 4-5 mice 
each group). Scale bars, 25 µm. P = ns. P values were obtained using two-tailed Student’s t-test. The means ± 
s.e.m. are shown.  
3.1.6.8 Dlk1 in lesion formation induced by disturbed flow  
To further study the role of Dlk1 in flow-induced atherosclerosis, Dlk1 expression was 
silenced in partially ligated carotid arteries of miR-126+/+Apoe-/- mice using perivascular 
application of Dlk1-siRNA. Silencing of Dlk1 following reduced lesion formation 6 weeks 
after partial ligation as compared to control-siRNA treatment (Fig. 49), indicating that Dlk1 
promotes disturbed flow-induced atherosclerosis. 
 
Figure 49: Role of Dlk1 in disturbed flow-induced atherosclerosis. Partially ligated carotid arteries of miR-
126+/+Apoe-/- mice were perivascularly treated with siRNA against Dlk1 (Dlk1-siRNA) or a non-targeting control 
siRNA (Ctrl-siRNA). Representative images are shown. Scale bars, 100 μm. Lesion formation was quantified in 
carotid sections stained with EVG stain by planimetry. n = 5 mice per group. *P < 0.05. P values were obtained 
using two-tailed Student’s t-test. The means ± s.e.m. are shown. 
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In addition, the effect of Dlk1 on EC proliferation in partially ligated carotid 
arteries was studied by combined immunostaining for PCNA and CD31 in miR-126+/+Apoe-/- 
mice. The percentage of PCNA+ ECs was significantly increased after Dlk1-siRNA compared 
with control-siRNA treatment (Fig. 50). These results indicate that up-regulation of Dlk1 by 
disturbed flow inhibits endothelial proliferation.  
 
 
Figure 50: Effects of DLK1 on EC proliferation during flow-induced atherosclerosis. 
Partially ligated carotid arteries of miR-126+/+Apoe-/- mice were perivascularly treated with siRNA against Dlk1 
(Dlk1-siRNA) or a non-targeting control siRNA (Ctrl-siRNA). The proliferation of ECs was determined by 
combined immunostaining for CD31 (red) and PCNA (green). The arrows indicate PCNA+ ECs. Scale bars, 50 
µm. n = 5 mice per group. *P < 0.05. P values were obtained using two-tailed Student’s t-test. The means ± 
s.e.m. are shown. 
3.1.6.9 miR-126-5p and EC proliferation in human atherosclerotic lesions 
To investigate whether the expression of miR-126-5p in human atherosclerosis is also 
associated with increased endothelial proliferation, reduced DLK1 expression, and diminished 
lesional macrophage accumulation, the expression of miR-126-5p and miR-126-3p was 
correlated with endothelial proliferation, endothelial DLK1 expression, and the relative 
lesional macrophage content in atherosclerotic lesions from human carotid arteries. In contrast 
to miR-126-3p, the expression levels of miR-126-5p correlated with increased luminal EC 
proliferation (determined by double immunostaining of Ki67 and vWF) (Figs. 51a, d and 52), 
a reduced percentage of DLK1 expressing ECs (determined by double immunostaining of 
DLK1 and CD31) (Figs. 51b, e and 53), and a reduced accumulation of lesional CD68+ 
macrophages (determined by immunostaining of CD68) (Fig. 51c, f). These data indicate that 
reduced expression levels of miR-126-5p are associated with impaired EC proliferation, 
elevated endothelial DLK1 expression, and enhanced lesion macrophage accumulation in 
human atherosclerosis like in mice.  
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Figure 51: The correlation of expression levels of miR-126 strands with endothelial proliferation, 
endothelial DLK1 expression, and macrophage accumulation in human atherosclerotic lesions. Increased 
expression levels of miR-126-5p but not of miR-126-3p (as determined by qRT-PCR) were associated with 
increased EC proliferation (a and d; as determined by combined Ki67 and vWF staining; n = 22), a reduced 
percentage of DLK1+ luminal ECs (b and e; as determined by combined DLK1 and vWF staining; n = 24), and 
a diminished accumulation of lesional macrophages (c and f; as determined by CD68 staining; n = 27) in human 
carotid lesions. Pearson correlation calculations were performed to obtain R2 and P values. 
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Figure 52: miR-126-5p expression and EC proliferation in human atherosclerotic lesions. The proliferation 
of ECs was determined in human carotid lesions by double immunostaining for Ki67 (red) and vWF (green). 
Representative images from plaques with low and high relative expression of miR-126-5p are shown. The nuclei 
were counterstained with DAPI (blue). Scale bars, 20 μm. 
 
 
Figure 53: miR-126-5p expression and endothelial DLK1 expression in human atherosclerotic lesions. The 
expression of DLK1 in ECs of human atherosclerotic plaques was determined by double immunostaining for 
DLK1 (red) and vWF (green). Representative images from lesions with low and high relative expression of miR-
126-5p are shown. The nuclei were counterstained with DAPI (blue). Scale bars, 200 μm. 
3.1.6.10 Role of miR-126-5p in atherosclerosis in miR-126-/-Apoe-/- mice 
The findings of the current study indicate that exacerbated atherosclerosis in miR-126-/-Apoe-/- 
mice is mediated by impaired endothelial proliferation due to the lack of miR-126-5p 
expression. To further study whether miR-126-5p supplementation can ameliorate 
atherosclerosis, miR-126-/-Apoe-/- mice were treated with miR-126-5p mimics by systemic 
injection. Lesion formation was compared between miR-126-5p mimic- or control mimic-
treated miR-126-/-Apoe-/- mice (100 µg per injection, every third d for 4 weeks) 4 weeks after 
partial ligation of the carotid artery and feeding a HCD. The miR-126-5p mimic treatment 
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reduced lesion formation in thoraco-abdominal aortas compared to control mimic treatment as 
determined by Oil Red O staining (Fig 54). 
 
Figure 54: Effect of miR-126-5p mimic treatment lesion formation in the throaco-abdominal aorta. MiR-
126-/-Apoe-/- mice on a HCD were systemically treated with miR-126-5p mimics or control oligonucleotides 
dissolved in a neutral lipid emulsion (every 3rd d, IV, 100 μg per injection) for 4 weeks. Lesion formation was 
determined in Oil Red O-stained, en face prepared aortas (n = 3-4 mice per group) *P < 0.05. P values were 
obtained using two-tailed Student’s t-test. The means ± s.e.m. are shown. 
 
Moreover, lesion formation was substantially reduced by miR-126-5p mimic in the 
aortic root of miR-126-/-Apoe-/- mice compared to control mimic treatment as determined by 
planimetry in EVG-stained cross sections (Fig. 55).  
 
 
Figure 55: Aortic root lesion formation after miR-126-5p mimic treatment. MiR-126-/-Apoe-/- mice on a HCD 
were systemically treated with miR-126-5p mimics or control oligonucleotides dissolved in a neutral lipid 
emulsion (every 3rd d, IV, 100 μg per injection) for 4 weeks. Lesion formation was determined in cross sections 
of aortic roots stained with EVG stain by planimetry (n = 3-4 mice per group). Scale bars, 200 μm. *P < 0.05. P 
values were obtained using two-tailed Student’s t-test. The means ± s.e.m. are shown. 
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To study the effect of miR-126-5p mimic on EC proliferation, double 
immunostaining for Ki67 and CD31 was performed in aortic root sections of miR-126-/-Apoe-/- 
mice. The percentage of Ki67+ ECs was significantly increased in miR-126-5p mimic-treated 
compared with control mimic-treated mice (Fig. 56). These data indicate that miR-126-5p 
mimic treatment can improve EC proliferation and limit the exacerbated atherosclerosis in 
miR-126 deficient mice. 
 
 
Figure 56: EC proliferation in aortic roots of miR-126-/-Apoe-/- mice after miR-126-5p mimic treatment. EC 
proliferation was determined by double immunostaining for Ki67 (green) and CD31 (red) in sections of aortic 
roots of miR-126-/-Apoe-/- mice on a HCD, which were treated with miR-126-5p mimics or control 
oligonucleotides dissolved in a neutral lipid emulsion (every 3rd  d, IV, 100 μg per injection) for 4 weeks. (n = 3 
mice per group). The arrows indicate Ki67+ ECs. Scale bars, 50 μm. *P < 0.05. P values were obtained using 
two-tailed Student’s t-test. The means ± s.e.m. are shown. 
 
Furthermore, NOTCH1 activity in ECs of aortic roots was quantified by double 
immunostaining for vWF and cleaved NOTCH1 in miR-126-/-Apoe-/- mice after 4 weeks of a 
HCD. The percentage of active NOTCH1+ ECs was markedly increased after treatment with 
miR-126-5p mimics compared to control mimics (Fig. 57), indicating that treatment with miR-
126-5p reduces DLK1 activity in ECs. 
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Figure 57: Effect of miR-126-5p treatment on endothelial NOTCH1 activation in miR-126-/-Apoe-/- mice. 
Combined immunostaining for vWF (green) and cleaved NOTCH1 (red) was performed in aortic root sections of 
miR-126-/-Apoe-/- mice treated with miR-126-5p mimics or non-specific oligonucleotides (n = 3-4 mice per 
group). The nuclei were counterstained with DAPI (blue). The star indicates autoflourescence of elastin (red) in 
the tunica media. The arrows indicate endothelial nuclei that are immunopositive for activated NOTCH1. Scale 
bars, 50 μm. *P < 0.05. P values were obtained using two-tailed Student’s t-test. The means ± s.e.m. are shown.  
 
To study the effect of miR-126-5p mimic treatment on disturbed flow-induced 
atherosclerosis, lesion formation was analyzed in partially ligated carotid arteries of miR-126-
/-Apoe-/- on a HCD, which were systemically treated with miR-126-5p mimics. Administration 
of miR-126-5p mimics reduced lesion formation in the carotid artery 4 weeks after partial 
ligation as compared to control mimics (Fig. 58), suggesting that miR-126-5p plays a 
protective role in disturbed flow-induced atherosclerosis.  
 
Figure 58: Effect of miR-126-5p treatment on flow-induced lesion formation in miR-126-/-Apoe-/- mice. The 
lesion size in the carotid artery after partial ligation was analyzed in miR-126-/-Apoe-/- mice treated with miR-126-
5p mimics or non-specific oligonucleotides in sections stained with EVG stain. Representative images are 
shown. Scale bars, 100 μm (n = 3-4 mice per group). *P < 0.05. P values were obtained using two-tailed 
Student’s t-test. The means ± s.e.m. are shown. 
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In addition, the effect of miR-126-5p mimic treatment on EC proliferation in 
partially ligated carotid arteries of miR-126-/-Apoe-/- mice was studied using combined 
immunostaining of CD31 and Ki67 or PCNA. Following 4 weeks of miR-126-5p mimic 
treatment, the percentage of Ki67+ (Fig. 59) or PCNA+ ECs (Fig. 60a) was increased as 
compared to control mimic treatment. Moreover, the increased endothelial proliferation after 
miR-126-5p mimic treatment was associated with a reduced percentage of DLK1 expressing 
ECs as determined by double immunostaining of DLK1 and CD31 (Fig. 60b), indicating that 
suppression of DLK1 expression by the miR-126-5p treatment promotes endothelial 
proliferation during disturbed flow-induced atherogenesis.  
 
 
Figure 59: Effect of miR-126-5p treatment on EC proliferation after partial ligation of carotid arteries in 
miR-126-/-Apoe-/- mice. In partially ligated carotid arteries of miR-126-/-Apoe-/- mice, EC proliferation was 
determined by double immunostainings for Ki67 (green) and CD31 (red) (n = 3 mice per group). Representative 
images are shown. The arrows indicate Ki67+ ECs. Scale bars, 20 µm. *P < 0.05. P values were obtained using 
two-tailed Student’s t-test. The means ± s.e.m. are shown. 
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Figure 60: Effect of miR-126-5p treatment on EC proliferation and endothelial DLK1 expression in 
disturbed flow-induced atherosclerosis in miR-126-/-Apoe-/- mice. (a), EC proliferation was measured after 
partial ligation using combined immunostaining for CD31 (red) and PCNA (green) in sections of the carotid 
artery of miR-126-/-Apoe-/- mice treated with miR-126-5p mimic or a non-specific oligonucleotide (n = 3-4 mice 
per group). Arrows indicate PCNA+ ECs. The nuclei were counterstained with DAPI (blue). Scale bars, 25 μm. 
(b), Endothelial DLK1 expression was determined by DLK1 and CD31 double immunostaining (n = 3-4 mice 
per group). *P < 0.05. P values were obtained using two-tailed Student’s t-test. The means ± s.e.m. are shown.  
3.1.6.11 Role of miR-126-5p in atherosclerosis in miR-126+/+Apoe-/- mice 
Hitherto, the results of the current study suggest that treatment with miR-126-5p mimics can 
limit the exacerbated atherosclerosis in miR-126-/-Apoe-/- mice. To address whether miR-126-
5p mimic treatment can also reduce atherosclerosis in Apoe-/- mice that express miR-126, 
lesion formation was studied in thoraco-abdominal aortas, aortic roots, and partially ligated 
carotid arteries of Apoe-/- mice after treatment with miR-126-5p mimics.  
In aortic roots of Apoe-/- mice, lesion formation was quantified by planimetry of 
EVG stained cross sections after 4 weeks of treatment with miR-126-5p or control mimics. 
The lesion size in the aortic root was reduced in miR-126-5p mimic-treated as compared to 
control mimic-treated mice (Fig. 61a). Additionally, lipid deposition was studied in en face 
prepared aortic arches by Oil Red O staining. Treatment with miR-126-5p mimics reduced the 
lipid deposition in the aortic arch of Apoe-/- mice compared with control mimic treatment (Fig. 
61b). 
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Figure 61: Effect of miR-126-5p mimic treatment on lesion formation in Apoe-/- mice. MiR-126-5p mimics or 
control oligonucleotides dissolved in a neutral lipid emulsion were injected (every 3rd d, IV, 100 μg per 
injection) for 4 weeks to Apoe-/- mice on a HCD. (a), Lesion formation was determined in sections of aortic roots 
stained with EVG stain (n = 3 mice per group) and (b) in Oil Red O-stained, en face prepared aortic arches (n = 
3 mice per group). Scale bars, 100 μm. *P < 0.05. P values were obtained using two-tailed Student’s t-test. The 
means ± s.e.m. are shown. 
 
Moreover, the effect of miR-126-5p mimic treatment on EC proliferation in the 
aortic root of Apoe-/- mice was determined by double immunostainings for PCNA and CD31. 
The percentage of PCNA+ ECs was significantly increased in the aortic root after 4 weeks of 
miR-126-5p mimic compared with control mimic treatment (Fig. 62).  
 
Figure 62: EC proliferation in aortic roots of Apoe-/- mice after miR-126-5p mimic treatment. 
Apoe-/- mice on a HCD were systemically treated with miR-126-5p mimics or control 
oligonucleotides. EC proliferation was determined by double immunostaining for PCNA (green) and 
CD31 (red) in sections of aortic roots (n = 4 mice per group). The nuclei are stained with DAPI 
(blue). The arrows indicate proliferating ECs. Scale bars, 25 μm. *P < 0.05. P values were obtained 
using two-tailed Student’s t-test. The means ± s.e.m. are shown. 
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To determine whether disturbed flow-induced lesion formation could be 
ameliorated by miR-126-5p mimic treatment also in Apoe-/- mice that express miR-
126, lesion size was studied 4 weeks after partial ligation of the carotid artery. 
Treatment with miR-126-5p mimics significantly reduced lesion formation in 
partially ligated carotid arteries of Apoe-/- mice as compared to control mimics (Fig. 
63). These results indicate that miR-126-5p mimics reduce atherosclerosis at 
predilection sites characterized by diminished miR-126-5p expression.  
 
Figure 63: Effect of miR-126-5p treatment on flow-induced lesion formation in Apoe-/- mice. 
The lesion formation in the partially ligated carotid arteries of Apoe-/- mice treated with miR-126-5p 
mimics or non-specific oligonucleotides was quantified by planimetry in sections stained with EVG 
stain (n = 4 mice per group). Representative images are shown. Scale bar, 100 µm. *P < 0.05. P 
values were obtained using two-tailed Student’s t-test. The means ± s.e.m. are shown. 
3.2 Role of miR-155 in atherosclerosis  
3.2.1 MiR expression profile in atherosclerosis and M1 
macrophages  
Macrophages play important roles in atherosclerosis by enhancing the vascular inflammatory 
response, removal of subendothelial lipoproteins, and phagocytosis of dead cells. The aim of 
the second part of this study was to identify miRs that mediate the inflammatory macrophage 
response in atherosclerosis. Therefore, the miR expression profile was determined in partially 
ligated carotid arteries, which develop macrophage-rich lesions, and in pro-inflammatory 
macrophages by qRT-PCR array. The miR expression profile in lesions of the carotid artery 
of Apoe-/- mice 6 weeks after partial ligation and feeding a HCD was characterized by the up-
regulation of 33 miRs and the suppression of 83 miRs as compared to the unligated, 
contralateral carotid artery (Fig. 64a). In addition, the miR expression profile in murine 
BMDMs stimulated with LPS and IFNγ was compared with that of unstimulated BMDMs. 
Following LPS and IFNγ stimulation, 6 miRs were up- and 26 miRs were down-regulated 
compared with unstimulated BMDMs (Fig. 64b). Notably, the expression of miR-155 and 
miR-147 was increased in lesions of partially ligated carotid arteries and in proinflammatory 
macrophages. 
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Figure 64: MiR expression profiles in atherosclerotic lesions and inflammatory macrophages. (a) The miR 
expression profile in carotid lesions of Apoe-/- mice 6 weeks after partial ligation was compared with that in the 
unligated, contralateral carotid artery (n = 6 mice per group). (b) Expression profile of miRs in LPS- and IFNγ–
stimulated and unstimulated BMDMs (n = 5 each group). The miR expression profiles were determined by qRT-
PCR array. Data represent means. 
 
To further study the role of miR-155 and miR-147 expression in the development of 
atherosclerosis, their expression was quantified in a mouse model of diet-induced 
atherosclerosis. The miR-155 expression levels were significantly higher in the aortic wall of 
Apoe-/- mice after 10 as compared to 3 months of a HCD or a regular chow diet (Fig. 65a). 
Similar to miR-155, the expression of miR-147 in the murine aortic wall was increased only 
after 10 but not after 3 months of a HCD compared with regular chow diet (Fig. 65b). 
Moreover, the expression of miR-155 and miR-147b, the human homolog of murine miR-147, 
was higher in human carotid plaques than in the medial and adventitial carotid wall (Fig. 65c 
and d). 
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Figure 65: Effect of hyperlipidemia on the expression of miR-155 and miR-147 in the aorta. Expression of 
miR-155 (a) and miR-147 (b) in the aortic wall of Apoe-/- mice on a HCD for 3 or 10 months as compared to 
mice fed a regular diet (ctrl) (n = 3–5 mice per group). *P < 0.05 vs. ctrl and 3 months. P value was obtained 
using one-way analysis of variance. Expression of miR-155 (c) and miR-147b (d) in human carotid plaque 
samples and vessel walls (control) (n = 3–4 per group). *P < 0.05. P values were obtained using two-tailed 
Student’s t-test. The means ± s.e.m. are shown for all panels. 
 
Moreover, the miR expression profile of laser-microdissected aortic root lesions 
from Apoe-/- mice was compared with that of nonatherosclerotic, normal arterial walls within 
the same mice after 3 and 10 months of a HCD. In contrast to miR-147, the miR-155 
expression in laser-microdissected lesions was increased after 3 months of a HCD compared 
with that of the normal arterial wall (Fig. 66a). In addition, 4 other miRs, including miR-342-
5p, miR-296-5p, miR-146b, and miR-21*, were significantly upregulated in atherosclerotic 
lesions after 3 months of HCD as compared to the normal arterial wall (Fig. 66a). However, 
there was no significant difference in the miR-155 and miR-147 expression level between 
aortic root lesions and the non-atherosclerotic arterial wall after 10 months of a HCD (Fig. 
66b). Intrestingly, miR-684 and miR-702 were the only upregulated miRs in atherosclerotic 
lesions after 10 months of a HCD (Fig. 66b).  
These data indicate that upregulation of miR-155 was consistently present in 
different mouse models of atherosclerosis and in human plaques, whereas up-regulation of 
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miR-147 expression in atherosclerosis was more variable. Therefore, the role of miR-155 in 
atherosclerosis was studied further. 
 
Figure 66: MiR-155 and miR-147 expression levels in atherosclerotic lesions. The miR expression profile in 
laser-microdissected plaque samples from the aortic root of Apoe-/- mice after (a) 3 and (b) 10 months of a HCD 
was compared with that in the healthy arterial wall. The upregulated miRNAs are labeled in red. (n = 3 or 4 mice 
per group). The miR expression profiles were determined by qRT-PCR array. RQ indicates relative 
quantification value. Data represent means. 
3.2.2 Cellular localization of miR-155 in atherosclerotic lesions 
of Apoe-/- mice 
To determine the cellular source of miR-155 in atherosclerotic lesions, in situ hybridization 
for miR-155 was performed in lesions of the partially ligated carotid artery of Apoe-/- mice. 
First, the specificity of the in situ hybridization for miR-155 was verified using miR-155-/- 
mice as negative controls (Fig. 67). In Apoe-/- mice, miR-155 staining was present in 
numerous lesional cells, whereas in miR-155-/- mice only negligible background staining was 
observed (Fig. 67a and b). Moreover, only minor background staining was found in lesions of 
Apoe-/- mice using a scrambled in situ probe as a negative control staining (Fig. 67c). In 
contrast, using an U6-specific probe resulted in extensive staining throughout the lesions in 
the positive control stainings (Fig. 67d).  
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Figure 67: Localization of miR-155 in murine atherosclerotic plaques. (a) MiR-155 was detected by in situ 
hybridization in atherosclerotic plaques induced by partial carotid ligation in Apoe-/- mice. (b) MiR-155 was not 
detectable in carotid plaques of miR-155-/-Apoe-/- mice. (c) A scrambled probe showed only negligible 
background staining in Apoe-/- mice. (d) An U6-specific probe was used as a positive control for in situ 
hybridization. Scale bars, 50 μm. 
 
Next, in situ hybridization for miR-155 was combined with immunostaining for the 
macrophage marker MAC2 or the SMC marker α-SMA. The combined stainings 
demonstrated that the majority of lesional macrophages and some SMCs expressed miR-155 
(Fig. 68a and b). Therefore, both hematopoietic and vessel wall–derived cells in 
atherosclerotic lesions expressed miR-155. 
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Figure 68: Cellular expression of miR-155 in atherosclerotic lesions. (a) In situ hybridization for miR-155 
(red) and immunostaining for MAC2 (green) was performed in murine carotid artery plaques induced by partial 
ligation. Arrows denote macrophages expressing miR-155. (b) In situ hybridization for miR-155 (red) and 
immunostaining for α-SMA (green) was performed in murine carotid artery plaques. Arrows denote SMCs 
expressing miR-155. Scale bars, 20 μm.  
3.2.3 MiR-155 expression upon activation of macrophages  
To study the role of miR-155 in activated macrophages, miR-155 expression levels were 
quantified during differentiation of BM-derived cells into macrophages and also after 
activation of BMDMs by different stimuli. The miR-155 expression was downregulated after 
4 and 7 d compared with 2 d of culturing BM-derived cells in L929-conditioned medium to 
induce macrophage differentiation (Fig. 69a). Polarization of BMDMs into proinflammatory 
M1-type macrophages by stimulation with LPS and IFNγ induced miR-155 expression (Fig. 
69b). In contrast, anti-inflammatory M2-type polarization by IL4 did not significantly affect 
miR-155 expression (Fig. 69b). Native LDL and moxLDL treatment slightly increased miR-
155 expression, whereas oxLDL reduced the expression of miR-155 (Fig. 69b). Of note, 
stimulation of BMDMs with moxLDL and IFNγ up-regulated miR-155 expression to a similar 
extend as treatment with LPS and IFNγ. These data indicate that the degree of LDL oxidation 
plays a role in the effect of modified LDL on miR-155 expression and that moxLDL 
combined with IFNγ also induces M1-type polarization of macrophages. 
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Figure 69: Expression of miR-155 in macrophage differentiation and activation. (a) miR-155 expression as 
determined by qRT-PCR in murine BM cells cultured in L929-conditioned medium to induce macrophage 
differentiation. (b) Regulation of miR-155 expression in BMDMs by modified LDL was quantified and 
compared with classical and alternative macrophage activation by qRT-PCR. *P < 0.05, ***P < 0.001 vs. all 
other groups; #P < 0.05 vs. control, oxLDL, IL4, LPS + IFNγ, and moxLDL + IFNγ; ‡P <0.05 vs. control, native 
LDL, moxLDL, oxLDL, and IL4. Three independent experiments were conducted per group. P value was 
obtained using one-way analysis of variance. The means ± s.e.m. are shown for all panels. 
3.2.4 Proinflammatory macrophage activation by moxLDL and 
IFNγ  
Next, the expression of known markers of classically and alternatively activated macrophages 
was studied to determine whether treatment with moxLDL and IFNγ is sufficient to induce 
M1 polarization. Similar to LPS and IFNγ, stimulation of macrophages with moxLDL and 
IFNγ induced M1-type macrophage markers, such as Nos2 and Tnfa (Fig. 70a, b), but did not 
affect the expression of the M2-type markers, like arginase 1 (Arg1) and mannose receptor 
(Mrc1) (Fig. 70c, d). Neither native nor moxLDL alone did significantly change the 
expression of M1- or M2-type macrophage markers. However, oxLDL treatment up-regulated 
the M2-type marker Mrc1, but also, though much weaker, induced the expression of the M1-
marker Nos2. These data indicate that moxLDL-stimulated macrophages develop a M1 
phenotype in the presence of IFNγ characterized by an increased expression of miR-155. 
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Figure 70: Expression of M1- and M2-type macrophage markers following stimulation. (a) Tnfa mRNA 
expression was quantified in BMDMs after stimulation. *P < 0.05 versus control (Ctrl), native LDL, moxLDL, 
oxLDL, and IL4; #P < 0.05 versus native LDL, moxLDL, LPS + IFNγ, and moxLDL + IFNγ. (b) The 
expression of Nos2 was studied by qRT-PCR in BMDMs after stimulation as indicated. *P < 0.05 versus 
oxLDL, LPS + IFNγ, and moxLDL + IFNγ; #P < 0.05 versus Ctrl, native LDL, moxLDL, oxLDL, and IL4; ‡P < 
0.05 versus moxLDL. The expression of the M2-type markers, Arg1 (c) and Mrc1 (d), was analyzed in BMDMs. 
*P < 0.05 versus all other groups; #P < 0.05 versus native LDL, oxLDL, IL4, LPS + IFNγ, and moxLDL + 
IFNγ; ‡P < 0.05 versus moxLDL. P value was obtained using one-way analysis of variance.  The means ± s.e.m. 
are shown for all panels. Three independent experiments were conducted per group.  
3.2.5 Role of miR-155 in proinflammatory macrophage 
activation 
To investigate the role of miR-155 in proinflammatory macrophage activation, the expression 
of M1-type markers following moxLDL and IFNγ stimulation of BMDMs isolated from miR-
155 deficient and wild type mice was determined. In contrast to moxLDL- and IFNγ–
stimulated miR-155+/+ BMDMs, miR-155-/- BMDMs showed a reduced expression mainly of 
Ccl2 mRNA but also of Tnfa mRNA, whereas no substantial difference in Il1b and Nos2 
expression was detectable between miR-155+/+ and miR-155-/- BMDMs (Fig. 71).  
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Figure 71: Expression of M1-type markers in the absence of miR-155. Expression of inflammatory 
macrophage markers was analyzed by qRT-PCR in BMDMs from miR-155+/+ and miR-155-/- mice after 
stimulation with moxLDL and IFNγ. *P < 0.05. vs. miR-155+/+. P value was obtained using two-way analysis of 
variance.  The means ± s.e.m. are shown. 3 independent experiments were conducted per group. 
3.2.6 Effect of leukocyte-specific miR-155 deficiency in 
atherosclerosis  
To study the role of miR-155 in atherogenesis, partial carotid ligation was performed in miR-
155+/+Apoe-/- mice transplanted with miR-155-/-Apoe-/- BM cells and in miR-155-/-Apoe-/- mice 
transplanted with miR-155+/+Apoe-/- BM. MiR-155+/+Apoe-/- mice repopulated with miR-
155+/+Apoe-/- BM cells were used as controls. Atherosclerotic lesion formation and the 
number of macrophages per plaque were determined using planimetry of EVG-stained carotid 
sections and MAC2 immunostaining, respectively. The plaque size and the number of lesional 
macrophages were significantly reduced in miR-155+/+Apoe-/- mice harboring miR-155-/-Apoe-
/- BM compared with the other 2 experimental groups (Fig. 72a, b). 
3 Results 
99 
 
 
Figure 72: Role of miR-155 in atherosclerosis. Following whole body irradiation, miR-155+/+Apoe-/- mice 
harboring miR-155+/+Apoe-/- (miR-155+/+ BM/miR-155+/+ [n = 7]) or miR-155-/-Apoe-/- BM  (miR-155-/- BM/miR-
155+/+ [n = 8]) and miR-155-/-Apoe-/- mice harboring miR-155+/+Apoe-/- BM (miR-155+/+ BM/miR-155-/- [n = 6]) 
were subjected to partial carotid ligation. (a) Plaque size and medial area was quantified 6 weeks after partial 
ligation by planimetry of EVG-stained section. Representative images are shown. (b) The number of 
macrophages in carotid lesions was determined by MAC2 immunostaining of carotid sections. Representative 
images are shown. Scale bars, 100 µm. *P < 0.05. P values were obtained using one-way analysis of variance. 
The means ± s.e.m. are shown for all panels. 
 
However, the relative macrophage plaque content as determined by the MAC2+ 
cell number and MAC2+ area normalized to the number of lesional cells and the plaque area, 
respectively, was not significantly different between the groups (Fig. 73a and b). Accordingly, 
miR-155 deficiency in BM cells or in recipient mice did not substantially alter the 
macrophage cell size in the lesions calculated by the MAC2+ area divided by the number of 
DAPI+ nuclei surrounded by MAC2+ staining (Fig. 73c). These results suggest that miR-155 
deficiency in BM cells reduces the number of lesional macrophages, but not the composition 
of the lesion or the macrophage size. 
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Figure 73: Effect of miR-155 deficiency on lesional macrophages. The relative number of macrophage cells 
(a), the relative macrophage content (b), and the macrophage cell size (c) were determined by macrophage-
specific MAC2 immunostaining in carotid plaques induced by partial ligation in Apoe-/- mice harboring either 
miR-155+/+Apoe-/- (miR-155+/+ BM/miR-155+/+) or miR-155-/-Apoe-/- (miR-155-/- BM/miR-155+/+) BM and in miR-
155-/-Apoe-/- mice harboring miR-155+/+Apoe-/- BM (miR-155+/+ BM/miR-155-/-). n = 6–8 mice per group. P = ns. 
P values were obtained using one-way analysis of variance. The means ± s.e.m. are shown for all panels. 
 
The lesional SMC content was determined in α-SMA-immunostainings of carotid 
sections from BM-transplanted mice. The α-SMA-positive area per lesion area tended to be 
decreased in miR-155+/+Apoe-/- mice harboring miR-155-/-Apoe-/- BM (Fig. 74a). Moreover, 
CD3, MPO, and collagen type I immunostainings did not show a significant difference in the 
relative number of CD3+ T cells and MPO+ neutrophils, and the relative lesional collagen 
type I content between the three groups (Fig. 74b-d). The percentage of apoptotic 
macrophages determined by combined TUNEL and MAC2 staining was also similar between 
the three groups (Fig. 74e). 
 
 
Figure 74: Effect of miR-155 deficiency on the cellular composition of atherosclerotic lesions. Lesional 
content of SMCs, T cells, neutrophils, collagen, and apoptotic macrophages were assessed by immunostaining 
for α-SMA (a), CD3 (b), MPO (c), collagen type I (d), and combined TUNEL staining and MAC2 
immunostaining in sections of partially ligated carotid arteries of Apoe-/- mice harboring either miR-155+/+Apoe-/- 
(miR-155+/+ BM/miR-155+/+) or miR-155-/-Apoe-/- (miR-155-/- BM/miR-155+/+) BM, and in miR-155-/-Apoe-/- mice 
harboring miR-155+/+Apoe-/- BM (miR-155+/+ BM/miR-155-/-). n = 6–8 mice per group. *P < 0.05. P values were 
obtained using one-way analysis of variance. The means ± s.e.m. are shown for all panels. 
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To assess the lipid accumulation in lesional miR-155-/- and miR-155+/+ 
macrophages, MAC2 immunostaining and Oil red O staining were combined. The Oil red O 
and MAC2 double positive area was significantly lower in miR-155-/- than in miR-155+/+ 
macrophages (Fig. 75). These results indicate that the expression of miR-155 in lesional 
macrophages not only increases macrophage accumulation in the lesions but also promotes 
lipid accumulation.  
 
Figure 75: Lipid accumulation in lesional miR-155-/- macrophages. Combined immunostaining for MAC2 
(green) and Oil red O (red) was performed in sections of partially ligated carotid arteries from miR-155+/+Apoe-/- 
mice harboring either miR-155+/+Apoe-/- (miR-155+/+ BM) or miR-155-/-Apoe-/- (miR-155-/- BM) BM. 
Representative images are shown. Scale bars, 20 μm. The Oil red O-stained area per MAC2+ area was 
quantified. n = 3-4 mice per group. *P < 0.05. P values were obtained using two-tailed Student’s t-test. Data are 
mean ± SEM. 
3.2.7 Effect of miR-155 on CCL2 expression in atherosclerotic 
lesions 
To study the effect of miR-155 on CCL2 expression in lesional macrophages combined 
immunostaining for CCL2 and MAC2 was performed. The number of CCL2-expressing 
macrophages was considerably reduced in carotid lesions of miR-155+/+Apoe-/- mice with 
miR-155-/-Apoe-/- BM compared with that in miR-155+/+Apoe-/- and miR-155-/-Apoe-/-mice 
harboring miR-155+/+Apoe-/- BM (Fig. 76). These data indicate that miR-155 deficiency 
reduces the expression of CCL2 in lesional macrophages, similar to the effect observed in 
miR-155-/- BMDMs stimulated with moxLDL and INF-γ. The reduced CCL2 expression in 
lesional macrophages in the absence of miR-155 may impair the recruitment of monocytes 
and thus the accumulation of macrophages in the lesions. 
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Figure 76: Role of miR-155 in CCL2 expression by lesional macrophages. Expression of CCL2 (green) was 
assessed in MAC2+ macrophages (red) from plaques 6 weeks after partial carotid ligation in Apoe-/- mice 
harboring miR-155+/+Apoe-/- or miR-155-/-Apoe-/-BM and in miR-155-/-Apoe-/- mice harboring miR-155+/+Apoe-/- 
BM by double immunostaining. Representative overlays of CCL2 and MAC2 immunostaining are shown (top). 
CCL2 expressed in macrophages is shown in yellow. The percentage of CCL2+ macrophages was determined. 
Adjacent sections were stained with EVG to demonstrate lesion morphology (bottom). Scale bars, 20 μm. n = 6-
8 mice per group. *P < 0.05. P values were obtained using one-way analysis of variance. The means ± s.e.m. are 
shown.  
3.2.8 Identification of miR-155 targets in macrophage 
activation 
To identify the miR-155 target that regulate CCL2 expression, the mRNA expression levels of 
3 known (Hif1a, Socs1, and Sfpi1) and 4 predicted (Rela, TCF7l2, Bcl6, and Pparγ) miR-155 
targets were studied in unstimulated miR-155-/- and miR-155+/+ BMDMs. In miR-155-/- 
BMDMs, the expression of Bcl6, Pparγ, and Sfpi1 were increased compared with miR-155+/+ 
BMDMs (Fig. 77a). Following stimulation with moxLDL and IFNγ, the expression of Hif1a, 
Rela, Socs1, Tcf7l2, and Sfpi1 was higher in miR-155-/- than in miR-155+/+ BMDMs (Fig. 
77b), indicating that the effect of miR-155 on the expression of the potential targets differs 
between stimulated and unstimulated macrophages. 
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Figure 77: Identification of miR-155 targets in BMDMs. Effect of miR-155 deficiency on the expression 
levels of potential miR-155 targets Hif1a (n = 4) and Rela, Socs1, Tcf7l2, Bcl6, Pparγ, and Sfpi1 were assessed 
using qRT-PCR (n = 3 for each) in unstimulated (a) and moxLDL- and IFNγ–stimulated (b) BMDMs. *P < 0.05 
vs. miR-155+/+. P values were obtained using two-way analysis of variance. The means ± s.e.m. are shown. 
 
To further identify direct targets of miR-155 in the M1-type polarization of 
macrophages, EIF2C2-specific IP was performed in moxLDL- and IFNγ -stimulated miR-155-
/- and miR-155+/+ BMDMs. MiR-155 was found to be highly enriched in EIF2C2-containing 
miR-induced silencing complexes (mRISCs) in miR-155+/+, but not miR-155-/- BMDMs (Fig. 
78a). Out of the 7 potential targets of miR-155 in BMDMs, Rela, Tcf7l2, Socs1, Bcl6, and 
Sfpi1 were significantly enriched in the EIF2C2 immunoprecipitates of miR-155+/+ compared 
to miR-155-/- BMDMs (Fig. 78b). These data indicate that Rela, Tcf7l2, Socs1, Bcl6, and Sfpi1 
were directly repressed by miR-155 in moxLDL- and IFNγ–stimulated macrophages.  
 
 
Figure 78: Enrichment of miR-155 and its targets in the miRISC of BMDMs. Enrichment of miR-155 (a) 
and its targets (b) were determined in immunoprecipitates from moxLDL- and IFNγ–stimulated miR-155+/+ and 
miR-155-/- BMDMs by qRT-PCR. Precipitates were obtained after incubation of cell lysates with an anti-EIF2C2 
or nonspecific IgG control antibody (n = 3-4 independent experiments per group). Results are expressed as target 
enrichment in miR-155-/-normalized to that in miR-155+/+ BMDMs. *P < 0.05 vs. miR-155+/+ (a) and vs. IgG (b). 
P values were obtained using two-tailed Student’s t-test. The means ± s.e.m. are shown. 
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3.2.9  Effect of miR-155-mediated regulation of Bcl6 on 
macrophages  
To study the functional role of the miR-155 targets in the regulation of the Ccl2 and Tnfa 
expression, Socs1, Bcl6, or Sfpi1 were silenced in miR-155-/- BMDMs using RNA 
interference. The efficient inhibition of these targets was confirmed by qRT-PCR (Fig. 79).  
 
 
Figure 79: Confirmation of siRNA-mediated silencing of miR-155 targets. The expression of Socs1 (a), Bcl6 
(b), and Sfpi1 mRNA (c) was quantified by qRT-PCR in miR-155-/- BMDMs stimulated with moxLDL and IFNγ 
and treated with non-targeting siRNA (siNTC) or siRNA against Socs1 (siSocs1, a), Bcl6 (siBcl6, b), and Sfpi1 
(siSfpi1, c). Three independent experiments were conducted for each group. *P < 0.05. P values were obtained 
using two-tailed Student’s t-test. Data are mean ± SEM. 
 
Interestingly, silencing Bcl6, but not Socs1 or Sfpi1, increased Ccl2 and Tnfa mRNA 
expression in miR-155-/- BMDMs (Fig. 80). Thus, derepression of the miR-155 target Bcl6 in 
miR-155-/- macrophages reduced atherogenic cytokine expression. 
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Figure 80: Bcl6 suppression mediates the proinflammatory effects of miR-155. The expression of Ccl2 and 
Tnfa mRNA in miR-155-/- BMDMs was quantified by qRT-PCR following treatment with non-targeting control 
siRNA (siNTC) or siRNA against Socs1 (a, siSocs1), Bcl6 (b, siBcl6), and Sfpi1(c, siSfpi1). n = 3-4 each group. 
*P < 0.05 vs. control. P values were obtained using two-way analysis of variance. The means ± s.e.m. are 
shown. 
 
By in silico analysis, two binding sites of miR-155 were predicted within the 3′UTR 
of Bcl6. To confirm the direct repression of Bcl6 by miR-155, luciferase reporter assays were 
performed using the full length, wild type 3′UTR of Bcl6 and a Bcl6 3′UTR that contained a 
mutated miR-155 binding site (Fig. 81a). The luciferase activity of the wild type Bcl6 3′UTR 
was significantly reduced by miR-155 (Fig. 81b). The reduction of the luciferase activity by 
miR-155 was not observed using the mutated Bcl6 3′UTR (Fig. 81b). These findings clearly 
indicate that miR-155 directly targets Bcl6 through binding to one of the predicted sites in its 
3′UTR.  
 
Figure 81: Luciferase reporter assay for miR-155 and 3′UTR of Bcl6. (a), Target sites for miR-155 in the 
3′UTR of murine Bcl6 mRNA as predicted by the miRanda prediction algorithm (sites A and B; blue). Target 
site A (sequence highlighted in green) was mutated in the binding region. (b), Luciferase reporter assays were 
performed in HEK293 cells treated with miR-155 mimics or nontargeting control mimics using the pEZX-MT01 
vector containing the Bcl6 3′UTR or the Bcl6 3′UTR with mutations (mutBcl6) in predicted miR-155 binding site 
A. n = 3 independent experiments per group). *P < 0.05 vs. control. P values were obtained using two-tailed 
Student’s t-test. The means ± s.e.m. are shown. 
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Since miR-155 can target Bcl6 in macrophages in vitro, the Bcl6 expression was 
studied in atherosclerotic lesions of mice harboring miR-155-/- BM cells by double 
immunostainings for Bcl6 and MAC2. The number of Bcl6-expressing macrophages was 
increased in miR-155+/+Apoe-/- mice harboring miR-155-/-Apoe-/- BM compared with miR-
155+/+Apoe-/- and miR-155-/-Apoe-/- mice harboring miR-155+/+Apoe-/- BM (Fig. 82a-b). 
Moreover, Bcl6 mRNA expression was higher in partially ligated carotid arteries from mice 
harboring miR-155-/- BM than in those from mice with miR-155+/+ BM (Fig. 82c), indicating 
that miR-155 also targets Bcl6 in lesional macrophages. 
 
 
Figure 82: Expression of Bcl6 in atherosclerotic lesions. (a) Combined immunostaining for Bcl6 (red) and 
MAC2 (green) was performed in plaques of partially ligated carotid arteries from miR-155+/+Apoe-/- mice 
harboring miR-155+/+Apoe-/- or miR-155-/-Apoe-/- BM and in miR-155-/-Apoe-/- mice harboring miR-155+/+Apoe-/- 
BM. Representative images are shown. Nuclei were counterstained with DAPI (blue). Arrows indicate Bcl6-
expressing macrophages. Scale bars, 50 μm. (b) Bcl6+ macrophages were quantified in sections of carotid 
lesions immunostained for BCL6 and MAC2 (n = 6–8 mice per group). (c) Bcl6 mRNA expression was 
determined by qRT-PCR in lesions of carotid arteries 6 weeks after partial ligation in miR-155+/+Apoe-/- mice 
harboring miR-155+/+Apoe-/- or miR-155-/-Apoe-/- BM (n = 4 mice per group). *P < 0.05. P values were obtained 
using one-way analysis of variance (b) or two-tailed Student’s t-test (c) The means ± s.e.m. are shown. 
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3.2.10 Effects of Bcl6 suppression on atherogenesis in mice with 
miR-155-/-BMs 
In order to study the role of Bcl6 in miR-155-induced atherosclerosis, Bcl6 expression was 
silenced in partially ligated carotid arteries of miR-155+/+Apoe-/- mice harboring miR-155-/-
Apoe-/- BM. The efficient silencing of Bcl6 by locally treatment with either Bcl6 siRNA or 
nonspecific control siRNA in partially ligated carotid arteries was confirmed by qRT-PCR 
(Fig 83). 
 
Figure 83: Suppression of Bcl6 mRNA expression in vivo. Partially ligated carotid arteries of miR-
155+/+Apoe-/- mice harboring miR-155-/-Apoe-/- BM were perivascularly treated once weekly with siRNA against 
Bcl6 (siBcl6) or non-targeting control siRNA (siNTC). The Bcl6 mRNA expression was quantified in the carotid 
arteries by qRT-PCR. n = 3-4 mice per group. *P < 0.05. P values were obtained using two-tailed Student’s t-
test. Data are means ± s.e.m. 
 
Effects of Bcl6 siRNA treatment on plaque development in partially ligated carotid 
arteries of miR-155+/+Apoe-/- mice harboring miR-155-/-Apoe-/- BM were studied by planimetry 
of EVG-stained carotid sections. Local treatment with Bcl6 siRNA significantly increased the 
size of carotid lesions as compared with nonspecific control siRNA, whereas no change was 
observed in the medial area of miR-155+/+Apoe-/- mice harboring miR-155-/-Apoe-/- BM (Fig. 
84). 
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Figure 84: Role of Bcl6 in miR-155–mediated atherosclerosis. Partially ligated carotid arteries from miR-
155+/+Apoe-/- mice harboring miR-155-/-Apoe-/- BM were perivascularly treated with Bcl6 siRNA (siBcl6) or 
nontargeting control siRNA (siNTC). Lesion area and medial area were determined by planimetry in carotid 
artery sections stained with EVG stain. Representative images are shown. Scale bars, 100 µm. n = 4-5 mice per 
group. *P < 0.05. P values were obtained using two-tailed Student’s t-test. Data are means ± s.e.m. 
 
To study the effect of Bcl6 inhibition on lesional macrophage cell number, MAC2 
immunostaining was performed in carotid sections of miR-155+/+Apoe-/- mice harboring miR-
155-/-Apoe-/- BM treated with Bcl6 or nontargeting control siRNA. Perivascular application of 
Bcl6 siRNA in partially ligated carotid arteries substantially increased the number of 
macrophages per lesion as compared to nonspecific control siRNA-treated carotid arteries 
(Fig. 85a). However, the relative macrophage number (Fig. 85b) and the relative MAC2+ 
lesion area (Fig. 85c), and the lesional macrophage cell size (Fig. 85d) were unchanged.  
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Figure 85: Effects of silencing Bcl6 on the lesional miR-155-/- macrophages. The number of lesional 
macrophages from partially ligated carotid arteries of miR-155+/+Apoe-/- mice harboring miR-155-/-Apoe-/- BM 
treated perivascularly with either Bcl6 siRNA (siBcl6) or nontargeting control siRNA (siNTC) was analyzed by 
immunostaining for MAC2 (green). (a) Representative images are shown. The number of MAC2+ cells per 
lesion was determined. Scale bars, 100 µm. n = 4-5 mice per group. *P < 0.05. (b) The relative macrophage cell 
number, (c) the relative lesional macrophage area, and (d) the macrophage cell size was determined in carotid 
artery sections immunostained for MAC2. n = 4 mice per group. P = ns. P values were obtained using two-tailed 
Student’s t-test. Data are means ± s.e.m. 
 
In addition, the lesional SMC content as determined by α-SMA immunostaining 
was determined in the Bcl6 siRNA-treated arteries. The relative α-SMA+ area in the lesions 
tended to increase after Bcl6 siRNA treatment compared with nontargeting control siRNA 
treatment in miR-155+/+Apoe-/- mice harboring miR-155-/-Apoe-/- BM (Fig. 86). 
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Figure 86: Effect of Bcl6 on lesional SMCs. Partially ligated carotid arteries from miR-155+/+Apoe-/- mice 
harboring miR-155-/-Apoe-/- BM were perivascularly treated with siRNA against Bcl6 (siBcl6) or non-targeting 
control siRNA (siNTC). The relative SMC content was quantified in α-SMA-immunostained (red) sections of 
the carotid artery lesions. n = 4 mice per group. Scale bars, 100 μm. P = ns. P values were obtained using two-
tailed Student’s t-test. Data are means ± s.e.m. 
 
Finally, CCL2 expression was assessed in lesional macrophages after Bcl6 siRNA 
treatment of partially ligated carotid arteries of miR-155+/+Apoe-/- mice harboring miR-155-/-
Apoe-/- BM. CCL2 immunostaining of the lesions showed that the percentage of CCL2-
expressing miR-155-/- macrophages was increased in arteries treated with Bcl6 siRNA 
compared to control siRNA (Fig. 87), indicating that derepression of Bcl6 reduces the CCL2 
expression in miR-155-/- lesional macrophages. 
 
 
Figure 87: Effect of BCL6 on CCL2 expression in lesional macrophages. Combined immunostaining for 
CCL2 (green) and MAC2 (red) was performed in carotid artery sections of miR-155+/+Apoe-/- mice harboring 
miR-155-/-Apoe-/- BM. Representative overlays of CCL2 and MAC2 immunostaining are shown. Nuclei were 
counterstained with DAPI (blue). Scale bars, 100 μm. The percentage of CCL2+ macrophages (yellow) was 
quantified. n = 4–5 mice per group. *P < 0.05. P values were obtained using two-tailed Student’s t-test. Data are 
means ± s.e.m. 
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3.2.11 Role of miR-342-5p in atherosclerosis 
The miR expression profiles in laser-microdissected plaque samples from the aortic root of 
Apoe-/- mice showed that miR-342-5p and miR-155 are concomitantly up-regulated in these 
atherosclerotic lesions. 
To sudy the role of miR-342-5p on atherogenesis, carotid arteries of Apoe-/- mice 
were subjected to partial ligation. The expression of miR-342-5p was quantified at 1, 2, and 6 
weeks after partial ligation of caroid arteries. MiR-342-5p expression levels were upregulated 
at 1 week and remained high until 6 weeks after partial ligation as compared with nonligated 
carotid arteries (Fig. 88a). To address the role of miR-342-5p during atherogenesis, miR-342-
5p expression was suppressed in partially ligated carotid arteries using perivascular 
application of miR-342-5p antagomir. Suppression of miR-342-5p strongly reduced the 
atherosclerotic lesion size as compared to control antagomir-treated partially ligated arteries 
(Fig. 88b). Analysis of the plaque composition showed that the macrophage area and cell 
number (Fig. 88c), and the SMC content (Fig. 88d) were significantly reduced in partially 
ligated arteries treated with miR-342-5p antagomir as compared to control antagomir. These 
data indicate that miR-342-5p enhances atherogenesis. Furthermore, inhibition of miR-342-5p 
induced Akt1 expression and reduced miR-155, Nos2, and IL6 expression in carotid arteries at 
6 weeks after partial ligation (Fig. 88e). Akt1 is known to the inflammatory response of LPS-
stimulated macrophages by inhibiting miR-155 expression209. Therefore, miR-342-5p may 
induce miR-155 expression by targeting Akt1, and thus amplifies the inflammatory activation 
of macrophages during atherosclerosis210. 
3 Results 
112 
 
 
Figure 88: Role of miR-342-5p in atherosclerosis. (a) MiR-342-5p expression after partial ligation of the 
carotid artery in Apoe-/- mice fed a HCD for 1, 2, and 6 weeks (1w, 2w, and 6w). Non-ligated carotid arteries 
were used as controls (Ctrl). n = 3-4 mice per group. (b) Effects of perivascular application of miR-342-5p or 
control antagomirs on atherosclerotic lesion formation were studied in partially ligated carotid arteries from 
Apoe-/- mice fed a HCD for 6 weeks. Representative images of EVG-stained sections are shown. Scale bars, 100 
µm. The lesion size was determined by planimetry in carotid artery sections stained with EVG stain. n = 5-6 
mice per group. (c) Lesional macrophage area and cell number was determined by MAC2 immunostaining of 
carotid sections from partially ligated carotid arteries treated with the miR-342-5p antagomir or control 
antagomir. n = 5-6 mice per group. (d) The relative SMC content was quantified in α-SMA-immunostained 
sctions of the partially ligated carotid arteries treated with the miR-342-5p or control antagomirs. n = 5-6 mice 
per group. (e) Akt1, miR-155, Nos2, and Il6 expression was quantified in carotid arteries treated with the miR-
342-5p or control antagomirs 6 weeks after partial carotid ligation in Apoe-/- mice fed a HCD. n = 5-6 mice per 
group. *P<0.05. P values were obtained using two-tailed Student’s t-test (b through e). Data are means ± s.e.m.  
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4  Discussion 
4.1 MiR-126 protects against neointima formation and 
atherosclerosis 
4.1.1 MiR-126 limits neointima formation by enhanced 
endothelial recovery 
MiR-126 is abundantly expressed in ECs and in highly vascularized tissues146 211. MiR-126 
deficiency in mice causes leaky vessels, hemorrhage, and partial embryonic lethality, due to 
the loss of vascular integrity and defects in EC proliferation, migration, and angiogenesis146. 
Several studies indicate that endothelial recovery and restoration of EC function after 
endothelial denudation is crucial for the prevention of lesion formation79 90 212 213. Repair of 
injured ECs can be rapidly achieved by proliferation and migration of resident ECs207. 
Therefore, miR-126 may support endothelial repair after vascular injury, and thus limits 
neointima formation.  
In line with this hypothesis, increased neointima formation was found in miR-126 
deficient mice after vascular injury in the present study. Moreover, the endothelial recovery 
and proliferation of ECs were impaired in miR-126-/- mice, indicating that miR-126 limits 
neointimal hyperplasia by promoting endothelial repair. The exacerbated neointima formation 
in miR-126-/- mice was due to an increased accumulation of macrophages in the neointima, 
whereas the SMC content remained unchanged. Lesional macrophages are derived from 
circulating monocytes, which are recruited to the arterial vessel walls during atherogenesis214 
215. The number of macrophages in the lesions was similar between miR-126-/- and miR-126+/+ 
mice, suggesting that increased macrophage accumulation in miR-126-/- mice is not due to 
enhanced recruitment of monocytes. However, an increased macrophage cell size was 
observed in miR-126-/- mice, which indicates that the expansion of the lesional macrophage 
content may be caused by an enlargement of the individual macrophages. Following vascular 
injury and de-endothelialization, the permeability of the vessel wall for LDL increases 
substantially, and thus macrophages recruited to injured vessel are exposed to higher LDL 
concentration, if the endothelium is damaged33 216-218. The elevated LDL concentration in the 
injured artery may enhance the uptake of lipids by macrophages, which accelerates foam cell 
formation and increases macrophage cell size (Fig. 88). Thus, enhanced endothelial repair by 
miR-126 may protect from lesion formation through reduced lipid accumulation, which limits 
macrophage “hypertrophy”.  
A crucial role of reendothelialization in neointima formation has been previously 
suggested by several studies17 219. However, direct evidence for an protective effect of 
endothelial recovery in neointima formation is scarce due to experimental difficulties to 
specifically address the role of the endothelium89 90 220. The current study clearly demonstrated 
that genetic deficiency of miR-126 in arterial ECs promotes neointima formation by impairing 
EC proliferation, indicating that enhanced endothelial repair is of central importance for 
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limiting neointimal growth. Thus, these findings provide further evidence for a beneficial role 
of endothelial repair following vascular injury. 
Although miR-126 is highly expressed in ECs, bone marrow-derived cells, such as 
hematopoietic stem cells, early progenitors, and pro-angiogenic CD34+ PBMCs also express 
miR-126221. Moreover, despite the finding that the miR-126 expression was very low in 
peripheral blood cells, monocyte/macrophage-derived miR-126 may directly affect the size of 
neointimal macrophages. In addition, BM-derived cells or endothelial progenitor cells can 
contribute to endothelial repair222 223. Therefore, the role of miR-126 expression in BM cells 
and resident ECs was dissected. The results of the experiments using mice harbouring miR-
126 deficient BM cells demonstrated that only the expression of miR-126 in resident ECs, but 
not in BM cells, mediates the effect on endothelial recovery and neointima formation. Taken 
together, these findings indicate that miR-126 expression in circulating pro-angiogenic cells 
and macrophages does not play a role in the formation of neointimal lesions following 
vascular injury.  
 
Figure 88: Protective role of miR-126 following endothelial denudation. MiR-126 deficiency dramatically 
increases neointima formation and the neointimal accumulation of enlarged macrophages. This enhanced 
neointima formation resulted from delayed endothelial recovery due to reduced EC proliferation after vascular 
injury. The macrophage enlargement may be due to increased influx of lipids into de-endothelialized arteries 
rather than by a functional role of miR-126 in BM-derived cells.  
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4.1.2 MiR-126-5p promoted endothelial repair following 
vascular injury 
Following processing of the hairpin structured pre-miR by Dicer into duplexes, one strand 
(the guide strand) remains loaded onto Argonaute proteins in the RISC, while the other strand 
(the passenger strand) is usually degraded224. Although the mechanism of miR strand 
selection is unclear, it involves differential selection of one of the two individual RNA strands 
by Dicer and its associating proteins225. According to the strand bias theory, the strand with 
the less stable hydrogen bonds at its 5' end within the original duplex is selectively stabilized 
and forms the mature miR strand, whereas its complementary strand is degraded226. 
Moreover, Argonaute proteins, the effectors of RNA silencing, may also contribute to miR 
strand selection by binding and stabilizing mature miRs225 227. However, the passenger and the 
guide strand can co-accumulate as miR pairs in a tissue-dependent manner and each strand 
can suppress a distinct set of target genes135. Although the strand at the 3' end of the pre-miR-
126, miR-126-3p, primarily accumulates in ECs150 228, the expression level of the mature miR 
derived from the 5' end, miR-126-5p, is up-regulated in vascular precursor cells and ECs 
during embryogenesis where its expression can even be higher than the expression level of 
miR-126-3p149. In human atherosclerotic lesions, the expression of miR-126-5p is significantly 
increased compared to normal arteries229. However, Wang et al. reported that miR-126-5p is 
expressed only in trace amounts in mouse tissues146. The quantification of miR expression can 
be difficult by methods such as northern hybridization or microarray analysis due to great 
variability between samples230. In contrast, stem loop-specific qRT-PCR detects and 
quantifies mature miRs in a specific, accurate, and reliable manner230. Wang et al. studied the 
expression levels of miR-126 strands by northern blot, which has less sensitivity in detection 
miRs and it often leads to high background signal from the pre-miR231. In the current study, 
the expression levels of miR-126-5p were comparable to that of miR-126-3p using qRT-PCR 
in most tissues. In murine arteries, the miR-126-5p expression was slightly lower than that of 
miR-126-3p. Moreover, the expression of miR-126-3p and miR-126-5p was only detectable in 
ECs and regulated similarly following endothelial denudation. Thus, both miR-126 strands are 
expressed in adult tissues and each strand may play a functional role in vascular repair.  
In mice with a genetic deficiency of miR-126, pre-miR-126 is not expressed and 
thus both mature miR-126 strands cannot be generated146. Therefore, each of the mature miR-
126 strands may contribute to the effect of miR-126 deficiency on neointima formation and 
endothelial regeneration. In contrast to previous studies, which addressed mainly the effect of 
miR-126-3p in ECs, the role of the individual miR-126 strands was studied by strand-specific 
inhibition of miR-126-3p and miR-126-5p in the injured artery in the present study. The 
results of the current study demonstrated that inhibition of miR-126-5p, but not of miR-126-
3p, exacerbate neointima formation and impair endothelial repair by reducing EC 
proliferation. Therefore, the passenger strand of miR-126, miR-126-5p, plays a crucial role in 
endothelial repair in injured arteries. 
In accordance with the unexpected finding that only miR-126-5p is instrumental in 
neointima formation, gene expression analysis demonstrated that mainly potential targets of 
miR-126-5p were up-regulated in arteries of miR-126-/- mice 2 weeks after wire injury. 
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Moreover, only the up-regulation of the predicted miR-126-5p target Dlk1 was confirmed by 
qRT-PCR. Dlk1 is widely expressed during embryonic development, including ECs181. In the 
adult, however, Dlk1 expression is restricted to neuroendorcrine tissues, pancreas, central 
nervous system, and the reproductive system171. Moreover, expression of Dlk1 in ECs from 
various species has been detected in vitro182. In injured arteries, the expression of Dlk1 was 
mainly restricted to ECs. Moreover, Dlk1 expression was increased by the miR-126-5p-
specific antagomir, indicating that targeting of Dlk1 by miR-126-5p promotes EC proliferation 
and thereby limits neointimal hyperplasia. Thus, the up-regulation of Dlk1 in ECs during 
endothelial repair is in line with its regulation by miR-126-5p during neointima formation.  
By contrast, the expression of already established targets of miR-126-3p, such as 
Spred1, PIK3R2, VCAM-1, or RGS16, was not significantly increased. Apart from VCAM-1, 
all of these targets are regulated by miR-126-3p through mRNA degradation, like most of the 
miR targets146 149 151 232. Therefore, the effect of miR-126-3p deficiency on their expression 
should be detectable at the mRNA level. However, VCAM-1 is suppressed by miR-126-3p in 
humane ECs only at the protein level, whereas VCAM-1 mRNA expression is also increased 
in murine miR-126-/- ECs146 150. Akin to the mRNA expression of Spred1, PIK3R2, and 
RGS16, there was no difference in VCAM-1 protein expression following treatment with miR-
126-3p antagomirs. However, due to the small sample size and the rather modest regulation of 
the target expression by miRs, up-regulation of the miR-126-3p targets in injured arteries of 
miR-126-/- mice might not have reached a statistically significant level. Moreover, the effect 
of miR-126-3p on VCAM-1 expression appears to be heterogeneous throughout the vascular 
system. In TNFα-treated mice, up-regulation of VCAM-1 was found in the microvascular ECs 
of the glomeruli, but not in capillaries of the lung and heart233. VCAM-1 is also substantially 
up-regulated in neointimal SMCs following vascular injury, which may mask potential effects 
of miR-126-3p on endothelial VCAM-1 expression when the whole artery is studied234. In 
contrast to the microarray results obtained at 2 weeks after injury in miR-126-/- mice, Spred1 
mRNA expression was significantly increased in miR-126-3p antagomir-treated arteries at 4 
weeks, when neointima formation is completed. This finding would be compatible with a 
delayed regulation of Spred1 by miR-126-3p following vascular injury, maybe due to reduced 
transcription of Spred1 in the early phase of neointima formation. Nevertheless, neointima 
formation was not altered by inhibiting miR-126-3p, indicating that the potential regulation of 
Spred1 by miR-126-3p is not instrumental in vascular repair. Taken together, these findings 
demonstrate a crucial role of miR-126-5p in vascular repair and indicate that Dlk1 is the main 
target of miR-126-5p that mediates enhanced neointima formation and reduced EC 
proliferation in miR-126-/- mice.  
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4.1.3 DLK1 mediated the effects of miR-126-5p in vascular 
repair 
MiRs mainly regulate their mRNA targets through complementary base pairing between 
nucleotides 2 and 7 at the 5' end of the miR, the ‘seed’ sequence, and the target site in the 
3'UTR of the mRNA204. Different types of seed pairing can be discerned, which differ in the 
site efficacy. The far most efficient canonical seed pairing (also called a 8mer site) comprises 
the nucleotides 2-8 of miR and includes an unpaired adenine in the mRNA site across position 
1 of the miR seed204. The advantage of a mismatched adenine for the specificity of target 
recognition might be related to an improved pairing due to interaction of the adenine at 
position 1 to a protein of the RISC204. Moreover, supplementary and compensatory base 
pairing to the 3' portion of the miR may play a role in target recognition204. The 3' 
supplementary pairing involves at least 3-4 contiguous Watson-Crick pairs between the miR 
nucleotides 13-16 and the respective region in the mRNA UTR204. However, supplementary 
pairing makes the miR-induced target suppression only slightly more effective and may thus 
play a modest role in target recognition204. In addition, 3'-compensatory pairing has been 
suggested, which cannot only supplement the seed pairing, but compensate for single-
nucleotide mismatches in the seed region204. These 3'-compensatory sites include at least nine 
contiguous Watson-Crick pairs centered on miR nucleotides 13-17204. However, 3'-
compensatory binding sites have so far only rarely been identified to play a role in the 
targeting of mRNAs by miRs204. Furthermore, specific features of the UTR context can 
enhance the site efficiency, like positioning of the target site at least 15 nt from the stop 
codon, localization at the ends of a long UTR rather than in the center, increased site 
accessibility due to an AU-rich nucleotide composition near the site, and proximity to sites for 
coexpressed miRs204. 
A single target site for miR-126-5p was predicted in the 3'UTR of the Dlk1 mRNA 
by different prediction algorithms, such as Targetscan, MicroCosm, and miRDB. The 
predicted target site consists of stringent pairing of nucleotides 2-8 of the 5' miR-126-5p seed 
and an adenine at across position 1 in the Dlk1 3'UTR and therefore has the typical features of 
a canonical 8mer site. Moreover, 6 additional Watson–Crick pairs were observed between the 
Dlk1 target site and the 3' end of miR-126-5p, including the nucleotides 13 and 14 of miR-
126-5p. However, these pairs do not form a 3' supplementary site, which would require at 
least 3 contiguous pairs. Therefore, it is unlikely that these 3 pairs contribute to target 
recognition, but may support the stability of the binding to the target site204. In addition, the 
predicted miR-126-5p target site is not centered in the Dlk1 3'UTR and the target site includes 
an adenosine opposite to position 9 of the miR, which makes this UTR position more 
accessible for the silencing complex. Thus, the predicted target site at the 3′ UTR of Dlk1 has 
many features of a highly effective sequence for the interaction with miR-126-5p. In line with 
these predictions, the current study showed that miR-126-5p indeed specifically targets the 
3'UTR of murine Dlk1 via the predicted seed match. Notably, the 3'UTR of human Dlk1 
contains the identical miR-126-5p target site, suggesting that miR-126-5p can also suppress 
the expression of human Dlk1.  
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Although miRs generally suppress the expression of their targets, in the injured 
artery the expression of miR-126-5p and Dlk1 was not regulated in the opposite direction. 
After a transient reduction at 1 d after vascular injury, the expression of miR-126-5p 
recovered quickly at 7 d and remained at the same level during vascular repair. However, 
Dlk1 mRNA expression was strongly up-regulated at 7 d after injury and subsequently 
declined to baseline. These data indicate that Dlk1 expression following vascular injury is 
transiently regulated at the transcriptional level in addition to the posttranscriptional 
suppression by miR-126-5p. MiR-126-5p appears to moderate the strong up-regulation of 
Dlk1 expression at day 7 and thereby tunes the DLK1 protein level to a more optimal range. 
This finding is in line with the concept of a tuning interaction of miRs in which constitutively 
expressed miRs act as a rheostat that dampen the expression of up-regulated genes to a more 
optimal but still functional level204 235 236 . According to this mechanism, one might expect that 
the miR-126-5p expression level remains constant after vascular injury; however, the miR-
126-5p expression was substantially diminished shortly after endothelial denudation. This 
reduction in miR-126-5p expression may be explained by the removal of the endothelium, 
which is the main miR-126-5p-expressing cell type in the vessel wall. Interestingly, 
differences between the neointima formation and the endothelial recovery were observed only 
after 14 and 28 d but not at 7 d. These results suggest that miR-126 does not play a role in 
early re-endothelialization and becomes functional only after up-regulation of the miR-126-5p 
target, Dlk1.  
Dlk1 is expressed in different types of ECs and inhibits EC proliferation during 
angiogenesis182. In line with these results, suppression of Dlk1 in miR-126-/- mice promoted 
EC proliferation and endothelial recovery, thereby limiting the exacerbated neointima 
formation. These findings clearly demonstrate that uncontrolled expression of Dlk1 in ECs 
mediates the effect of miR-126 deficiency on vascular repair. However, the precise 
mechanism of Dlk1-mediated inhibition of EC proliferation is unclear. DLK1 can interact 
with NOTCH1 through extracellular interaction of NOTCH1 and EGF-like repeats in DLK1, 
but DLK1 lacks the DSL domain required for NOTCH1 activation by classical ligands208. 
This structural feature might explain the inhibitory effects of DLK1 on NOTCH1 activation in 
various cell types208 237-239. Endothelial NOTCH1 plays an important role in angiogenesis 
downstream of VEGF during development and tumor formation by suppressing tip cell 
behavior in stalk cells240. The inhibition of angiogenesis and EC proliferation by DLK1 has 
been attributed to reduced NOTCH1 activation171. However, several in vitro studies mainly 
provided evidence for an inhibitory effect of NOTCH1 on EC proliferation241-243, indicating 
that the precise effects of NOTCH1 signaling in ECs is context- and ligand-dependent244. The 
current study indicates that NOTCH1 activation in ECs is reduced during vascular repair in 
miR-126-/- mice, which may be due to increased Dlk1 expression. Of note, interaction of 
soluble DLK1 released after proteolytic cleavage with transmenbrane-bound DLK1 can 
inhibit the differentiation of pre-adipocytes, whereas interactions of the intracellular DLK1 
domains impair the differentiation and reduce the proliferation of hematopoietic cells177. 
Therefore, Dlk1-mediated inhibition of EC proliferation may also be mediated by other 
mechanisms than NOTCH1 inhibition. 
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Figure 92: miR-126-5p negatively regulates Dlk1 expression and controls vascular repair. In endothelial 
cells miR-126-5p targets Dlk1 mRNA, an inhibitor of EC proliferation, and thereby promotes EC proliferation. 
DLK1 may inhibit EC proliferation directly and indirectly by the intracellular domain and by interaction of the 
extracellular domains with the NOTCH1 receptor, respectively. MiR-126-5p-mediated EC proliferation is critical 
for vascular re-endothelialization and reduces the neointima formation following vascular injury. 
4.1.4 MiR-126 deficiency promoted atherogenesis and inhibited 
EC proliferation 
Akin to the effect of genetic miR-126 deficiency on neointima formation, diet-induced 
atherosclerotic lesions were also substantially increased in the thoraco-abdominal aorta and 
carotid arteries of miR-126-/-Apoe-/- mice. However, exacerbated atherosclerosis was not 
observed in the aortic root (a predilection site of atherosclerosis) of miR-126-/-Apoe-/- mice, 
indicating that the absence of miR-126 promotes atherosclerosis primarily in arterial regions 
that are normally resistant to atherosclerosis. Indeed, regional analysis of lesion formation 
showed that atherosclerosis was only increased at non-predilection sites of miR-126-/-Apoe-/- 
mice. Up-regulation of miR-126 transcription by hemodynamic forces (e.g., via the 
transcription factor KLF2) during development and high shear stress has been reported147 245, 
suggesting that low-shear stress in predilection sites might repress miR-126 transcription and 
thus abate the athero-protective effects of miR-126 on atherosclerosis in these regions.  
The miR-126-5p expression levels were reduced in athero-prone regions with 
disturbed blood flow, such as aortic branches or the aortic root. Furthermore, miR-126-5p 
expression levels were diminished following induction of disturbed blood flow in carotid 
artery. Therefore, reduced miR-126-5p expression was associated with increased lesion 
formation at predilection sites and in disturbed flow-induced atherosclerosis. Conversely, 
miR-126 deficiency did not affect disturbed flow-induced lesion formation but exacerbated 
atherosclerosis primarily at non-predilection sites including the carotid artery. Moreover, 
absence of miR-126 in hyperlipidemic mice reduced luminal EC proliferation in the carotid 
artery, but not in aortic roots or in disturbed flow-induced lesions, suggesting that decreased 
miR-126-5p expression under disturbed flow inhibits EC proliferation. Interestingly, systemic 
administration of miR-126-5p mimics reversed the effects of miR-126 deficiency on diet-
induced atherosclerosis and in reduced lesion formation in vascular regions with disturbed 
flow-induced suppression of miR-126-5p, and improved EC proliferation. These data indicate 
that miR-126-5p mimics do not only limit atherosclerosis in the absence of miR-126 but also 
protect against atherosclerosis at predilection sites in miR-126 wild type mice with reduced 
levels of miR-126-5p due to disturbed flow. Thus, miR-126-5p may have a protective role in 
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atherosclerosis by increasing EC regeneration similar to its role in neointima formation after 
vascular injury. 
Complete endothelial denudation, as it occurs after mechanical injury, is not a 
common feature during atherosclerotic plaque formation9. In contrast, inflammatory 
activation of ECs characterized by increased expression of adhesion molecules and cytokines 
is closely linked to atherogenic monocyte recruitment6. Although EC proliferation in arteries 
is generally a rare event in adults, the mitosis rate of ECs at predilection sites of 
atherosclerosis, such as branching points, is increased and can be further enhanced by 
hyperlipidemia61 246 247. Disturbed flow and low shear stress are characteristic for these 
predilection sites and promote EC proliferation and activation248. Because of this increased 
EC proliferation at predilection sites, it has been suggested that EC proliferation promotes 
lesion formation61. Moreover, the influx of lipoproteins to the vessel wall is greatly enhanced 
in regions of increased EC turnover and EC proliferation has been linked to monocyte 
adhesion through up-regulation of p21 under low shear stress conditions in vitro249 250. 
However, direct evidence for the effect of EC proliferation on atherosclerosis is not available.  
In addition to EC proliferation, apoptosis of ECs occurs in the vessel wall and the 
apoptosis rate also correlates with increased permeability of the vessel wall62 251 252. EC 
apoptosis is enhanced by low shear stress in vitro and in human atherosclerotic plaques, 
especially in plaque regions with low shear stress, like the downstream plaque region65 253-255. 
Hypercholesterolemia and oxidized LDL can further promote EC turnover, presumably by 
increasing both EC apoptosis and proliferation, indicating that hyperlipidemia may exacerbate 
EC injury under atherogenic conditions61 256 257. In summary, a pro-atherogenic role of EC 
proliferation has been postulated, although direct evidence for this effect of EC proliferation 
on lesion formation is missing61. Unfortunately, EC proliferation during atherosclerosis has 
not been considered in the context of a concomitantly increased EC apoptosis, which would 
be in agreement with the concept that enhanced EC proliferation represents a regenerative 
response, and may thus limit atherosclerosis. In this regard, the EC proliferation at 
predilection sites would be insufficient to meet the increased demand for endothelial 
regeneration during disturbed flow and hyperlipidemia. In line with this concept, results of the 
present study suggest a protective role of EC proliferation against atherosclerotic lesion 
formation, which is mediated by miR-126-5p expression. In this model, the expression of 
miR-126-5p plays a crucial role to maintain a sufficient high EC proliferation at non-
predilections sites, although these sites are characterized by a lower requirement for EC 
regeneration than at predilections sites due to laminar flow. Conversely, disturbed flow-
induced suppression of miR-126-5p at predilection sites appears to critically limit endothelial 
regeneration, which may promote atherosclerosis by increasing lipid influx into the vessel 
wall and macrophage accumulation. Therefore, the findings of the current study indicate that 
the expression of miR-126-5p controls regional susceptibility to atherosclerosis through 
enhancing EC proliferation. 
Dlk1 mediated the effect of miR-126-5p on EC proliferation during neointima 
formation, suggesting that a similar mechanism may be instrumental in diet-induced 
atherosclerosis. In line with this hypothesis, the Dlk1 and miR-126-5p expression were 
inversely regulated in predilection and non-predilection sites, in aortic roots, and in partially 
ligated carotid arteries. Moreover, the results of the current study indicate that increased Dlk1 
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expression after induction of disturbed blood flow promotes atherosclerosis by increasing EC 
proliferation. The finding that treatment with miR-126-5p mimics reduced the Dlk1 
abundance in ECs further support the concept that targeting of Dlk1 by miR-126-5p protects 
from atherogenesis. Of note, a negative correlation of miR-126-5p expression levels and 
endothelial DLK1 expression was also observed in human atherosclerotic lesions, indicating 
that the results from murine atherosclerosis may be transferable to humans.  
However, the results of the present study cannot exclude a role of miR-126-3p in 
increasing atherosclerosis in miR-126 deficient mice. Inhibition of miR-126-3p can increase 
endothelial VCAM-1 expression and thus enhance monocyte adhesion150 258. Moreover, miR-
126-3p is released in apoptotic bodies and mediates the recruitment of angiogenic cells to the 
vessel wall151. These recruited cells may not differentiate into ECs but rather support the 
recovery of resident ECs151. Moreover, circulating or microparticle-associated miR-126-3p 
levels are reduced in patients with coronary artery disease or type-2 diabetes259 260. These data 
suggest a protective role of miR-126-3p in atherogenesis. In addition, the current study 
demonstrated that miR-126-5p enhances EC proliferation thereby limiting atherosclerosis. 
Taken together both miR-126 strands may play important roles in endothelial regeneration by 
forming a regulatory system with complementary functions. However, the results of the 
current study would be compatible with the concept that miR-126-5p and miR-126-3p act 
sequentially in endothelial regeneration. Whereas miR-126-5p is primarily important in 
inducing EC repair by proliferation, miR-126-3p from apoptotic ECs may trigger EC 
regeneration by circulating progenitor cells as a back-up system when miR-126-5p fails, e.g., 
due to suppression in regions with disturbed flow.  
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4.2 MiR-155 promotes atherosclerosis  
4.2.1 MiR-155 links proinflammatory macrophages with 
atherosclerotic plaques  
Following differentiation from monocytes, macrophages can polarize into functionally 
specialized subtypes, such as classically-activated (alias M1-type) and alternatively-activated 
(alias M2-type) macrophages. Polarization into M1-type macrophages, which secrete high 
levels of proinflammatory mediators, such as IL1β, TNFα, iNOS, and IL12, is induced by 
stimulation with LPS and INF-γ261. In contrast, M2-type macrophages, which polarize from 
unstimulated macrophages after activation with IL4, produce primarily high levels of anti-
inflammatory factors, such as IL10261 262. M1-type as well as M2-type macrophages are 
present in human and mouse atherosclerotic lesions indicating that macrophage heterogeneity 
plays a role in atherosclerosis262-267. However, a direct functional link between macrophage 
subsets and atherosclerosis is missing, although first evidence indicates a pro-atherogenic role 
of M1-type macrophages 262 266.  
MiRs, such as let-7c, miR-210, miR-29b, and miR-155, regulate the polarization of 
macrophages268-270. In addition, macrophage polarization changes the expression profile of 
miRs, including miR-29b and miR-155, in THP-1 cells268. Moreover, inflammatory activation 
of macrophages induces the expression of miRs, such as miR-155 and miR-147153 268 271. In 
line with these data, the current study showed that M1-type polarization of BMDMs by 
stimulation with LPS and INF-γ induced the expression of a specific set of miRs, including 
miR-155 and miR-147. By contrast, miR-155 was not regulated after M2-type polarization by 
IL4, suggesting that miR-155 is a specific marker for proinflammatory, M1-type 
macrophages. Furthermore the current study showed that the miR expression profile in 
experimentally induced, macrophage-rich atherosclerotic lesions is characterized by up-
regulation of miR-155 and miR-147. Interestingly, mainly lesional macrophages expressed 
miR-155, indicating that proinflammatory macrophages (M1-type) are present in 
atherosclerotic lesions and that they may play a role during atherogenesis.  
The functional roles of miR-155 and miR-147 in macrophages differ. MiR-155 
mainly induces proinflammatory cytokines, while miR-147 is part of a negative feedback loop 
that inhibits the inflammatory response209 268 271. The current study demonstrated that 
increased miR-155 and miR-147 expression is characteristic for M1-type macrophages and the 
arterial wall of hyperlipidemic mice. In contrast to miR-147 expression, which was not 
significantly different between atherosclerotic lesions and non-atherosclerotic arteries in mice, 
miR-155 expression was significantly upregulated in atherosclerotic plaques in mice and 
humans. A broad range of inflammatory mediators, like LPS, IFNγ, or TNFα, induces miR-
155 expression in macrophages272-274. Moreover, Akt1 negatively regulates the expression of 
miR-155 in LPS-stimulated macrophages, which in turn dampens M1-type macrophage 
polarization209 275. These data indicate that miR-155 may affect atherogenesis by regulating 
the pro-inflammatory activation of lesional macrophages.  
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The current study showed that the expression levels of miR-155 were increased in 
advanced atherosclerotic lesions of hyperlipidemic mice and in inflammatory macrophages. 
Moreover, miR-155 is induced in the aortic wall of Apoe-/- mice only after 10 months of HCD. 
However, in atherosclerotic lesions, miR-155 is induced after 3 months but not after 10 
months of a HCD. This difference in the induction of miR-155 may be due to the more 
advanced plaque phenotype in the aortic root compared to the aortic wall. Accordingly, the 
lesional cell composition varies between early and late lesions, which might contribute to 
differences in miR-155 expression. Similar to murine plaques, miR-155 expression was also 
increased in human atherosclerotic lesion. These data are supported by findings from 
Raitoharju et al., who reported elevated levels of miR-155 in human atherosclerosis276. These 
data demonstrate that increased miR-155 expression is characteristic not only of M1-type 
macrophages, but also of mouse and human atherosclerotic plaques.  
In addition to macrophages, miR-155 is expressed in ECs and induced by high 
shear stress277. In ECs, miR-155 reduces the angiotensin II-induced proinflammatory 
activation by co-targeting AT1R and Ets-1278. However, in the current study miR-155 was not 
detectable in ECs covering atherosclerotic lesions. Overexpression of miR-155 diminishes the 
AT1R induced α-SMA expression in vascular adventitial fibroblasts279 and increases the SMC 
content in atherosclerotic lesions of thoracic aortas from Apoe-/- mice fed a HCD for 6 
weeks280. These data suggest that miR-155 may increase SMC proliferation by inhibiting 
SMC differentiation. Although in the current study, miR-155 was detected in some of the 
lesional SMCs, atherosclerotic lesion formation was unaltered in miR-155-/- mice harboring 
miR-155+/+ BM cells, indicating that miR-155 in vascular SMCs was not involved in 
atherosclerosis. Therefore, the predominant localization of miR-155 in lesional macrophages 
suggests that the effects of miR-155 on atherosclerosis are primarily mediated by 
macrophages. 
Modified LDL and INF-γ are proinflammatory and proatherogenic factors that are 
abundant in atherosclerotic plaques and activate many genes in macrophages281-283. The effect 
of modified LDL on miR-155 expression is controversial and both up- and down-regulation of 
miR-155 by oxLDL have been found in monocytes and macrophages157 159 284. In contrast to 
profoundly oxidized LDL, moxLDL can induce inflammatory activation of macrophages by 
activating TLR411. The current study showed that native LDL and moxLDL induced, whereas 
highly oxLDL reduced the expression of miR-155 in BMDMs. These data suggest that the 
degree of oxidation of LDL may determine the miR-155 expression in macrophages. 
Moreover, INF-γ stimulation greatly enhanced the up-regulation of miR-155 by moxLDL in 
macrophages to a similar extend as treatment with LPS and INF-γ. Accordingly, stimulation 
of macrophages with moxLDL and INF-γ induced M1-type macrophage polarization, 
indicating that atherogenic factors present in atherosclerotic plaques can induce miR-155 
expression in macrophages. 
Taken together, the results of the current study suggest that atherogenic factors 
induce miR-155 expression in lesional macrophages, which may in turn increase the 
proinflammatory response during atherogenesis and that miR-155 as a specific marker for M1 
type macrophages directly links inflammatory macrophages with the development of 
atherosclerosis.  
4 Discussion 
124 
 
4.2.2 MiR-155 potentiates the inflammatory response of 
macrophages 
The exact regulatory role of miR-155 in inflammation is still unclear. In Raw264.7 
macrophages, introduction of miR-155 augments the LPS response by inducing 
proinflammatory mediators, such as, TNFα, IL6, IL17, and CCL2209. Moreover, treatment 
with miR-155 mimics induces CXCL9, IL6, and TNFα expression in THP-1 cells268. In line 
with these evidences, the current study showed that miR-155 promotes the expression of 
inflammatory factors Ccl2 and Tnfα in moxLDL- and IFNγ-stimulated macrophages. 
However, the expression of IL1β and Nos2 was not affected by miR-155. These data indicate 
a proinflammatory role of miR-155 in macrophages by inducing Ccl2 and Tnfα during the 
inflammatory response. Moreover, the results of present study demonstrate that miR-155 
deficiency in hematopoietic cells reduces Ccl2 expression in lesional macrophages. Ccl2 
expression by macrophages promotes atherosclerosis by both increased monocyte recruitment 
and oxidized lipid  accumulation in atherosclerotic lesions285. Therefore, the current data 
indicate that pro-inflammatory effects of miR-155 in macrophages may enhance 
atherosclerotic lesion formation by up-regulation of Ccl2. MiR-155 increases inflammatory 
macrophage activation by directly targeting Inpp5d (SHIP1), a negative regulator of the 
PI3K/Akt and TLR4 signalling pathways, and the inhibitor of cytokine signaling, SOCS1209 
286 287. In addition, IL10 represses miR-155 expression, which leads to up-regulation of Inpp5d 
and may thus mediate the anti-inflammatory effects of IL10288. Conversely, miR-155 also 
inhibits the expression of IL10289.  
However, there are also evidences for an antiinflammatory role of miR-155 in 
macrophages. MiR-155 suppresses inflammatory cytokines, such as IL1β and TNFα, in 
monocyte-derived dendritic cells upon LPS stimulation164. In addition, over expression of 
miR-155 decreases the expression of inflammatory cytokines, such as IL6 and TNFα, in 
oxLDL-stimulated macrophages, while inhibition of miR-155 increases their secretion280. In 
oxLDL-treated THP-1 macrophages, miR-155 inhibits NF-κB activity and reduces the 
secretion of IL6 and TNFα159. Moreover, miR-155 suppresses IL1β, CCL5, and IL12 in 
macrophages164. These findings suggest an anti-inflammatory role of miR-155 in 
macrophages. In line with these findings, Donners et al. demonstrated that deficiency of miR-
155 in peritoneal macrophages reduces IL10 expression and therefore plays an anti-
inflammatory role in macrophages.  
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4.2.3 MiR-155 promotes advanced atherosclerosis 
Although the role of miR-155 in hematopoietic cells has been studied in vitro, the functional 
role of miR-155 in atherosclerosis is unclear. The current study showed that lack of miR-155 
in hematopietic cells limited advanced atherosclerotic lesion formation, probably due to 
reduced CCL2 production by miR-155-/- macrophages, which may limit the monocyte 
recruitment to the lesions. However, absence of miR-155 did not alter the macrophage 
apoptosis and migration in vitro202. Thus, the result of current study indicates a 
proinflammatory role for miR-155 in macrophages during atherogenesis.  
In contrast to these data, Donner et al. showed that leukocyte-specific deficiency of 
miR-155 in Ldlr-/- mice on a HCD for 10 weeks leads to increased atherogenesis290. In 
addition, Zhu and colleagues recently reported that over expression of miR-155 does not 
affect lesion size but reduces the lesional macrophage content and the lesional Il6 and Tnfα 
expression in the thoracic aorta of Apoe-/- mice on HCD for 6 weeks280. These studies 
suggested an anti-inflammatory role for miR-155 during atherosclerosis. These contradictory 
findings could be explained by different mouse models, which lead to different degree of 
lesions. In general, Ldlr-/- mice develop smaller and less advanced lesions than Apoe-/- mice on 
a HCD291. However, in the current study partial ligation of carotid artery, as a model of 
acutely disturbed blood flow, in combination with hypercholesterolemia induces advanced 
atherosclerotic lesions and arterial stenosis in Apoe-/- mice292. Therefore, miR-155 may have 
opposite effects on lesion formation depending on the stage of atherosclerosis and the pro- or 
anti-inflammatory roles of miR-155 seem to be dependent on the disease context. Moreover, 
miR-155 is expressed in both lymphoid and myeloid cells293. In the current study, lesional 
neutrophil content was unchanged in the absence of miR-155 in hematopoietic cells. In 
contrast, lesional neutrophil accumulation was increased in Ldlr-/- mice harboring miR-155-/- 
BM cells290. Neutrophils play role in early atherosclerosis294 and neutrophil accumulation in 
atherosclerotic plaques is associated with the progression of lesion295. Therefore, the effect 
observed in Donner et al. study may be due to the role of miR-155 in neutrophils. Moreover, 
miR-155 positively regulates the differentiation of regulatory T cells by targeting Socs1296. 
Notably, regulatory T cells, which play an anti-inflammatory role in atherogenesis, were 
reduced in the circulation of Ldlr-/- mice harboring miR-155-/- BM cells297. However, the 
current study showed that lesional T-cell content was unaltered, indicating that the effect of 
miR-155 on atherosclerosis is primarily mediated by inflammatory macrophages.  
The proatherogenic chemokine Ccl2 plays a pivotal role in the recruitment of 
monocytes into atherosclerotic lesions and thereby promotes the atherogenesis298. The current 
study demonstrated that miR-155 deficiency impaired the expression of Ccl2 in inflammatory 
activated macrophages and reduced the lesional macrophage content, indicating that the up-
regulation of Ccl2 by miR-155 in lesional macrophages promotes monocyte recruitment to the 
lesions.  
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4.2.4 Bcl6 mediates the proinflammatory effects of miR-155 in 
macrophages 
Although bioinformatic analysis using TargetScan 6.2 (release date June, 2012) predicted 308 
potential targets of miR-155 in mouse (http://www.targetscan.org/), only 26 mRNA targets of 
miR-155 have been experimentally validated by Luciferase reporter assay293. Several targets 
of miR-155 have been described in macrophages, including Socs1, and Sfpi1. SFPI1 and 
SOCS1 regulate developmental processes and inflammatory responses in monocytes and 
macrophages209 273 293. In the current study, potential or confirmed targets of miR-155 were 
studied, which can regulate Ccl2 and Tnfα expression in macrophages. The transcription 
factor Sfpi1, a validated target of miR-155 in B-cells299, was up-regulated in miR-155-/- 
macrophages and directly targeted by miR-155, as detected by EIF2C2 IP. However, 
knockdown of Sfpi1 in hematopoietic stem cells does not affect the expression of Ccl2, but it 
is slightly increases Tnfα expression300. Furthermore, the current study showed that the 
inhibition of Sfpi1 did not rescue the induction of Ccl2 and Tnfα in miR-155-/- macrophages. 
Therefore, Sfpi1 does not mediate the effect of miR-155 in macrophages. Socs1 is a direct 
target of miR-155 in T cells and regulates T cell development and differentiation296 301. In 
LPS-induced TLR signaling, miR-155 suppresses Socs1 and thereby mediates the 
inflammatory response of macrophages209. However, there are no direct evidences for 
functional role of Socs1 mediating the effects of miR-155 in these studies. In the current study 
also it seemed that Socs1 was targeted by miR-155 but suppression of Socs1 did not mediate 
the effect of miR-155 on the expression of Ccl2 and Tnfα. 
Genome-wide transcriptome analysis of B cells isolated from Eμ-miR-155 mice, 
which express high levels of miR-155 in B cells, revealed significant reduction of Bcl6 
expression302. Moreover, Bcl6 negatively regulates the expression of Ccl2 in macrophages190. 
The present study showed that miR-155 directly targets Bcl6 in macrophages. Notably, 
suppression of Bcl6 in miR-155-/- macrophages improved the expression of Ccl2 and TNFα. 
These data clearly show that Bcl6 mediates the effect of miR-155 in inflammatory 
macrophages. Although, Socs1 and Sfpi1 were targeted by miR-155, only Bcl6 regulated the 
effect of miR-155 on Ccl2 and Tnfα expression in inflammatory macrophages. Moreover, the 
current study showed that silencing of Bcl6 in Apoe-/- mice harboring miR-155-/- BM cells 
increased Ccl2 expression in macrophages, thus enhancing monocyte recruitment to the 
atheroscleroric plaques, which in turn promoted atherogenesis. Therefore, inhibition of Bcl6 
prevents the beneficial effect of genetic miR-155 deficiency in BM cells. Intrestingly, in Ldlr-
/- mice wich were reconstituted with Bcl6-/- BM cells and fed an atherogenic diet for 2 weeks, 
the Ccl2 expression was increased in aorta and in the BM cells. In addition Ccl2 was up-
regulated in atherosclerotic plaques of Ldlr-/- mice harboring Bcl6-/- BM cells after 8 weeks of 
atherogenic diet feeding303. In macrophages, Bcl6 recruits corepressors SMRT and NCoR to 
the promoter region of inflammatory mediators, such as Ccl2, and thus inhibis their 
expression303.  
In dendritic cells, the expression of miR-155 and of its sister strand, miR-155*, is 
induced upon TLR7 stimulation and they play opposite effects on IFN production304. This 
indicates that not only different leukocyte cell types, but also the functional role of different 
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strands may be involved in the progress of disease. However, the results of the current study 
indicate that the effect of miR-155 in lesional macrophages is mediated by Bcl6, which is a 
direct target of miR-155 strand and therefore the proatherogenic role of proinflammatory M1-
type macrophages in advanced atherosclerosis driven by miR-155 and not by miR-155*.  
Taken together, these data indicate that miR-155-mediated inhibition of Bcl6 
induces the inflammatory activation of macrophages by increased expression of Ccl2 and 
thereby exacerbates atherosclerosis. 
 
 
Figure 89: MiR-155 plays a proinflammatory role in macrophages. MiR-155 is induced in response to 
inflammatory activation of macrophage with moxLDL/ IFNγ. MiR-155 targets the transcriptional repressor, 
Bcl6, and thereby induces the expression of inflammatory mediators, including Ccl2 and Tnfα, which increases 
the recruitment of monocytes to the atherosclerotic plaques and exacerbates atherogenesis. 
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4.2.5 MiR-342-5p regulates miR-155 expression in macrophages 
The current study showed that miR-342-5p was one of the most highly upregulated miRs in 
the atherosclerotic lesions of Apoe-/- mice after 3 months of a HCD. Moreover, miR-342-5p 
expression was induced following partial ligation of carotid arteries of Apoe-/- mice, 
suggesting that miR-342-5p plays a role in atherosclerosis. Interestingly, suppression of miR-
342-5p in partially ligated arteries limited atherogenesis due to the reduced accumulation of 
macrophages and SMCs in atherosclerotic lesions. These data suggest a proatherogenic role of 
miR-342-5p in atherosclerosis. In partially ligated arteries of Apoe-/- mice, Akt1 expression 
was induced following suppression of miR-342-5p. Akt1 is a serine/threonine protein kinase 
that is directly targeted by miR-342-5p210 and negatively regulates the expression of miR-155 
in macrophages209. These data indicate that miR-342-5p regulates the expression of miR-155 
via Akt1 and plays a proinflamatory role in macrophages. In line with these data, the current 
study showed that miR-155, Nos2, and Il6 expression were diminished following suppression 
of miR-342-5p in partially ligated arteries. Taken together, these data indicate that miR-342-
5p is one of the upstream regulators of miR-155 in macrophages. MiR-342-5p induces miR-
155 expression by targeting Akt1 and thereby increases macrophage inflammatory response, 
which in turn promotes atherosclerosis.  
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5 Summary 
MiRs play a pivotal role in the progression of atherosclerosis by regulating the function of 
ECs, SMCs, and macrophages. The expression of miRs is regulated by different stimuli 
implicated in the atherosclerotic lesion formation. Conversely, miRs regulate several 
pathways involved in the development of atherosclerosis, such as vascular inflammation and 
cholesterol metabolism. 
Endothelial miR-126 regulates angiogenesis and vascular integrity. Moreover, 
transfer of miR-126 via endothelial apoptotic bodies impedes atherosclerosis; however, the 
role of miR-126 in EC regeneration is unknown. Therefore, the current study aimed to assess 
the function of miR-126 during vascular injury and atherogenesis. 
Endothelial denudation of the carotid arteries in miR-126-/-Apoe-/- and miR-
126+/+Apoe-/-mice revealed that miR-126 deficiency increased neointima formation due to 
impaired endothelial repair, which was due to reduced EC proliferation. Genome-wide array 
analysis showed that only in silico predicted target of the passenger strand miR-126-5p, Dlk1, 
was up-regulated in injured carotid arteries of miR-126-/-Apoe-/- mice. Direct targeting of Dlk1 
by miR-126-5p was confirmed by luciferase assay. Strand specific silencing of miR-126-3p 
and miR-126-5p strands in injured arteries of Apoe-/- mice showed that only suppressing miR-
126-5p increased lesion formation and impaired EC proliferation. Thus, miR-126-5p controls 
EC regeneration following vascular injury. Accordingly, suppression of Dlk1 in injured 
arteries of miR-126-/-Apoe-/- mice reduced the lesion size and improved EC proliferation. 
Therefore, Dlk1 is a direct target of miR-126-5p, which regulates EC proliferation following 
vascular injury. 
Furthermore, miR-126 deficiency exacerbated atherosclerosis in mice fed a HCD for 3 
months due to reduced EC regeneration, which suggested that the miR-126-5p/Dlk1 axis 
modulates the progression of diet-induced atherogenesis. In contrast to the aortic root, 
atherogenesis was substantially increased in the thoraco-abdominal aorta of miR-126-/-Apoe-/- 
mice. Quantification of miR-126 strands in different parts of the aorta showed that the 
expression of miR-126-5p, but not of miR-126-3p was lower in the aortic root and at 
predilection sites of atherosclerosis. This suppression of miR-126-5p was associated with 
increased Dlk1 expression in these regions. These data suggest that miR-126-5p expression is 
suppressed at sites of disturbed flow. Interestingly, acutely disturbed flow in partially ligated 
carotid arteries of Apoe-/- mice reduced miR-126-5p and increased Dlk1 expression. In contrast 
to aortic roots and partially ligated carotid arteries, EC proliferation was greatly reduced in the 
carotid arteries of miR-126-/-Apoe-/- compared to miR-126+/+Apoe-/- mice. Furthermore, in 
human atherosclerotic lesions, miR-126-5p expression levels were negatively correlated with 
the endothelial DLK1 abundance and positively correlated with EC proliferation, which 
suggests a protective role of miR-126-5p against atherogenesis. Interestingly, systemic 
delivery of miR-126-5p mimics packaged in nanoparticles significantly reduced lesion 
formation and enhanced EC proliferation in both miR-126-/-Apoe-/- and miR-126+/+Apoe-/- 
mice, which showed the therapeutic potential of miR-126-5p in atherosclerosis.  
Thus, miR-126-5p strand regulates EC regeneration following vascular injury and 
during the progression of atherosclerosis by targeting Dlk1. Therefore, miR-126-5p plays a 
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protective role in ECs following vascular injury and diet-induced atherosclerosis. Increasing 
miR-126-5p levels by systemic treatment seems to be a promising therapeutic strategy against 
atherosclerosis. 
MiRs regulate gene expression in a variety of immune cells such as T-cells, 
Neutrophils, dendritic cells, and macrophages232 271. Macrophages affect the initiation and 
progression of atherosclerotic plaques by driving inflammatory responses, degrading 
lipoproteins, and phagocytosis of dead cells19. MiRs, such as miR-155, miR-146a, and miR-
17, control differentiation and inflammatory responses of macrophages by targeting important 
signaling pathways, such as NF-κB268, 271. However, the functional role of macrophage-related 
miRs in the inflammatory response during atherogenesis is unknown.  
MiR gene expression profiling in inflammatory macrophages stimulated with 
LPS/IFNγ and in atherosclerotic lesions of partially ligated carotid arteries in Apoe-/- mice 
revealed that miR-155 was specifically up-regulated in pro-inflammatory macrophages and in 
atherosclerotic plaques. Similar to LPS/IFNγ, miR-155 expression was induced in 
macrophages by moxLDL and IFNγ stimulation, which indicates that miR-155 plays a role 
during the inflammatory response of macrophages. Interestingly, leukocyte-specific 
deficiency of miR-155 greatly reduced atherosclerotic lesion formation due to reduced number 
of lesional macrophages in partially ligated carotid arteries of Apoe-/- mice. The expression 
level of the chemokine CCL2 was significantly reduced in miR-155-/- BMDMs following 
stimulation of macrophages with moxLDL/IFNγ compared with miR-155+/+ BMDMs. CCL2 
promotes the recruitment of monocytes to atherosclerotic plaques, indicating that lack of miR-
155 in macrophages limits atherosclerosis by reduced monocyte recruitment. Accordingly, 
lack of miR-155 reduced the expression of CCL2 in lesional macrophages, which suggested a 
pro-inflammatory role of miR-155 during atherosclerosis. In miR-155-/- macrophages, 
silencing of Bcl6 rescued the suppression of CCL2 after stimulation with moxLDL/IFNγ, 
which indicates that Bcl6 is a functional target of miR-155 regulating CCL2 expression in 
macrophages. BCL6 is a transcription factor that attenuates pro-inflammatory NF-κB 
signaling; therefore, increased levels of Bcl6 in miR-155-/- lesional macrophages reduced the 
inflammatory response and atherosclerosis. Furthermore, silencing of Bcl6 in mice harboring 
miR-155-/- macrophages enhanced plaque formation and Ccl2 expression in partially ligated 
carotid arteries, which confirmed the functional role of Bcl6 in development of 
atherosclerosis. 
Taken together, these data demonstrate that miR-155 plays a pro-inflammatory role 
in macrophages and promotes atherosclerosis by targeting Bcl6, which leads to increased 
CCL2 expression and thus increased macrophage recruitment. 
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